# Title: Plasma multi-omics analysis reveals very long chain ceramides as validated biomarkers of Friedreich's ataxia

Authors: Dezhen Wang,<sup>1</sup> M. Grazia Cotticelli,<sup>2</sup> Blanca E. Himes,<sup>3</sup> David R. Lynch,<sup>4</sup> Clementina Mesaros<sup>1\*</sup>

#### **Affiliations:**

<sup>1</sup>Department of Systems Pharmacology and Translational Therapeutics and Center for Excellence in Environmental Toxicology, University of Pennsylvania; Philadelphia, PA, 19104, USA.

<sup>2</sup> Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia; Philadelphia, PA, 19104, USA.

<sup>3</sup> Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania; Philadelphia, PA, 19104, USA.

<sup>4</sup> Departments of Neurology and Pediatrics, Children's Hospital of Philadelphia; Philadelphia,

PA, 19104, USA.

\* Corresponding author. Email: mesaros@upenn.edu.

**One Sentence Summary:** New plasma lipids biomarkers of Friedreich's Ataxia (FRDA) were validated using a discovery-validation design with two independent cohorts.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### Abstract

Friedreich's Ataxia (FRDA) is an autosomal neurodegenerative disease caused by the deficiency of the protein frataxin. Frataxin is a critical enzyme in the assembly of iron-sulfur clusters that are cofactors for several metabolic enzymes. To identify metabolic features that could be used as potential biomarkers for FRDA in plasma, we performed a multi-omics analysis using a discovery-validation cohort design. We combined metabolomics, lipidomics and proteomics from several liquid chromatography-high resolution mass spectrometry platforms. The analyses revealed that FRDA patients compared to healthy controls and unaffected carriers had dysregulated sphingolipids metabolism, phospholipid metabolism, citric acid cycle, amino acid metabolism, and apolipoprotein metabolism. Using an ROC, the decreased very long chain ceramides can distinguished FRDA patients from healthy controls with AUC from 0.75 to 0.85. Using induced pluripotent stem cell differentiated cardiomyocytes (iPSC-CMs), we demonstrated that frataxin deficiency preferentially affected ceramide synthase (CerS2), enriching long chain ceramides, and depleting very long chain ceramides. The ceramide metabolism was differentially regulated in two of the affected tissues in FRDA: heart and muscles. A machine-learning model improved the prediction of FRDA using the combination of three plasma metabolites (AUC > 0.9). In conclusion, decreased very long chain ceramides are reliable plasma biomarkers for FRDA patients.

Keywords: Friedreich's Ataxia (FRDA), metabolomics, lipidomics, ceramide, biomarker

#### **INTRODUCTION**

Friedreich's Ataxia (FRDA) is an autosomal recessive neurodegenerative disease characterized by progressive mobility loss, impairment of speech, <sup>1</sup> and eventual loss of vision <sup>2</sup> and hearing 3. Individuals with FRDA exhibit clinical manifestations of ataxia, hypertrophic cardiomyopathy, scoliosis, and diabetes mellitus <sup>4-7</sup>. Cardiac complications are the major cause of early death in FRDA<sup>8</sup>. Most disease alleles in FRDA have a guanine-adenine-adenine (GAA) repeat expansion in the first intron of the disease gene FXN, this repeat leads to the silencing of the FXN gene and decreased frataxin protein levels 9, 10. Frataxin acts in the assembly of iron-sulfur (Fe-S) clusters, which are important for iron homeostasis and optimal functions of metabolic enzymes for citric acid cycle, electron chain transport, and fatty acid breakdown <sup>11-14</sup>. Defective mitochondrial metabolism and mitochondrial functions are observed in different models of FRDA<sup>15-17</sup> including Fe–S containing aconitase and respiratory chain complexes <sup>18</sup> that result in a failure of energy (ATP) production <sup>19, 20</sup>. Frataxin-deficient cardiomyocytes present altered thiol-redox state and a decrease content in pyruvate dehydrogenase (PDH A1)<sup>21</sup> and decreased pyruvate oxidation and increased fatty acid oxidation was observed in platelets from FRDA patients <sup>22</sup>. Frataxin deficiency influences the peroxisome-proliferator activator receptor gamma (PPAR $\gamma$ )/PPAR $\gamma$  coactivator 1 alpha (Pgc1a) pathway in cellular and animal models, which is linked to mitochondrial biogenesis and lipid metabolism <sup>23</sup>. Frataxin reduction induces iron accumulation and enhances the sphingolipid/PDK1/Mef2 pathway, which triggers neurodegeneration in fly and mouse models <sup>24, 25</sup>. As discussed in a 2019 summary of FRDA biomarkers <sup>26</sup>, metabolic dysfunctions are significant features of FRDA patients, but larger population studies are necessary to discover and validate actionable biomarkers. A recent study <sup>27</sup> uncovered dysregulation in the one carbon metabolism in plasma from FRDA patients. A common feature of all previous human studies is the limited number of FRDA patients and the lack of validation of the new finding in an independent cohort.

To understand the pathophysiology of FRDA, a high-throughput and large-scaled screening strategy could be employed to investigate the metabolic dysfunctions of FRDA and discover new biomarkers. Metabolomics and proteomics-based profiling provide a useful tool to unravel such biomarkers. Omics profiling have been widely used for biomarker discoveries, drug response prediction, and pathogenesis-related pathway revelation for other diseases <sup>28-30</sup>. Recently, ceramide levels were shown to be accurate biomarkers of adverse cardiovascular disease outcomes in human serum <sup>31</sup>.

To identify potential blood biomarkers in FRDA, we performed metabolomics, lipidomics, and proteomics analysis using discovery-validation design in two independent cohorts of fasting plasma samples. Our results showed that very long chain ceramides distinguish FRDA patients from healthy controls. We further investigated the ceramide metabolism in human induced pluripotent stem cell derived cardiomyocytes (iPSC-CMs) using high-resolution mass spectrometry (HRMS) lipidomics and isotope tracing assays, and consistently found that frataxin deficiency disrupted ceramide synthesis and preferentially enriched long chain ceramides but depleted very long chain ceramides. Using several cell lines from different affected tissues in FRDA patients, we demonstrated that ceramide metabolism was tissue specific differentially regulated. Our study provides new validated plasma biomarkers for

FRDA patients, and these biomarkers could be potential therapeutic targets.

#### **RESULTS**

#### Experimental design and targeted multi-omics workflow

To identify metabolic features that can be used for potential biomarkers in FRDA plasma, we developed independent targeted metabolomics, lipidomics and proteomics workflows using ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS), and measured hundreds of metabolites, lipids, and proteins (Fig. 1A).

Using pooled plasma samples (Supplementary Table 1) or standard solutions, we build-up reliable MS<sup>2</sup> spectral libraries by analyzing pooled samples in a data-dependent acquisition (DDA) mode. We included more than 50 internal standards (<sup>13</sup>C, <sup>2</sup>H, or chain length analogs) (Supplementary Table 2) in combination with quality controls (QC) for locally estimated scatterplot smoothing (LOESS) to normalize for signal intensity drift. Next, well annotated (see experimental part), metabolites, lipids, and peptides were used to generate scheduled window-based inclusion lists for each individual omics experiment (Supplementary Table 3-5) for targeted analysis (Supplementary Fig. 1-3).

To validate the reproducibility and the robustness of our workflows, we separately processed and analyzed 10 technical replicates formed from pooled plasma samples for each of the workflow for metabolomics, lipidomics, and proteomics. We analyzed all the samples in full scan (FS) and parallel reaction monitoring (PRM) modes providing untargeted profiling in combination with more specific targeted quantification without significantly compromising the data acquisition speed. Excellent chromatographic reproducibility was observed for the positive (Fig. 1B) and negative (Fig. 1C) modes for the lipidomics workflow. For all the analyses, we combined the positive and negative mode data. Metabolomics analysis included 123 metabolites and Pearson correlation showed high coefficients (R<sup>2</sup>, 0.97-1) between 10 technical replicates for metabolomics (Fig. 1D). For lipidomics (Fig. 1E) and proteomics (Fig. 1F), even higher correlation coefficients ( $R^2 > 0.99$ ) were observed for the 10 technical replicates, indicating the high reproducibility of the workflow for these assays. To test the reproducibility of all the tested features, we calculated the coefficient of variance (CVs) for all quantified metabolites, lipids, and peptides. For metabolomics, three metabolites had CVs higher than 30%, and 14 metabolites had CVs higher than 20% (Fig. 1G). For lipidomics, out of 630 lipids, only four metabolites showed CVs higher than 20% (Fig. 1H). For proteomics, four peptides had CVs higher than 30%, and 12 peptides had CVs higher than 20% (Fig. 1I). All these preliminary technical data demonstrated that our approach using a targeted multiomics workflow is a robust method for biomarker identification.

#### Metabolomics and lipidomics analysis revealed dysregulated metabolism in FRDA.

Using this targeted multi-omics workflow, we performed both metabolomics and lipidomics analysis using the discovery set of EDTA fasting plasma samples that included 15 controls and 33 FRDA patients (Supplementary Table 1). Those samples were collected between 2012-2019 as part of a Natural History study at the Children's Hospital of Pennsylvania. The average age of the FRDA patients was 25.6±8.1 and the age of the controls was not significantly different 32.7±11.0. This discovery set also included 11 unaffected carriers, with a significantly different

age, as the carriers are usually parents or relatives of the FRDA patients. All groups were balanced on sex as shown in Supplementary Table 1. We visualized the data distribution globally by principal component analysis (PCA). A clear but partial separation of the FRDA group (light blue) from the Control/Carrier groups was observed on the PC1 (Fig. 2A), indicating the metabolic features correlated with disease condition. Most small molecule analytes showed small CVs in our QCs (Supplementary Fig. 4). To identify significantly changed metabolites and lipids, we performed pairwise comparison using a *t*-test. There were no significantly different metabolites between the Control and Carrier groups in the volcano plot from Fig. 2B, which suggests that the Carriers are not metabolically different compared with controls. However, more than 30 metabolites or lipids had a false discovery rate (FDR) < 0.05 and were dysregulated in the FRDA patients in comparison with healthy controls (Fig. 2C). We next applied multivariate statistical analysis method (least square discrimination analysis (PLS-DA)) to calculate the contribution of metabolites or lipids to model discrimination between the Control and FRDA groups (variable importance in projection-VIP). We found that all the metabolites having significant P values also showed higher VIP values (Fig. 2D). To visualize the distribution of the top 50 metabolites or lipids (FDR<0.1), we plotted these as a heatmap for carriers, controls, and FRDA patients (Fig. 2E). To detect the functional groups of metabolites that changed in FRDA patients, we performed correlation analysis on the amount of top 50 compounds (FDR < 0.1). The compounds can be categorized into several groups based on their structure and biological data. On the basis of partial correlation relationships, we build the metabolite correlation network (Fig. 2F and Supplementary Fig. 5) that showed three major clusters. The largest cluster was composed of multiple ceramides, and high intra-correlations were observed for these ceramides. The second largest cluster was the phospholipid cluster, composed of phosphocholines (PC), lyso-PC (LPC), phosphatidic acids (PA), phosphoinositols (PI), and lyso-PI (LPI).

#### Pathway analysis revealed abnormal sphingolipid metabolism in FRDA

We further examined the pathway changes by performing Metabolite Set Enrichment Analysis (MSEA). For lipids, ceramides, PCs, and PIs had the highest enrichment ratio (Fig. 3A). For metabolites, the most enriched ones were categorized into purine metabolism, citric acid cycle, and amino acid metabolism (Fig. 3B). To quantify the metabolic pathway activity, we performed PCA for each mapped KEGG pathway, and calculated PC1 score as the proxy of pathway activity (Fig.3C). Hierarchical clustering showed three main clusters of metabolic pathways. The downregulated pathways (cluster 1) in FRDA patients were mainly lipid metabolism related pathways, including sphingolipid metabolism, glycerophospholipid metabolism, and glycerolipid metabolism. The upregulated pathway (cluster 3) in FRDA patients included the citric acid cycle, amino acid metabolism, and fatty acid degradation. We then performed statistical analysis for several top altered pathway using pathway activity score (scaled PC1 score). Consistent with the results from MSEA, sphingolipid metabolism and glycerophospholipid metabolism decreased in plasma from FRDA patients, while citric acid cycle and amino acid metabolism were increased Fig. 3D).

Decreased very long chain ceramides distinguished FRDA patients from healthy controls Ceramides were the most affected metabolites (lipids) in FRDA patients in this first discovery

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

experiment. The long chain ceramides (C16 and C18 fatty acyl chain) showed no significant differences between FRDA patients and healthy controls (Fig. 4A, top left), while very long chain ceramide (C22 - C26 fatty acyl chain) were significantly decreased in FRDA patients (Fig. 4A). These differential regulations resulted in the increased ratio of long chain ceramide to very long chain ceramides (C16/C24 and C16/C26) (Fig. 4B), being an indicator of higher cardiometabolic risk as previously shown in non-FRDA patients <sup>32, 33</sup>. To test the very long chain ceramides abilities to distinguish FRDA patients from healthy controls, we plotted the receiver operating characteristic (ROCs) analysis using different ceramides as predictor. All very long chain ceramides showed good predictive capacities with area under the curve (AUC) values from 0.75 to 0.85 (Fig. 4C).

#### Validation of very long chain ceramides as FRDA biomarkers in plasma

To validate the discovery results an independent cohort of EDTA fasting plasma was collected. The new cohort was collected between 2020-2022with plasma isolated within 1 h after draw in a research lab (as opposed to the clinical lab that did the isolation for the discovery cohort with no known timing associated between draw and isolation). This validation set did not sample from carriers as we detected no metabolic biomarkers that differentiated Carriers from the Controls (Fig. 2B). The validation set had similar numbers of controls and FRDA patients (Fig. 4D) as the discovery set (Supplementary Table 1). In the validation set, we found that very long chain ceramides were also significantly decreased in the FRDA patients (Fig. 4E and Supplementary Fig. 6A). The validation set also showed the ratio ceramides C16/C24 significantly increased (Fig. 4F) predicting a higher cardiometabolic risk <sup>31, 32</sup>. The predictive powers from the ROC (Fig. 4G) remained similarly strong compared to the discovery set with AUC from 0.7 to 0.82, suggesting very long chain ceramides as plasma biomarkers of FRDA.

#### Quantification of upstream and downstream metabolites from known deficient enzymes

Because frataxin is directly involved in the regulation of citric acid enzyme aconitase, we quantified the levels of upstream and downstream metabolites of this enzyme. The upstream metabolites citric acid and aconitic acid increased in both the discovery and validation sets (raw P value < 0.05), while the downstream metabolite iso-citric acid was not significantly different (Supplementary Fig. 6B,C). The alteration of citric acid intermediates indicated that enzyme activity is directly reflected in the plasma concentration.

#### Unbalanced ceramide synthesis in frataxin-deficient cardiomyocytes

To investigate if the alterations of ceramides in FRDA plasma reflects the dysfunction of clinically affected tissues, we used siRNA to knockdown FXN in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and then examined ceramide metabolism (Fig. 5A). We used two independently derived iPSC-CM lines. Line SV20 was obtained the Penn iPSC Core Facility and line 11713 was obtained from Fujifilm Cellular Dynamics (see Materials and Methods). FXN knockdown using two different siRNA, dramatically decreased the frataxin protein levels in both cell lines (Fig. 5B,C and Supplemental Fig. 7A, using an additional cell line). Lipidomics analysis showed that both lines of frataxin-deficient cardiomyocytes had significantly decreased very long chain ceramides (Fig. 5D,E). For line 11713, higher scalability allowed us to perform lipidomics analysis with two siFRX KDs that

demonstrated the same trends versus control (Fig. 5E,G). The unbalanced alterations of ceramides increased the ratios of long chain to very long chain ceramides (Fig. 5F,G), similar to prior observations in the fibroblast cells from FRDA patients <sup>34</sup>. The *de novo* synthesis of long chain ceramides, and very long chain ceramides is regulated by different ceramide synthase (CerS1-6) that each have tissue and acyl-CoA chain length specificity. Ceramide synthase 2 (CerS2 or LASS2) preferentially select very long chain fatty acyl-CoA (C20-26) as the substrate <sup>35</sup>. Consistent with the lipidomics results, CerS2 protein levels decreased in iPSC-CMs after FXN knockdown in comparison with control (Fig. 5H and Supplementary Fig. 7 B,C).

To further test unbalanced ceramide regulation in frataxin-deficient cardiomyocytes, we performed <sup>13</sup>C<sub>16</sub>-palmitate based isotope tracing experiments using a sensitive LC-HRMS targeted method <sup>34</sup> to quantify the mass isotopomer distribution of ceramides. Long chain ceramides (C16,C18) were not significantly changed after FXN knockdown, while very long chain ceramides (C22 and C24) had lower fractions of the labeled form in frataxin-knockdown cardiomyocytes (Fig. 5I and Supplemental Fig. 7D,E). The isotopic labeling fractions of ceramides in FXN-KD cardiomyocytes had similar patterns in the three different cell lines: SV20 (Fig. 5J), 11713 (Fig. 5K), and an additional line from the Penn core, 233 SeV4 (Fig. 5L) All cell lines showed around 40% incorporation from  ${}^{13}C_{16}$ -palmitate in the very long chain ceramides and all were significantly reduced in 12h (Fig. 5J-L). As the precursors in ceramides biosynthesis are palmitate and serine (Fig. 5A), we also used <sup>13</sup>C<sub>3</sub>, <sup>15</sup>N-serine tracing in one of the cell lines (SV20) and similar results were observed after frataxin knockdown, with decreased labeling fractions of very long chain ceramides (Fig. 5M). All these data indicated that frataxin deficiency in cardiomyocytes led to unbalanced ceramide biosynthesis, with CerS2 being reduced at protein levels and enzymatic activity.

#### Ceramides were differentially regulated in primary skeletal muscle cells

To examined if, ceramide dysfunction was a ubiquitous outcome of frataxin deficiency in another affected FRDA tissues, we chose human primary skeletal muscle cells (HSkMC). We used three different siRNA-mediated FXN knockdown (Fig. 6A) and performed the lipidomics and <sup>13</sup>C<sub>16</sub>-palmitate based isotope-tracing experiments. For HSkMC, FXN knockdown significantly increased the levels of ceramides, including both long chain and very long chain ceramides, with long chain ceramides increasing more significantly than very long chain ceramides (Fig. 6B). The ratios of long chain to very long chain ceramides increased in FXNknockdown HSkMC (Fig. 6C), similar to results observed in frataxin-deficient cardiomyocytes, but the increase was most likely driven by the large increase in the long chain ceramides. For isotopic labeling experiments, FXN knockdown increased the fraction of isotope labeled forms (fatty acid chain, sphingosine base, and dual) for most of ceramides based on mass isotopomer distribution data (Fig. 6D). The isotopic labeling fractions were dramatically increased in FXN-KD cells for all ceramides except Cer(d18:1/24:0) in HSkMCs (Fig. 6E), indicating that the FXN knockdown differentially regulated ceramides in cells originating from different affected tissues.

#### Proteomics revealed decreased apolipoprotein levels.

Using a similar targeted omics workflow, we performed proteomics analysis for the plasma

discovery set. By inspecting for contamination biomarkers for coagulation, erythrocyte, and platelet <sup>36</sup>, our samples appeared to reflect high quality plasma, except for two samples contaminated by platelets (Supplementary Fig. 8). When the quantified proteins were plotted in a heatmap (Fig. 7A), the plasma proteins measured cannot distinguish FRDA patients from healthy controls in the discovery set (Fig. 7B). Statistical analysis revealed 9 proteins that were significantly altered in FRDA patients in comparison with healthy controls, with 8 decreased and 1 increased (FDR < 0.05) in FRDA patients (Fig. 7C). Most of these dysregulated proteins belonged to the apolipoprotein family (Fig. 7D). However, only one apolipoprotein (APOD) could be verified in the validation set (Fig. 7E). A previous report using a stable isotope dilution quantification of APOA1 in FRDA serum samples also observed the decrease of APOA1<sup>37</sup>. Considering the label-free quantification strategy and the smaller number of samples in the validation set a more targeted method with a larger number of samples could help the validation of additional apolipoproteins in plasma similar to the reduced levels of ApoA in FRDA serum 37

#### Machine learning identified metabolic features for FRDA prediction

To improve the predictive powers of ceramides as biomarkers for FRDA, we performed machine learning based optimization (Fig. 8A). First, we included 26 metabolites that were robustly altered in FRDA patients in both, discovery set, and validation set. Next, we chose the top 4 metabolites by linear support vector machine (SVM) based feature selection strategy, namely Cer(m19:0/24:0), 3-methoxytyrosine, Cer(m18:1/22:0), and putrescine (Fig. 8B). To reduce the redundancy, a k-means clustering (KM) was performed to exclude Cer(m18:1/22:0) that showed similar behavior with Cer(m19:0/24:0), creating a final model with three metabolites (Cer(m19:0/24:0), 3-methoxytyrosine, and putrescine). Using three metabolites, we optimized linear SVM models using the discovery set and verified the model in the validation set. The ROC curves showed that these three-metabolite combination improved the predictive capability, with AUC as high as 0.924 (0.850-0.998) in the discovery set (Fig. 8C) and 0.923 (0.842-1.000) in the validation set (Fig. 8D).

#### DISCUSSION

FRDA is a multi-systemic mitochondrial disease caused by the frataxin deficiency. The important role of frataxin in the iron-sulfur cluster assembly results in multiple altered metabolic pathways in FRDA. However, there is no readily available metabolic biomarker adequately validated for use in human blood samples. To identify metabolic features as potential biomarkers, we performed multi-omics profiling and evaluated systematic metabolic changes in FRDA fasting plasma samples compared with healthy controls. Multiple metabolic pathways, including sphingolipid metabolism, phospholipid metabolism, citric acid cycle, and apolipoprotein metabolism were consistently affected in FRDA plasma samples (Fig. 2F).

In our lipidomics analysis, long chain ceramides were unchanged in FRDA plasma (C16-20), while very long chain ceramides (C22-26) were significantly decreased (Fig. 4A,F), resulting in the increased ratio of long chain ceramide to very long chain ceramides (Fig. 4B,G). The decreased very long chain ceramides were validated in an independent cohort, indicating the robust results of our multi-omics studies. An increasing number of clinical studies are

reporting associations between ceramides and cardiovascular outcomes, to the extent that the Mavo Clinic is marketing diagnostic tests to measure ceramides <sup>32</sup>. Of note, unbalanced ceramide levels, with preferentially decreased very long chain ceramide, were first observed in human heart tissue collected post-mortem from FRDA patients, but the number of tissue samples used was very low (n=6) and this tissue is obviously not routinely accessible <sup>25</sup>.

The preferential depletion of very long chain ceramide along with enrichment of long chain ceramides were replicated in frataxin-deficient human cardiomyocytes (Fig. 5D,E) from two independent sources. Furthermore, frataxin deficient cardiomyocytes consistently showed the enrichment of long chain ceramide and depletion of very long chain ceramide. The biosynthesis enzyme CerS2 that is responsible for preferential synthesis of very long chain ceramide was decreased after FRX KD (Fig. 5H). Long-chain ceramide (C16) is usually thought to be deleterious, whereas very-long-chain ceramides (such as C24:0) are considered to be benign or protective <sup>38-41</sup>. Ceramides act as a second messenger in the apoptotic cascade, with long chain ceramides (C16 and C18) being the main ceramides activators of apoptosis. CerS5 or CerS6 (long chain ceramide synthesis) overexpression leads to more cells undergoing apoptosis whereas CerS2 overexpression protected cells from death <sup>42, 43</sup>. Heart-specific Sptlc2-deficient (hSptlc2 KO) mice showed decreased C18:0 and very long chain ceramides but led to cardiac dysfunction <sup>44</sup>. Therefore, balanced ceramide metabolism is important for normal functions; thus, unbalanced ceramides in FRDA may also contribute to the pathophysiology of cardiac hypertrophy or heart failure in FRDA. Further studies testing the effects of modulating different ceramides on cardiac functions of FRDA could answer this question. Very recently, a potent Nacetylgalactosamine-conjugated antisense oligonucleotide engineered to silence CerS2 in hepatocytes *in vivo*, prompts the modulation of blood plasma ceramides <sup>45</sup>. This recent study points that circulating ceramides can be modulated by ceramide biosynthesis in hepatocytes.

Our studies provide very long chain ceramides as robust biomarkers for FRDA patients. Ceramide dysfunctions are involved in many neurodegenerative and cardiovascular diseases <sup>46-49</sup>. Targeting ceramide metabolism can ameliorate neurological symptoms and cardiac hypertrophy and heart failure <sup>50, 51</sup>. In FRDA, ceramides accumulated in a fly model and were associated with neurodegeneration in FRDA <sup>24, 25</sup>, so we did not test the effect of frataxin knockdown in neurons due to these robust pre-existing data.

However, ceramide metabolism was differentially regulated in human primary skeletal muscle cells in response to frataxin knockdown (Fig. 6A,B), with the skeletal muscles being one of the first affected tissues in FRDA. In contrary to the finding in the cardiomyocytes, where only long chain ceramide increased after frataxin deficiency, most of ceramides were increased in the skeletal muscle cells. Noteworthy, C18 ceramide, which is mediated by CerS1an isoform highly expressed in muscles, was the most increased ceramide followed by C16 ceramides. In skeletal muscle, elevated levels of long chains ceramides (such as C16:0 or C18:0) was demonstrated to induce insulin resistance and hepatic steatosis, whereas very long chain ceramides (for instance, C24:0 or C24:1) do not <sup>39, 40, 52</sup>. The dramatic increase in C16 and C18 long chain ceramides in skeletal muscles cells, if replicated in the muscles, could add to the increased risk of diabetes and insulin resistance in FRDA patients, also driven by the lack of beta cells in FRDA. The tissue-specific alterations in FRDA were also revealed in a functional genomic analysis of heart and muscle tissues in FRDA mice models <sup>23</sup>. Therefore, tissue-specific intervention strategy should be considered for targeted therapy. Muscles tissues

analysis would be easier available through muscles biopsy, than heart or brain tissue.

Frataxin deficiency directly affected Fe-S containing enzyme aconitase and respiratory chain complexes. Decreased aconitase activity was observed in FRDA heart tissues and yeast models <sup>18</sup>. However, blood cells (lymphocytes, platelets, and peripheral blood mononuclear cell) from FRDA patients failed to replicate this finding though frataxin protein levels were significantly decreased in whole blood <sup>53</sup> or different subtypes of blood cells <sup>54, 55</sup>. In our metabolomics analysis, we expectedly observed the increase of citric acid and aconitic acid, the upstream metabolites of aconitase in FRDA plasma, indicating defective activity of this enzyme. The alteration of citric acid cycle pathway activity was also demonstrated in our metabolomics analysis (Supplementary Fig. 6). These metabolic differences validate that plasma samples are relevant to the metabolic conditions of FRDA patients.

There are several limitations in this study, mostly deriving from the relatively small number of subjects in both cohorts. Although these small cohort samples showed robust metabolic and lipidomic alterations in FRDA patients, the numbers were not enough to reveal the proteomic changes. This may be due to the fact that no internal standards were used for the proteomics, workflow, but at least one internal standard per chemical class was used for the small molecule omics. Decreased levels of several apolipoproteins from our discovery cohort failed to validate in the validation cohort (8 out 9 could not be validated). By comparing the APOA1 levels between FRDA patients and healthy control in a larger cohort <sup>37</sup>, APOA1 levels were significantly decreased in FRDA serum samples. It appears that a larger cohort is necessary for robust proteomics biomarkers, due to the inherent challenges in measuring plasma proteins. This also seems to support the utility of small molecules biomarkers for clinical studies. We did demonstrated decreased long chain ceramides as robust biomarker for FRDA patients and replicated this finding in frataxin-deficient cardiomyocytes, consistent with of the reduced long chain ceramides in FRDA heart tissue <sup>25</sup> but direct correlation between plasma ceramide levels and heart ceramide levels in human subjects is not readily achievable. Further studies should be done to clarify if dysregulated ceramide levels can be potential biomarkers of cardiomyopathy in FRDA patients. Hammand et al <sup>56</sup> showed that the C24 ceramides are not affected by the fasting state, so the decreased ceramides biomarkers observed here open the possibility to utilize larger cohorts of archived non-fasting plasma samples, and evaluate their levels longitudinally. Due to their high blood concentrations (around 3  $\mu$ M), excellent ionization, and specific fragmentation pattern in collision induced dissociation, very long chain ceramides are feasible for translation into a routine lab assay in clinical settings.

In summary, by performing multi-omics profiling in fasting plasma samples, we identified and validated the very long chain ceramides as robust metabolic biomarkers for FRDA patients. We also demonstrated the clear reduction in the ceramide synthase 2 in frataxin-deficient cardiomyocytes that lead to the depletion of very long chain ceramides but observed different ceramide alterations in human primary skeletal muscle cells. Tissue-specific ceramide alterations should be considered when testing therapeutic approaches. Moreover, we applied machine learning based optimization, indicating that very long chain ceramide in combination with other two metabolites can improve the prediction of FRDA.

#### MATERIALS AND METHODS

#### Human blood sample collection

Plasma samples were collected in two different cohorts all enrolled in parallel in an ongoing natural history study at the Children's Hospital of Philadelphia. The blood samples were collected after overnight fasting, all before 10 AM the next morning. Written informed consent was obtained from each donor participating in the study and possible consequences of the studies were explained. If subjects were under the age of 18, written informed consent was obtained from a parent and/or legal guardian. The study was approved by the Institutional Review Board (IRB) of the Children Hospital of Philadelphia (IRB Protocol # 01-002609). Venous blood was drawn in 8.5 mL purple cap Vacutainer EDTA tubes and gently invert to mix. Plasma was collected after centrifugation at 1000xg for 15 min. All samples were immediately aliquoted to Eppendorf tubes and frozen at -80 °C until analysis. The discovery cohort was collected between 2012-2019 (Table S1). The validation cohort was collected between 2020-2022 (Table S1).

#### **Chemicals and reagents**

Optima LC/MS-grade methanol (A456-4), water (W6500), acetonitrile (A955-4), isopropanol (A461-4), formic Acid (A117-50), and ammonium formate (A11550) were purchased from fisher scientific (Waltham, MA, USA). HPLC-grade methyl tert-butyl ether (MTBE, E127-4) and 1-Butanol (A383SK-1) were purchased from Fisher Scientific (Waltham, MA, USA). Labeled internal standards were obtained as showed in Supplementary Table 2. Bovine Serum Albumin (fatty acid free, low endotoxin, lyophilized powder) (A8806), 2-Iodoacetamide (IAA, 8047440100), urea (U0631), ammonium bicarbonate (A6141), and DL-Dithiothreitol (DTT, D0632) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Pierce<sup>™</sup> Trypsin Protease, MS Grade (90058) was purchased from Thermo Scientific (Waltham, MA, USA).

Human induced pluripotent stem cell differentiated cardiomyocytes (iPSC-CMs). The iPSC-CMs line SV20 and 233 SeV4 were obtained from the Penn iPSC Core Facility. The iPSC-CMs (SV20 and 233 SeV4) were replated into 12 well plates (0.1% gelatin coated) in RPMI/20%FBS/1µM thiazovivin overnight and replaced with RPMI/B27+ for 2 days to recover. All the experiments for these two lines were conducted in RPMI/B27 medium. The iCell Cardiomyocytes 11713 (R1106) was ordered from Fujifilm Cellular Dynamics and maintained in iCell Cardiomyocyte Maintenance Medium (M1003) for all the experiments. We received the cell lines from the Penn iPSC and Fujifilm several times over 6 months period for repeated experiments, and each experiment had at least 3 technical replicates.

Human primary skeletal muscle cell culture. Human skeletal muscle cells (HSkMC, PCS-950-010) were ordered from ATCC (Manassas, VA, USA) and maintained in Mesenchymal Stem Cell Basal Medium (PCS-500-030, ATCC) supplemented with Primary Skeletal Muscle Growth Kit (PCS-950-040, ATCC).

#### siRNA knockdown

Silencer® Select siRNAs (s5361-siFXN-1, s530978-siFXN-2, and s5362-siFXN-3) targeting gene FXN and Silencer<sup>™</sup> Negative Control No. 1 (4404021-siCtrl) were purchased from Thermo Scientific (Waltham, MA, USA). FXN siRNA and negative control siRNA were transfected into targeted cells using Lipofectamine<sup>™</sup> RNAiMAX Transfection Reagent

(13778075, Invitrogen<sup>TM</sup>) at concentrations of 10-50 nM according to the manufacturer's instructions. The concentrations of siRNAs were optimized to bring down the frataxin protein levels to less than 50% of negative control cells. The knockdown efficiency was verified by western blot.

### Stable isotope tracing and cell lipidomics

iPSC-CMs and HSkMCs were cultured in their respective fresh medium containing 100 µM  $^{13}C_{16}$ -palmitate (conjunction with fatty acid free BSA with ratio 2:1) for 6 h or 24 h. Then cells were collected into 1 mL cold 80% methanol after washing 2x with 5 mL PBS. 2.4 mL MTBE and 0.6 mL water were sequentially added and vortex for 1 min. The phase separation was achieved after centrifugation at 3000xg for 10 min. The top organic phase was collected, dried under nitrogen, and reconstituted in MTBE/methanol (1:3, v/v) with 10 mM ammonium formate for LC-HRMS analysis. A parallel reactive monitoring (PRM) targeted method was used to quantify the mass isotopomer distributions of ceramides according to our previous method <sup>34</sup>.

For cell lipidomics analysis, the same protocol was used for sample preparation (iPSC-CMs and HSkMCs) after cells being spiked with the SPLASH® LIPIDOMIX® Mass Spec Standard (330707) and Cer/Sph Mixture I (LM6002). Data acquisition was performed using the sample method described in Lipidomics Section except the full scan mode was used for ceramides quantification.

### Western blot

Cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 20 mM Tris-HCl pH 7.5, 1 mM EGTA, 1% sodium deoxycholate, 1 mM Na<sub>2</sub>EDTA, 2.5 mM sodium pyrophosphate, 1mM beta-glycerophosphate, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1µg/ml leupeptin) containing protease inhibitors (A32963, Thermo Scientific). Total protein content was determined using the Pierce<sup>TM</sup> 660nm protein assay reagent (22660, Thermo Scientific). 20 µg of total protein (3:1 protein/loading buffer) was boiled at 95 °C for 5 min and then loaded onto NuPAGE 10% or 12% Bis-Tris gel. Following SDS-PAGE, proteins were transferred onto nitrocellulose membrane, blocked with 5% dry milk and incubated with primary antibodies against frataxin (1:500) and other target proteins (1:500-1:2000) overnight at 4 °C. Blots were then incubated with appropriate horseradish peroxidase-conjugated secondary antibodies and developed using ultra-sensitive enhanced chemiluminescent SuperSignal West Femto (34094, Thermo Scientific). Lass2 polyclonal antibody (PA5-115496), Lass5 polyclonal antibody (PA5-95899), Lass6 polyclonal antibody (PA5-20648), beta Tubulin Monoclonal Antibody (MA5-16308), and Actin monoclonal antibody (MA1-744) were purchased from Thermo Scientific (Waltham, MA, USA). FXN Polyclonal antibody (14147-1-AP) was purchased from Proteintech (Rosemont, IL, USA). Full Wester Blots are in Supplementary Fig. 9.

#### Flow cvtometry

iPSC-CMs was dissociated with Trypsin-EDTA, and fixed in 4% PFA for 10 min, and permeabilized in PBS containing 0.3% Tween 20 for 1h. Permeabilized cardiomyocytes were stained with a primary mouse anti-Troponin antibody (Abcam Ab8295) at dilution 1:200 overnight followed by goat anti mouse-Alexa Fluor 488 conjugated (Invitrogen 11001) at dilution 1:1000 for 1h. Data were acquired on an Amnis Image Stream and analyzed using open source Flowing Software (Turku Centre for Biotechnology). We routinely used iPSC-CMs that were 80% or above c-troponin positive. Nuclei were stained with DAPI (#P36935, Thermo

Fisher Scientific). Not stained cells were used for negative control.

#### **Metabolomics**

20 µL plasma, spiked with 30 µL internal standard (Supplementary Table 2), was vortex mixed with 200 µL methanol for 10 min, and incubated at -20°C for 1h. After 10 min centrifugation at 14000g at 4 °C, the supernatant was transferred to a new tube, dried under nitrogen, and resuspended in 50 µL acetonitrile/water (75/25, v/v). 5 µL of each sample was combined to make a quality control (QC) metabolomics sample and ran every ten samples in the sequence to monitor for retention time and signal intensity drift. The remaining samples (30 µL) were transferred into injection vials for metabolomic analysis. Samples were randomized before analysis for all the LC-HRMS runs.

Metabolites were separated using an Ascentis<sup>®</sup> Express HILIC HPLC column (2.1 mm x 150 mm, 2.7 µm particle size, #53946-U, SUPELCO Analytical) on an UltiMate 3000 quaternary UHPLC (Thermo Scientific, Waltham, MA) equipped with a refrigerated autosampler (4°C) and column heater (35°C). Solvent A (95% acetonitrile 10 mM ammonium acetate 0.1% acetic acid) and solvent B (5% acetonitrile with same modifiers as A) were used to elute the metabolites with a 26 min gradient, as follows: 10% B at 2 min, 30% B at 10 min, 100 % B at 15 min, 100 % B at 18 min, and back to 10 % B at 19 min. The flow rate was 0.25 ml/min. Samples were analyzed using a Q Exactive HF (QE-HF) (Thermo Scientific, Waltham, MA) equipped with a heated electro-spray ionization (HESI) source operated in both positive and negative ion mode. To build up metabolite spectral library for targeted analysis, we ran a plasma pooled sample extracted in 10x technical replicates in full scan/ddMS2 mode (untargeted metabolomics). The Full Scan settings were as follows: 120,000 resolution, AGC target, 1e6; Maximum IT, 200 ms; scan range, 60 to 900 m/z. Top 20 MS/MS spectral (dd-MS2) @ 15000 were generated with AGC target = 2e5, Maximum IT=25 ms, and (N)CE/stepped NCE = 20, 30, 40v. Metabolites detection and identification were performed using Compound Discovery 2.1 (Thermo Scientific, Waltham, MA) by searching against online database (mzCloud) and inhouse database built on Sigma metabolomics library (LSMLS, Sigma-Aldrich) (mzVault). Well annotated metabolites (by a combination of high-resolution  $m/z \pm 5$  ppm, natural isotope abundances, MS2 spectra and retention time similarity with authentic standard or a similar chemistry standard<sup>57</sup> were used to generate an inclusion list (Supplementary Table 3) for targeted PRM analysis. Final data acquisition was performed in Full scan and PRM modes. The PRM settings were as follows: resolution = 15000, AGC target = 2e5, Maximum IT=25 ms, loop count = 20, isolation window = 2.0, (N)CE was optimized for each metabolite.

#### Lipidomics

 $50 \,\mu\text{L}$  plasma, spiked with 20  $\mu\text{L}$  internal standard (Supplementary Table 2) was extracted with 1000 µL butanol/methanol (1/1, v/v, 10 mM ammonium formate) for 10 min on a shaker. Samples were pelleted by centrifugation at 4000g for 5 min at room temperature. The supernatant was moved to a clean glass tube, dried under nitrogen, and resuspended in 100 µL MTBE/methanol (1/3, v/v) with 10 mM ammonium formate. 5 µL of each sample was combined to make the QC-lipidomics sample that ran every ten samples in the mass spec sequence to monitor for retention time and signal intensity drift. The remaining samples were transferred into injection vials for lipidomic analysis. Lipids were analyzed exactly as we described before for plasma lipdiomics <sup>58</sup>.

#### **Proteomics**

5 µL plasma, was denatured in urea solution (8M), reduced with DTT (5 mM) at 37 °C for 30 min, alkylated with IAA (14 mM) for 30 min (in the dark), diluted with 100 mM ABC solution, and trypsin (1:50) digested at 37 °C overnight. The digestion was quenched by adding 10% formic acid. The digestion mixture was cleaned-up using Oasis HLB 1 cc (30 mg) SPE cartridges (WAT094225, Waters). The cartridges were activated with 500 µL solvent B (0.1% FA in 80% acetonitrile) x 3, equilibrated with 500 µL solvent A (0.1% FA in water) x 3, and after sample loading, washed with 750 µL solvent A x 4, eluted in 500 µL B x3, dried under nitrogen, and redissolved in 60 µL water with 0.1% FA. 5 µL of each sample was combined to make a QC-proteomics sample that ran every ten samples in the mass spec sequence to monitor for retention time and signal intensity drift. The remaining samples were transferred into injection vials for proteomics analysis.

Peptides were separated using a nanoACQUIY Peptide BEH C18 (130 Å, 1.7 µm, 150 µm x 100 mm) on a nanoAcquity system (Milford, MA, USA). Solvent A (99.5% water/0.5% acetonirtrile with 0.1% formic acid) and Solvent B (98 % acetonitrile/ 2% water with 0.1% formic acid) were used to elute the peptides with a 30 min gradient. The initial composition of 95% A was maintained for 3 min, and ramped to 70% A in 30 min, and washed at 2% A for 10 min and equilibrated at 95% A for 10 min. The flow rate was set at 2 µL/min. Samples were analyzed using a Q Exactive HF (QE-HF) (Thermo Scientific, Waltham, MA) equipped with a Michrom BioResources (AUBURN, CA, USA) source operated in positive ion mode. For DDA library generation (untargeted proteomics), data acquisition was performed on the pooled QC samples in Full Scan/ddMS2 mode @ 120,000 resolutions. The Full Scan settings as follows: 120,000 reolution, AGC target = 3e6; Maximum IT = 250 ms; scan range = 300 to 1650 m/z. Top 20 MS/MS spectral (dd-MS2) @ 15000 were generated with AGC target = 1e5, Maximum IT=25 ms, and (N)CE = 27 v. For untargeted proteomics analysis, ProteomeDiscover 4.2 (Thermo Scientific, Waltham, MA) was used for protein and peptide annotation. Well-annotated peptides (MS spectral match) were used to generate a inclusion list (Supplementary Table 5) for targeted proteomics analysis. Targeted proteomics were performed in full scan and PRM modes. The PRM settings were as follows: resolution = 15000, AGC target = 2e5, Maximum IT=25 ms, loop count = 32, isolation window = 2.0, (N)CE was set at 27 v.

#### **Data analysis**

Peak detection and integration were performed using Skyline for metabolomics, lipidomics, and proteomics. For metabolites and lipids, the representative MS2 fragmentation was used for final quantification, and for peptides, the Top 3 MS2 fragmentations were summed to represent the final intensity. The missing values were replaced by LoDs (1/5 of the minimum positive)value of each variable. Then data was log-transformed and normalized. For each analyte and each batch, a combination of internal standards and QC-locally estimated scatterplot smoothing (LOESS) was used for signal drift correction. We applied principal component analysis (PCA) to visualize the overall distribution of all samples (mean-centered and z-score scaled data) and exclude potential outliers using package FactoMineR and factoextra in R (https://www.rproject.org/).

To identify significantly altered metabolites or proteins, we firstly performed a two-tailed *t*-test

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

analysis (false discovery rate, FDR<0.05), volcano plots of statistical significance against log2(fold change) were used to visualize the differences. Then a multivariate statistical analysis parameter- variable importance in projection (VIP) based on partial least square discrimination analysis (PLS-DA) were used to validate the statistically different features (metabolites, lipids, or proteins). For multiple group comparison in cell experiments, a one-way Analysis of variance (ANOVA) with Fisher's LSD post hoc test was used to compute the significance. P < 0.05 \*, P < 0.01 \*\*, P < 0.001 \*\*\*. The data processing and visualization were performed using R package tidyverse, pheatmap, ggplot2, Hmisc, corrplot, ggsci, RColorBrewer, and pROC, and Graphpad Prism 9.0.

#### Metabolites and lipids set enrichment analysis (MSEA)

Metabolite (and we included the lipids too) set enrichment analysis (MSEA) was performed on statistically different metabolites (P < 0.05 and FDR < 0.1) using MetaboAnalyst 5.0 (<u>https://www.metaboanalyst.ca/MetaboAnalyst/</u>). MSEA used 84 metabolite sets based on KEGG human metabolic pathways, and LSEA used 1072 sub chemical class metabolite (lipids) sets. Enrichment Ratio was computed by Hits / Expected.

#### Metabolite correlation network

A debiased Sparse Partial Correlation (DSPC) algorithm was used to compute the correlation between all the quantified metabolites or significantly changed metabolites in Correlation Calculator 1.0.1.<sup>59</sup> The MetScape 3.1.3 within Cytoscape 3.4.0 was used for the visualization of metabolite correlation network. Each node represents a compound, and each edge represents the partial correlation coefficient between two nodes.

#### Pathway activity scoring

Pathway activity was assessed by metabolic pathway based PCA scores according to previous methods<sup>60, 61</sup>. Briefly, our quantified metabolite or lipids were mapped onto KEGG human metabolic pathways. For each pathway, intermediates were used to perform PCA, and the PC1 scores, which capture the maximum metabolite variances, were used as proxy of respective pathway activity.

#### **Machine Learning for FRDA prediction**

26 metabolites that were altered in both the discovery set, and the validation set were used for machine learning based FRDA prediction. We applied linear support vector machine (SVM) to evaluate the feature importance by Monte-Carlo cross validation (MCCV) based sub-sampling in MetaboAnalyst 5.0. The procedure was repeated multiple times to select the important features to build SVM models and a 5-fold cross validation was performed to optimize the best model using Caret package in R. We also applied k-means clustering (KM) to detect features with similar behavior to reduce the redundancy. The final fitted model was applied to the validation set for prediction and verification.

#### List of Supplementary Materials

Supplementary Fig. 1. The extracted ion chromatogram (XIC) of lipids in positive ion mode (a) and in negative ion mode (b).

Supplementary Fig. 2. The extracted ion chromatogram (XIC) of metabolites in positive ion mode (a) and in negative ion mode (b).

Supplementary Fig. 3. The extracted ion chromatogram (XIC) of protein (peptides) in positive

ion mode.

Supplementary Fig. 4. Coefficient of variances (CVs) of quantified metabolites (a) and lipids (b) in each of their quality control (QC) samples.

Supplementary Fig. 5. Metabolite correlation network based on all of metabolites and lipids. Each node represented one metabolite (lipid), and nodes were colored according to metabolite (lipid) class. The edge colored with red indicated positive correlation, while the edge with blue indicated negative correlation. The edge width represented the strength of partial correlation coefficient.

Supplementary Fig. 6. The relative abundance of long chain ceramides in validation set (a). Relative abundance of citric acid cycle intermediates between healthy controls and FRDA patients in discovery set (b) and validation set (c).

Supplementary Fig. 7. Unbalanced ceramide synthesis in frataxin-deficient cardiomyocytes.

a Western blots showing the frataxin levels in FXN-knockdown cardiomyocyte 233-SeV4

b,c Western blots showing the protein levels of ceramide synthase (CerS2) in cardiomyocyte 11713 (b) and 233-SeV4 (c) after siRNA-mediated FXN knockdown

doe The mass isotopomer distribution of ceramides from FXN-knockdown cardiomyocyte 11713 (d) and 233-SeV4 (e).

Supplementary Fig. 8. Quality assessment of each sample according to main contamination sources of coagulation (a), erythrocyte (b), and platelet (c).

Supplementary Fig. 9. Full Western blots used in the cellular work.

Supplementary Table 1. Demographic data for each cohort.

Supplementary Table 2. Internal Standards (ISTD) used for metabolomics and lipidomics analysis.

Supplementary Table 3. Inclusion list for targeted metabolomics (PRM).

Supplementary Table 4. Inclusion list for targeted lipidomics (PRM).

Supplementary Tables 5. Inclusion list for targeted proteomics (PRM)



Fig. 1. A multi-omics workflow to identify potential plasma biomarkers of FRDA. **A.** Multi-omics analysis workflow. Plasma samples from healthy controls and FRDA patients were pooled and processed in three different ways for metabolomics, lipidomics, or proteomics. Libraries were built by running the pooled plasma samples and authentic standards in a datadependent acquisition (DDA) mode. Narrow scheduled chromatographic windows (1-2 min) were set based on DDA libraries to acquire MS2 data in a parrel reaction monitoring (PRM) mode, and full scan (MS1) data was also acquired simultaneously to have a better annotation. Univariate and multivariate statistical analysis were performed to identify potential biomarkers of FRDA.B. The overlapped total ion counts (TICs) from 10 technical workflow replicates for lipidomics in positive mode. C. Same as B but in negative mode. Those showed excellent chromatographic reproducibly. **D.** Color-coded  $R^2$  values for the Pearson correlation comparison of 10 technical workflow replicates for metabolomics. E. lipidomics F. proteomics. R<sup>2</sup> values indicated high reproducibility. G. Intra-assay variability was evaluated by calculating the coefficient of variation (CV) for 10 technical workflow replicates for all quantified metabolites. H. lipids I. peptides; CV < 20% colored with blue, 20% < CV < 30%colored with yellow, and CV > 30% colored with grey.



Fig. 2. Metabolomics and lipidomics analysis revealed dysregulated metabolism in FRDA plasma. A. PCA score plot shows the plasma clustering according to disease conditions. Quality controls (QCs) were run every ten samples. The internal standard and QC-LOESS were combined to be used for signal drift correction. The closed clustering of the QC samples shows the robust methodology. B. Volcano plot of Carrier samples versus Control samples showed no statistical significance (-Log<sub>10</sub>P, two-sided *t*-test) against log2-fold change between the means. C. Volcano plot of statistical significance (-Log<sub>10</sub>P, two-sided *t*-test) against log2fold change between the means of FRDA patients versus Controls. Upregulated metabolites (lipids) were colored with red, and downregulated ones with blue. D. Volcano plot of statistical significance (VIP, PLS-DA) against log2-fold change between the means of FRDA patients versus Controls. Metabolites (lipids) were colored according to VIPs from blue (low) to red (high). E. Heatmap showing relative abundances of top 50 metabolites or lipids (P < 0.05 and FDR < 0.1) in Control, Carrier, and FRDA groups. The abundances of metabolites (lipids) were mean-centered and unit-scaled. F. Metabolite correlation network using MetScape and Cytoscape. Each node represented one metabolite (lipid), and nodes were colored according to metabolite (lipid) pathways. The edge colored with red indicated positive correlation, while the edge with blue indicated negative correlation. The edge width represented the strength of partial correlation coefficient.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 3. Pathway analysis indicated abnormal sphingolipid metabolism in FRDA. A. Lipid set enrichment analysis of significantly changed lipids (FDR adjusted P value less than 0.1). Enrichment Ratio is computed by Hits / Expected. B. Metabolite set enrichment analysis of significantly changed metabolites (FDR adjusted P value less than 0.1). Enrichment Ratio is computed by Hits / Expected. C. Metabolic pathway activity inferred by pathway score (PC1 scores) between healthy controls and FRDA patients. Hierarchical clustering of pathway scores were colored with pathway names labeled. D. Significant pathway scores changes of several metabolic pathways between FRDA patients and Controls. \* p<0.05, \*\* p<0.005.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 4. Decreased very long chain ceramides distinguished FRDA patients from healthy controls in two independent cohorts. A. Relative abundances of ceramides including long chain ceramides and very long chain ceramides between Controls and FRDA patients in the discovery set. B. The ratio of long chain ceramide (Cer(d18:1/16:0)) to very long chain ceramide (Cer(d18:1/24:0)) and (Cer(d18:1/26:0)) between Controls and FRDA patients in the discovery set. C. The receiver operating characteristic (ROC) curves for prediction of FRDA versus healthy controls using different ceramides, showed AUC values higher than 0.75. D. Independently obtained plasma samples have been include in the Validation set to verify the outcomes from the discovery set. E. Relative abundances of very long chain ceramides between heathy controls and FRDA patients in the validation set. F. The ratio of long chain ceramide (Cer(d18:1/16:0)) to very long chain ceramide (Cer(d18:1/16:0)) to very long chain ceramide (Cer(d18:1/16:0)) to very long chain ceramide (Cer(d18:1/24:0)) and FRDA patients in the validation set. G. The receiver operating characteristic (ROC) curves for prediction of FRDA versus healthy controls using different ceramide set. G. The receiver operating characteristic (ROC) curves for prediction of FRDA versus healthy controls using different ceramides in the validation set, and AUC values were calculated and stated in plot. \* p<0.05, \*\* p<0.005, \*\*\* p<0.005.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 5. Unbalanced ceramide synthesis in several lines of frataxin-deficient cardiomyocytes. A. Schematic depiction of *de nova* ceramide synthesis B. Western blots showing the frataxin levels in FXN-knockdown cardiomyocyte SV20 C. same as B but for a different cell line, 11713. D. The relative abundances of ceramides in cardiomyocyte SV20 and E. 11713 (after siRNA-mediated FXN knockdown. F. The ratios of long chain ceramide (C16) to very long chain ceramide (C24 and C26) in cardiomyocyte SV20 and G. in cardiomyocytes 11713, both after FXN-knockdown. H. Western blots showing the protein levels of ceramide synthase (CerS2, CerS5, and CerS6) in cardiomyocyte SV20 after siRNA-mediated FXN knockdown I. The mass isotopomer distribution of ceramides from FXN-knockdown cardiomyocyte SV20 J. The isotopic labeling fractions of ceramides in FXN-KD cardiomyocytes SV20 K. in cardiomyocytes 11713 and L. cardiomyocytes 233-SeV4, all after <sup>13</sup>C<sub>16</sub>-palmitate labeling. K. The isotopic labeling fractions of ceramides in FXN-KD cardiomyocytes SV20 after <sup>13</sup>C<sub>3</sub>, <sup>15</sup>N-serine labeling. \* p<0.05, \*\*\* p<0.005, \*\*\* p<0.005.



Fig. 6. Frataxin deficiency had different effect on the ceramide metabolism in primary skeletal muscle cells A. Western blots showing the frataxin levels in human primary skeletal muscle cells (HSkMC) after siRNA-mediated FXN knockdown B. The relative abundances of ceramides in FXN-knockdown HSkMC. C. The ratios of long chain ceramide (C16) to very long chain ceramide (C24 and C26) in FXN-knockdown HSkMC D. The mass isotopomer distribution of ceramides from control (siCtrl) and FXN-Knockdown HSkMCs. E. The isotopic labeling fractions of ceramides in FXN-knockdown HSkMC. \* p<0.05, \*\* p<0.005, \*\*\* p<0.005.



Fig. 7. Proteomics analysis showed decreased apolipoprotein levels in FRDA plasma.

A. Heatmap showing hierarchical clustering of peptides (proteins) in Control, Carrier, and FRDA groups. B. PCA score plot showing the plasma clustering according to disease conditions, and quality controls (QCs) were run every ten samples. The QC-LOESS were used for signal drift correction. C. Volcano plot of statistical significance (-Log10P, two-sided t-test) against log2-fold change between the means of FRDA patients versus healthy controls. Upregulated proteins were colored with red, and downregulated ones with blue. D. Protein-Protein Interaction Networks of significantly changed proteins (FDR corrected P value less than 0.05) using String. E. APOD was the only significantly decreased protein in FRDA patients versus healthy controls in the validation set. \* p<0.05.



**Fig. 8. Machine learning improves the prediction of FRDA. A.** Machine learning workflow for prediction of FRDA using metabolic features. **B.** Top 15 selected metabolites from Linear support vector machine (SVM) model. **C.** K-Means Clustering revealed different 4 clusters for these metabolites. **D.** The receiver operating characteristic (ROC) curves using three metabolites [Cer(m19:0/24:0), 3-methoxytyrosine, and putrescine] based SVM model in the discovery set **E**. same as D but in the validation set.

### References

1. Parkinson, M. H.; Boesch, S.; Nachbauer, W.; Mariotti, C.; Giunti, P., Clinical features of Friedreich's ataxia: classical and atypical phenotypes. *Journal of neurochemistry* **2013**, *126 Suppl 1*, 103-17.

2. Hamedani, A. G.; Hauser, L. A.; Perlman, S.; Mathews, K.; Wilmot, G. R.; Zesiewicz, T.; Subramony, S. H.; Ashizawa, T.; Delatycki, M. B.; Brocht, A.; Lynch, D. R., Longitudinal analysis of contrast acuity in Friedreich ataxia. *Neurology. Genetics* **2018**, *4* (4), e250.

3. Rance, G.; Corben, L.; Delatycki, M., Auditory processing deficits in children with Friedreich ataxia. *Journal of child neurology* **2012**, *27* (9), 1197-203.

4. Garg, M.; Kulkarni, S. D.; Shah, K. N.; Hegde, A. U., Diabetes Mellitus as the Presenting Feature of Friedreich's Ataxia. *Journal of neurosciences in rural practice* **2017**, 8 (Suppl 1), S117-s119.

5. McCormick, A.; Farmer, J.; Perlman, S.; Delatycki, M.; Wilmot, G.; Matthews, K.; Yoon, G.; Hoyle, C.; Subramony, S. H.; Zesiewicz, T.; Lynch, D. R.; McCormack, S. E., Impact of diabetes in the Friedreich ataxia clinical outcome measures study. *Annals of clinical and translational neurology* **2017**, *4* (9), 622-631.

6. Rummey, C.; Flynn, J. M.; Corben, L. A.; Delatycki, M. B.; Wilmot, G.; Subramony, S. H.; Bushara, K.; Duquette, A.; Gomez, C. M.; Hoyle, J. C.; Roxburgh, R.; Seeberger, L.; Yoon, G.; Mathews, K. D.; Zesiewicz, T.; Perlman, S.; Lynch, D. R., Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort. *Annals of clinical and translational neurology* **2021**, *8* (6), 1239-1250.

7. Lynch, D. R.; Schadt, K.; Kichula, E.; McCormack, S.; Lin, K. Y., Friedreich Ataxia: Multidisciplinary Clinical Care. *Journal of multidisciplinary healthcare* **2021**, *14*, 1645-1658.

8. Legrand, L.; Weinsaft, J. W.; Pousset, F.; Ewenczyk, C.; Charles, P.; Hatem, S.; Heinzmann, A.; Biet, M.; Durr, A.; Redheuil, A., Characterizing cardiac phenotype in Friedreich's ataxia: The CARFA study. *Arch Cardiovasc Dis* **2022**, *115* (1), 17-28.

9. Koeppen, A. H., Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. *Journal of the neurological sciences* **2011**, *303* (1-2), 1-12.

10. Li, Y.; Polak, U.; Bhalla, A. D.; Rozwadowska, N.; Butler, J. S.; Lynch, D. R.; Dent, S. Y. R.; Napierala, M., Excision of Expanded GAA Repeats Alleviates the Molecular Phenotype of Friedreich's Ataxia. *Molecular therapy : the journal of the American Society of Gene Therapy* **2015**, *23* (6), 1055-1065.

11. Cai, K.; Frederick, R. O.; Tonelli, M.; Markley, J. L., Interactions of iron-bound frataxin with ISCU and ferredoxin on the cysteine desulfurase complex leading to Fe-S cluster assembly. *Journal of inorganic biochemistry* **2018**, *183*, 107-116.

12. Cotticelli, M. G.; Crabbe, A. M.; Wilson, R. B.; Shchepinov, M. S., Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids. *Redox biology* **2013**, *1* (1), 398-404.

13. Schmucker, S.; Martelli, A.; Colin, F.; Page, A.; Wattenhofer-Donzé, M.; Reutenauer, L.; Puccio, H., Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. *PloS one* **2011**, *6* (1), e16199.

14. Clark, E.; Johnson, J.; Dong, Y. N.; Mercado-Ayon, E.; Warren, N.; Zhai, M.;

McMillan, E.; Salovin, A.; Lin, H.; Lynch, D. R., Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease. *Neuronal signaling* **2018**, *2* (4).

15. Britti, E.; Delaspre, F.; Sanz-Alcázar, A.; Medina-Carbonero, M.; Llovera, M.; Purroy, R.; Mincheva-Tasheva, S.; Tamarit, J.; Ros, J., Calcitriol increases frataxin levels and restores mitochondrial function in cell models of Friedreich Ataxia. *The Biochemical journal* **2021**, *478* (1), 1-20.

16. Chiang, S.; Braidy, N.; Maleki, S.; Lal, S.; Richardson, D. R.; Huang, M. L., Mechanisms of impaired mitochondrial homeostasis and NAD(+) metabolism in a model of mitochondrial heart disease exhibiting redox active iron accumulation. *Redox biology* **2021**, *46*, 102038.

17. Stepanova, A.; Magrané, J., Mitochondrial dysfunction in neurons in Friedreich's ataxia. *Molecular and cellular neurosciences* **2020**, *102*, 103419.

18. Rötig, A.; de Lonlay, P.; Chretien, D.; Foury, F.; Koenig, M.; Sidi, D.; Munnich, A.; Rustin, P., Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia. *Nature genetics* **1997**, *17* (2), 215-217.

19. DeBrosse, C.; Nanga, R. P. R.; Wilson, N.; D'Aquilla, K.; Elliott, M.; Hariharan, H.; Yan, F.; Wade, K.; Nguyen, S.; Worsley, D., Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders. *JCI insight* **2016**, *1* (18).

20. Lodi, R.; Cooper, J. M.; Bradley, J. L.; Manners, D.; Styles, P.; Taylor, D. J.; Schapira, A. H., Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. *Proceedings of the National Academy of Sciences* **1999**, *96* (20), 11492-11495.

21. Purroy, R.; Medina-Carbonero, M.; Ros, J.; Tamarit, J., Frataxin-deficient cardiomyocytes present an altered thiol-redox state which targets actin and pyruvate dehydrogenase. *Redox biology* **2020**, *32*, 101520.

22. Worth, A. J.; Basu, S. S.; Deutsch, E. C.; Hwang, W.-T.; Snyder, N. W.; Lynch, D. R.; Blair, I. A., Stable isotopes and LC–MS for monitoring metabolic disturbances in Friedreich's ataxia platelets. *Bioanalysis* **2015**, *7* (15), 1843-1855.

23. Coppola, G.; Marmolino, D.; Lu, D.; Wang, Q.; Cnop, M.; Rai, M.; Acquaviva, F.; Cocozza, S.; Pandolfo, M.; Geschwind, D. H., Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPAR $\gamma$  pathway as a therapeutic target in Friedreich's ataxia. *Human molecular genetics* **2009**, *18* (13), 2452-2461.

24. Chen, K.; Lin, G.; Haelterman, N. A.; Ho, T. S.-Y.; Li, T.; Li, Z.; Duraine, L.; Graham, B. H.; Jaiswal, M.; Yamamoto, S., Loss of Frataxin induces iron toxicity, sphingolipid synthesis, and Pdk1/Mef2 activation, leading to neurodegeneration. *Elife* **2016**, *5*, e16043.

25. Chen, K.; Ho, T. S.-Y.; Lin, G.; Tan, K. L.; Rasband, M. N.; Bellen, H. J., Loss of Frataxin activates the iron/sphingolipid/PDK1/Mef2 pathway in mammals. *Elife* **2016**, *5*, e20732.

26. Blair, I. A.; Farmer, J.; Hersch, S.; Larkindale, J.; Lynch, D. R.; Napierala, J.; Napierala, M.; Payne, R. M.; Subramony, S. H., The current state of biomarker research for Friedreich's ataxia: a report from the 2018 FARA biomarker meeting. *Future Sci OA* **2019**, *5* (6), Fso398.

27. O'Connell, T. M.; Logsdon, D. L.; Payne, R. M., Metabolomics analysis reveals

dysregulation in one carbon metabolism in Friedreich Ataxia. Mol Genet Metab 2022, 136 (4), 306-314.

Schult, T. A.; Lauer, M. J.; Berker, Y.; Cardoso, M. R.; Vandergrift, L. A.; Habbel, 28. P.; Nowak, J.; Taupitz, M.; Aryee, M.; Mino-Kenudson, M. A., Screening human lung cancer with predictive models of serum magnetic resonance spectroscopy metabolomics. Proceedings of the National Academy of Sciences 2021, 118 (51).

Shu, T.; Ning, W.; Wu, D.; Xu, J.; Han, Q.; Huang, M.; Zou, X.; Yang, Q.; Yuan, 29. Y.; Bie, Y., Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity **2020**, *53* (5), 1108-1122. e5.

Liang, L.; Rasmussen, M.-L. H.; Piening, B.; Shen, X.; Chen, S.; Röst, H.; Snyder, 30. J. K.; Tibshirani, R.; Skotte, L.; Lee, N. C., Metabolic dynamics and prediction of gestational age and time to delivery in pregnant women. Cell 2020, 181 (7), 1680-1692. e15.

31. Choi, R. H.; Tatum, S. M.; Symons, J. D.; Summers, S. A.; Holland, W. L., Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol 2021, 18 (10), 701-711.

Tippetts, T. S.; Holland, W. L.; Summers, S. A., The ceramide ratio: a predictor of 32. cardiometabolic risk. Journal of lipid research 2018, 59 (9), 1549-1550.

33. Anroedh, S.; Hilvo, M.; Akkerhuis, K. M.; Kauhanen, D.; Koistinen, K.: Oemrawsingh, R.; Serruys, P.; van Geuns, R.-J.; Boersma, E.; Laaksonen, R., Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. Journal of lipid research 2018, 59 (9), 1729-1737.

34. Wang, D.; Ho, E. S.; Cotticelli, M. G.; Xu, P.; Napierala, J. S.; Hauser, L. A.; Napierala, M.; Himes, B. E.; Wilson, R. B.; Lynch, D. R., Skin fibroblast metabolomic profiling reveals that lipid dysfunction predicts the severity of Friedreich's ataxia. Journal of lipid research 2022, 100255.

35. Levy, M.; Futerman, A. H., Mammalian ceramide synthases. *IUBMB life* 2010, 62 (5), 347-56.

Geyer, P. E.; Voytik, E.; Treit, P. V.; Doll, S.; Kleinhempel, A.; Niu, L.; Müller, J. 36. B.; Buchholtz, M. L.; Bader, J. M.; Teupser, D.; Holdt, L. M.; Mann, M., Plasma Proteome Profiling to detect and avoid sample-related biases in biomarker studies. EMBO Mol Med 2019, 11 (11), e10427.

37. Wang, O.; Guo, L.; Strawser, C. J.; Hauser, L. A.; Hwang, W. T.; Snyder, N. W.; Lynch, D. R.; Mesaros, C.; Blair, I. A., Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy. PloS one 2018, 13 (2), e0192779.

Hammerschmidt, P.; Ostkotte, D.; Nolte, H.; Gerl, M. J.; Jais, A.; Brunner, H. L.; 38. Sprenger, H.-G.; Awazawa, M.; Nicholls, H. T.; Turpin-Nolan, S. M., CerS6-derived sphingolipids interact with Mff and promote mitochondrial fragmentation in obesity. Cell 2019, 177 (6), 1536-1552. e23.

Turpin, S. M.; Nicholls, H. T.; Willmes, D. M.; Mourier, A.; Brodesser, S.; 39. Wunderlich, C. M.; Mauer, J.; Xu, E.; Hammerschmidt, P.; Brönneke, H. S., Obesity-induced CerS6-dependent C16: 0 ceramide production promotes weight gain and glucose intolerance. Cell metabolism 2014, 20 (4), 678-686.

Raichur, S.; Wang, S. T.; Chan, P. W.; Li, Y.; Ching, J.; Chaurasia, B.; Dogra, S.; 40. Öhman, M. K.; Takeda, K.; Sugii, S., CerS2 haploinsufficiency inhibits β-oxidation and

confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell metabolism 2014, 20 (4), 687-695.

Turpin-Nolan, S. M.; Brüning, J. C., The role of ceramides in metabolic disorders: when 41. size and localization matters. Nature Reviews Endocrinology 2020, 16 (4), 224-233.

42. Mesicek, J.; Lee, H.; Feldman, T.; Jiang, X.; Skobeleva, A.; Berdyshev, E. V.; Haimovitz-Friedman, A.; Fuks, Z.; Kolesnick, R., Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cellular signalling 2010, 22 (9), 1300-1307.

43. Hartmann, D.; Lucks, J.; Fuchs, S.; Schiffmann, S.; Schreiber, Y.; Ferreirós, N.; Merkens, J.; Marschalek, R.; Geisslinger, G.; Grösch, S., Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. The international journal of biochemistry & cell biology 2012, 44 (4), 620-628.

44. Lee, S.-Y.; Kim, J. R.; Hu, Y.; Khan, R.; Kim, S.-J.; Bharadwaj, K. G.; Davidson, M. M.; Choi, C.-S.; Shin, K.-O.; Lee, Y.-M., Cardiomyocyte specific deficiency of serine palmitoyltransferase subunit 2 reduces ceramide but leads to cardiac dysfunction. Journal of Biological Chemistry 2012, 287 (22), 18429-18439.

Schmidt, S.; Gallego, S. F.; Zelnik, I. D.; Kovalchuk, S.; Albæk, N.; Sprenger, R. R.; 45. Øverup, C.; Pewzner-Jung, Y.; Futerman, A. H.; Lindholm, M. W.; Jensen, O. N.; Ejsing, C. S., Silencing of ceramide synthase 2 in hepatocytes modulates plasma ceramide biomarkers predictive of cardiovascular death. Molecular therapy : the journal of the American Society of Gene Therapy 2022, 30 (4), 1661-1674.

Choi, R. H.; Tatum, S. M.; Symons, J. D.; Summers, S. A.; Holland, W. L., Ceramides 46. and other sphingolipids as drivers of cardiovascular disease. Nature Reviews Cardiology 2021, 1-11.

47. Vasile, V. C.; Meeusen, J. W.; Medina Inojosa, J. R.; Donato, L. J.; Scott, C. G.; Hyun, M. S.; Vinciguerra, M.; Rodeheffer, R. R.; Lopez-Jimenez, F.; Jaffe, A. S., Ceramide Scores Predict Cardiovascular Risk in the Community. Arteriosclerosis, thrombosis, and vascular biology 2021, 41 (4), 1558-1569.

48. Tong, M.; de la Monte, S. M., Mechanisms of ceramide-mediated neurodegeneration. Journal of Alzheimer's Disease 2009, 16 (4), 705-714.

49. Laaksonen, R.; Ekroos, K.; Sysi-Aho, M.; Hilvo, M.; Vihervaara, T.; Kauhanen, D.; Suoniemi, M.; Hurme, R.; März, W.; Scharnagl, H., Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. European heart journal 2016, 37 (25), 1967-1976.

Ji, R.; Akashi, H.; Drosatos, K.; Liao, X.; Jiang, H.; Kennel, P. J.; Brunjes, D. L.; 50. Castillero, E.; Zhang, X.; Deng, L. Y., Increased de novo ceramide synthesis and accumulation in failing myocardium. JCI insight 2017, 2 (9).

51. Russo, S. B.; Baicu, C. F.; Van Laer, A.; Geng, T.; Kasiganesan, H.; Zile, M. R.; Cowart, L. A., Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. The Journal of clinical investigation 2012, 122 (11), 3919-3930.

52. Hla, T.; Kolesnick, R., C16: 0-ceramide signals insulin resistance. Cell metabolism **2014,** *20* (5), 703-705.

Wang, Q.; Laboureur, L.; Weng, L.; Eskenazi, N. M.; Hauser, L. A.; Mesaros, C.; 53. Lynch, D. R.; Blair, I. A., Simultaneous Quantification of Mitochondrial Mature Frataxin and

Extra-Mitochondrial Frataxin Isoform E in Friedreich's Ataxia Blood. Front Neurosci 2022, 16, 874768.

54. Selak, M. A.; Lyver, E.; Micklow, E.; Deutsch, E. C.; Önder, Ö.; Selamoglu, N.; Yager, C.; Knight, S.; Carroll, M.; Daldal, F., Blood cells from Friedreich ataxia patients harbor frataxin deficiency without a loss of mitochondrial function. Mitochondrion 2011, 11 (2), 342-350.

55. Télot, L.; Rousseau, E.; Lesuisse, E.; Garcia, C.; Morlet, B.; Léger, T.; Camadro, J.-M.; Serre, V., Quantitative proteomics in Friedreich's ataxia B-lymphocytes: A valuable approach to decipher the biochemical events responsible for pathogenesis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 2018, 1864 (4), 997-1009.

Hammad, S. M.; Pierce, J. S.; Soodavar, F.; Smith, K. J.; Al Gadban, M. M.; 56. Rembiesa, B.; Klein, R. L.; Hannun, Y. A.; Bielawski, J.; Bielawska, A., Blood sphingolipidomics in healthy humans: impact of sample collection methodology. Journal of lipid research 2010, 51 (10), 3074-87.

Chen, L.; Lu, W.; Wang, L.; Xing, X.; Chen, Z.; Teng, X.; Zeng, X.; Muscarella, 57. A. D.; Shen, Y.; Cowan, A.; McReynolds, M. R.; Kennedy, B. J.; Lato, A. M.; Campagna, S. R.; Singh, M.; Rabinowitz, J. D., Metabolite discovery through global annotation of untargeted metabolomics data. Nat Methods 2021, 18 (11), 1377-1385.

Wang, D.; Xu, P.; Mesaros, C., Analytical considerations for reducing the matrix effect 58. for the sphingolipidome quantification in whole blood. *Bioanalysis* 2021, 13 (13), 1037-1049.

59. Basu, S.; Duren, W.; Evans, C. R.; Burant, C. F.; Michailidis, G.; Karnovsky, A., Sparse network modeling and metscape-based visualization methods for the analysis of largescale metabolomics data. Bioinformatics 2017, 33 (10), 1545-1553.

Cherkaoui, S.; Durot, S.; Bradley, J.; Critchlow, S.; Dubuis, S.; Masiero, M. M.; 60. Wegmann, R.; Snijder, B.; Othman, A.; Bendtsen, C., Epithelial-mesenchymal transition is the main driver of intrinsic metabolism in cancer cell lines. bioRxiv 2021.

Segura-Lepe, M. P.; Keun, H. C.; Ebbels, T. M. D., Predictive modelling using pathway 61. scores: robustness and significance of pathway collections. BMC Bioinformatics 2019, 20 (1), 543.

#### Acknowledgements

We thank Prof. Ian Blair for providing unlimited access to the use of LC-HRMS, Rachel Truitt for assistance with the iPSC-CMs, and Dr. Nathaniel Snyder for discussions and editing of the manuscript. We are very grateful to all FRDA patients for agreeing to give blood for research purposes and to the healthy volunteers that agreed to serve as controls. We recognize the positive support of the Hamilton and Finneran families and the Penn Medicine/CHOP Friedreich's Ataxia Center of Excellence.

#### **Funding:**

National Institutes of Health grant R21NS116315 (CM) National Institutes of Health grant P30ES013508 (CM) Friedreich's Ataxia Research Alliance (FARA) Postdoctoral Research Award (DW)

#### Author contributions:

Conceptualization: CM, DW, MGC Methodology: DW, MGC, BEH, DRL Investigation: DW, MGC, CM Visualization: DW, BEH Funding acquisition: CM, DW Project administration: CM, DRL Supervision: CM Writing original draft: DW, CM, DRL Writing review & editing: DW, MGC, CM, BEH, DRL

Competing interests: Authors declare that they have no competing interests.

**Data and materials availability:** All data are available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website (supported by NIH grant U2C-DK119886), the Metabolomics Workbench, https://www.metabolomicsworkbench.org where it has been assigned Project ID PR001432. The data can be accessed directly via it's Project DOI:10.21228/M8MQ5M. Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Clementina Mesaros, <u>mesaros@upenn.edu</u>.

# Supplementary material: Plasma multi-omics analysis reveals very long chain ceramides as validated biomarkers of Friedreich's ataxia

Authors: Dezhen Wang,<sup>1</sup> M. Grazia Cotticelli,<sup>2</sup> Blanca E. Himes,<sup>3</sup> David R. Lynch,<sup>4</sup> Clementina Mesaros<sup>1\*</sup>

<sup>1</sup>Department of Systems Pharmacology and Translational Therapeutics and Center for Excellence in Environmental Toxicology, University of Pennsylvania; Philadelphia, PA, 19104, USA.

<sup>2</sup> Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia; Philadelphia, PA, 19104, USA.

<sup>3</sup> Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania; Philadelphia, PA, 19104, USA.

<sup>4</sup> Departments of Neurology and Pediatrics, Children's Hospital of Philadelphia; Philadelphia, PA, 19104, USA.

\* Corresponding author. Email: <u>mesaros@upenn.edu</u>.



Supplementary Fig. 1. The extracted ion chromatogram (XIC) of lipids in positive ion mode (a) and in negative ion mode (b).



Supplementary Fig. 2. The extracted ion chromatogram (XIC) of metabolites in positive ion mode (a) and in negative ion mode (b).

## Proteomics



**Supplementary Fig. 3.** The extracted ion chromatogram (XIC) of protein (peptides) in positive ion mode.



Supplementary Fig. 4. Coefficient of variances (CVs) of quantified metabolites (a) and lipids (b) in each of their quality control (QC) samples.



Supplementary Fig. 5. Metabolite correlation network based on all of metabolites and lipids. Each node represented one metabolite (lipid), and nodes were colored according to metabolite (lipid) class. The edge colored with red indicated positive correlation, while the edge with blue indicated negative correlation. The edge width represented the strength of partial correlation coefficient.
medRxiv preprint doi: https://doi.org/10.1101/2022.09.27.22280432; this version posted September 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Supplementary Fig. 6. The relative abundance of long chain ceramides in validation set (a). Relative abundance of citric acid cycle intermediates between healthy controls and FRDA patients in discovery set (b) and validation set (c).

medRxiv preprint doi: https://doi.org/10.1101/2022.09.27.22280432; this version posted September 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .





Supplementary Fig. 7. Unbalanced ceramide synthesis in frataxin-deficient cardiomyocytes. a Western blots showing the frataxin levels in FXN-knockdown cardiomyocyte 233-SeV4 b,c Western blots showing the protein levels of ceramide synthase (CerS2) in cardiomyocyte 11713 (b) and 233-SeV4 (c) after siRNA-mediated FXN knockdown doe The mass isotopomer distribution of ceramides from FXN-knockdown cardiomyocyte 11713 (d) and 233-SeV4 (e)

medRxiv preprint doi: https://doi.org/10.1101/2022.09.27.22280432; this version posted September 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





Supplementary Fig. 8. Quality assessment of each sample according to main contamination sources of coagulation (a), erythrocyte (b), and platelet (c).

medRxiv preprint doi: https://doi.org/10.1101/2022.09.27.22280432; this version posted September 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





Supplementary Fig. 9. Full Western blots used in the cellular work.

medRxiv preprint doi: https://doi.org/10.1101/2022.09.27.22280432; this version posted September 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



**Supplementary Fig. 10. Machine learning improves the prediction of FRDA. A.** Machine learning workflow for prediction of FRDA using metabolic features. **B.** Top 15 selected metabolites from Linear support vector machine (SVM) model. **C.** K-Means Clustering revealed different 4 clusters for these metabolites. **D.** The receiver operating characteristic (ROC) curves using three metabolites [Cer(m19:0/24:0), 3-methoxytyrosine, and putrescine] based SVM model in the discovery set **E**. same as D but in the validation set.

	Discovery set (59)										
	Control FRDA Carrier				FRDA						
Gender	M(8)/F(7)	M(10)/F(19) 4 Unknown	M(4)F/(7)	M(7)/F(5)	M(17)/F(9)						
Age(mean±sd)	Age(mean±sd) 32.7±11.0 25.6±8.1		54.2±9.3	29.4±7.6	21.2±7.7						
GAA1(mean±sd)		634.9±184.2	_		693.3±198.2						
Age of onset (mean±sd)		11.8±5.4			11.6±4.2						

Supplementary Table 1. Demographic data for each cohort.

Supplementary Table 2. Internal Standards (ISTD) used for metabolomics and lipidomics analysis.

Internal Standard (ISTD)	Concentration in Mix (ng µL <sup>-1</sup> )	Supplier		
Metabolo	mics ISTD Mix			
Glycine (13C2, 99%; 15N, 99%)	11	CIL		
Serine (13C3, 98%; 15N, 98%)	60	CIL		
Isoleucine (13C6, 99%; 15N, 99%)	10.5	CIL		
Threonine-13C4,15N	11	SA		
Sodium Pyruvate (13C3, 99%)	10	CIL		
Arginine (13C6, 99%)	9.5	CIL		
Valine (13C5, 99%; 15N, 99%)	110	CIL		
Tryptophan (13C11, 99%)	11.5	CIL		
Lysine (13C6, 99%)	10	CIL		
Aspartic Acid (13C4, 99%; 15N, 99%)	10.5	CIL		
Glutamic Acid-13C5,15N	10	SA		
Glutamine-13C5,15N2	10	SA		
D-3-Hydroxybutyrate (13C4, 99%)	10.5	CIL		
Adenosine (Ribose-13c5, 98%+)	50	CIL		
Alpha-Ketoglutaric Acid (13C5, 99%)	2.5	CIL		
A-Hydroxyglutaric Acid-13C5	2.5	SA		
Fumaric Acid – [13]C4	N/A	CIL		
Succinic Acid-2,2,3,3-d4	11	SA		
Citric Acid-13C6	9	SA		
<sup>1</sup> Carnitine – D9	2.16	CIL		
<sup>1</sup> Acetylcarnitine – D3	0.77	CIL		
<sup>1</sup> Propionylcarnitine – D3	0.16	CIL		
<sup>1</sup> Butyrylcarnitine – D3	0.17	CIL		
<sup>1</sup> Isovalerylcarnitine – D9	0.18	CIL		

<sup>1</sup> Octanoylcarnitine – D3	0.21	CIL
<sup>1</sup> Myristoylcarnitine – D9	0.26	CIL
<sup>1</sup> Palmitoylcarnitine – D3	0.56	CIL
Lipidon	nics ISTD Mix	
<sup>2</sup> 15:0-18:1 PC – D7	80	APL
<sup>2</sup> 15:0-18:1 PE – D7	2.5	APL
<sup>2</sup> 15:0-18:1 PS – D7	2.5	APL
<sup>2</sup> 15:0-18:1 PG – D7	15	APL
<sup>2</sup> 15:0-18:1 PI – D7	5	APL
<sup>2</sup> 15:0-18:1 PA – D7	3.5	APL
<sup>2</sup> 18:1 LPC – D7	12.5	APL
<sup>2</sup> 18:1 LPE – D7	2.5	APL
<sup>2</sup> 18:1 Cholesterol Ester – D7	175	APL
<sup>2</sup> 18:1 MG – D7	1	APL
<sup>2</sup> 15:0-18:1 DG – D7	5	APL
<sup>2</sup> 15:0-18:1-15:0 TG – D7	27.5	APL
$^{2}18:1$ SM – D9	15	APL
<sup>2</sup> Cholesterol – D7	50	APL
Sphingosine (C17 base)	3.6	APL
Sphinganine (C17 base)	3.6	APL
Sphingosine-1-P (C17 base)	4.6	APL
Sphinganine-1-P (C17 base)	4.6	APL
Lactosyl(B) C12 Ceramide	8.1	APL
12:0 Sphingomyelin	6	APL
Glucosyl(β) C12 Ceramide	8	APL
12:0 Ceramide	10.1	APL
12:0 Ceramide-1-P	7	APL
25:0 Ceramide	8.3	APL
Palmitoyl-1,2,3,4-13C4-L- carnitine hydrochloride	2.2	SA

CIL = Cambridge Isotope Laboratories, Inc. (Tewksbury, MA, USA).

SA = Sigma-Aldrich (St. Louis, MO, USA)

TRC = Toronto Research Chemicals, Inc.,

APL = Avanti Polar Lipids (Birmingham, AL, USA). CC = Cayman Chemicals

<sup>1</sup> Labeled carnitine standards set B from CIL

<sup>2</sup> Splash Lipidomix Mass Spec Standards from APL

Supplementary Table 3. Inclusion list for targeted metabolomics (PRM).

Mass	For	For	Spe	С	Pola	Sta	En	(N)	(N)	Μ	Comment
[m/z]	mula	mula	cies	S	rity	rt	d	CE	CE	SX	
	[ <b>M</b> ]	type		[z		[mi	[mi		typ	ID	
				]		<b>n</b> ]	<b>n</b> ]		e		
61.04				1	Positi	1.3	3.3	10	NC		Urea
02					ve				Е		
62.06				1	Positi	7.7	9.7	10	NC		Ethanolamine
004					ve				Е		
76.03				1	Positi	8	10	20	NC		Glycine
931					ve				Е		
81.04				1	Positi	10	12	20	NC		Pyrimidine
473					ve				Е		
89.10				1	Positi	14.	18	10	NC		Putrescine
733					ve	9			Е		
90.05				1	Positi	7.5	9.5	20	NC		Alanine
496					ve				Е		
90.05				1	Positi	8.5	10.	20	NC		Sarcosine
496					ve		5		Е		
90.05				1	Positi	9.4	11.	20	NC		β-Alanine
496					ve		4		Е		
102.0				1	Positi	7	9	10	NC		1-
55					ve				Е		Aminocyclopropan
											ecarboxylic acid
103.0				1	Positi	12	14	20	NC		Acetoacetate
395					ve				Е		
104.0				1	Positi	6.8	8.8	20	NC		2-Aminoisobutyric
706					ve				Е		acid
104.0				1	Positi	8.5	10.	20	NC		Dimethylglycine
706					ve		5		Ε		
104.1				1	Positi	10.	12.	10	NC		Choline
075					ve	6	6		Е		
106.0				1	Positi	7.5	9.5	20	NC		Serine
499					ve				E		
112.0				1	Positi	2.4	4.4	10	NC		Cytosine
506					ve				Е		
112.0				1	Positi	10	12	20	NC		Histamine
869					ve				Ε		
113.0				1	Positi	1.1	3.1	10	NC		Uracil
346					ve				Е		
114.0				1	Positi	2.9	4.9	20	NC		Creatinine
662					ve				E		
116.0				1	Positi	7.9	9.9	20	NC		Proline
706					ve				Е		
118.0				1	Positi	7.8	9.8	40	NC		Guanidineacetic
611					ve				Е		acid
118.0				1	Positi	3.6	7	50	NC		Indole

656		ve				Е	
118.0	1	Positi	6.4	8.4	20	NC	Valine
863		ve				Е	
118.0	1	Positi	9	11	50	NC	Betaine
863		ve				Е	
120.0	1	Positi	7	9	20	NC	Threonine
655		ve		-		Е	
123.0	1	Positi	5	7	20	NC	Benzoic acid
439	-	ve	U	,	20	E	
123.0	1	Positi	1	3	50	NC	Nicotinamide
553	-	ve	1		20	E	
126.0	1	Positi	43	63	10	NC	Taurine
22	1	ve	т.5	0.5	10	F	Tuurme
127.0	1	Positi	1	3	20	NC	Thymine
501	1	I USILI VA	1	5	20	F	Thymne
130.0	1	Positi	5.0	8	20		Puroglutamic acid
150.0	1	1 OSIU	5.9	0	20	F	i yiogiutanne aciu
120.0	1	VC Dogiti	67	07	20		Dipagalia agid
150.0	1	rositi	0.7	0./	30		Fipecone acid
120.0	1		56	76	20		T hata
150.0	1	Positi	3.0	/.0	30		L-bela-
803	1	ve D '.'	0.2	11	20	E	Homoproline
131.1	1	Positi	9.2		20	NC E	N-Acetylputrescine
1/9	1	ve	7.5	2	10	E	
132.0	1	Positi	7.5	9.5	40	NC	trans-4-Hydroxy-
655		ve	- <b>-</b>	10	•	E	L-proline
132.0	1	Positi	8.7	10.	30	NC	Creatine
/68		ve		7		E	
132.1	1	Positi	5.2	7.2	20	NC	Leucine
019		ve				E	
132.1	1	Positi	5.5	7.5	20	NC	Isoleucine
019		ve				Е	
132.1	1	Positi	7.6	9.6	50	NC	Alanine betaine
019		ve				Е	
133.0	1	Positi	12.	15	10	NC	Ornithine
972		ve	3			Е	
136.0	1	Positi	1.9	3.9	50	NC	Adenine
618		ve				Е	
137.0	1	Positi	1.9	3.9	50	NC	Hypoxanthine
458		ve				E	
137.0	1	Positi	10.	12.	50	NC	1-
715		ve	3	3		Е	Methylnicotinamid
							e
138.0	1	Positi	8.9	10.	50	NC	Trigonelline
55		ve		9		Е	
139.0	1	Positi	4.5	6.5	10	NC	Urocanic acid
502		ve				Е	

146.0			1	Positi	4.7	6.7	20	NC	Guanidinobtyrate
924				ve				Е	
147.1			1	Positi	12	17	10	NC	Lysine
128				ve				Е	
148.0			1	Positi	6.5	8.5	20	NC	O-Acetyl-L-serine
605				ve				Е	
150.0			1	Positi	5.4	7.4	20	NC	Methionine
583				ve				Е	
153.0			1	Positi	2	4	50	NC	Xanthine
407				ve				Е	
156.0			1	Positi	10	13	20	NC	Histidine
768				ve				Е	
160.1			1	Positi	7.9	9.9	40	NC	4-Guanidinobutyric
337				ve				Е	acid
162.0			1	Positi	0.6	2.6	30	NC	O-Acetyl-L-
761				ve	4	4		Е	homoserine
162.0			1	Positi	5.9	7.9	20	NC	Glutamic acid
766				ve				Е	gamma methyl
									ester
162.1			1	Positi	12.	14.	40	NC	Carnitine
125				ve	2	2		Е	
166.0			1	Positi	4.5	6.5	20	NC	Phenylalanine
863				ve				Е	5
170.0			1	Positi	10.	12.	20	NC	1-Methylhistidine
924				ve	7	7		Е	5
170.0			1	Positi	14	16.	20	NC	3-Methylhistidine
924				ve		5		Е	
177.1			1	Positi	1.4	4	10	NC	Serotonin
021				ve				Е	
174.0			1	Positi	1.9	3.9	50	NC	2-
551				ve				Е	quinolinecarboxyli
									c acid
175.1			1	Positi	12.	14.	40	NC	Arginine
19				ve	1	1		Е	
176.1			1	Positi	8.8	10.	10	NC	Citrulline
03				ve		8		Е	
180.0			1	Positi	2.1	4.1	30	NC	Hippuric acid
655				ve				Е	11
181.0			1	Positi	0.8	2.8	50	NC	Theophylline
72				ve		_		Е	1 5
181.0			1	Positi	1	4	50	NC	1.7-
72			1	ve	-	-		E	Dimethylxanthine
182.0			1	Positi	5	7	20	NC	Tyrosine
812				ve	-	,		E	1,100.000
189 1			1	Positi	12	14	40	NC	Homoarginine
343			1	ve	3	3		F	Tomoarginine
575	1	1		νC	5	5	1		

189.1	1	Positi	10.	12.	40	NC	Nα-Acetyl-L-lysine
234		ve	3	3		Е	
189.1	1	Positi	8.4	10.	40	NC	N-epsilon-
234		ve	7	47		Е	Acetyllysine
189.1	1	Positi	14.	16.	40	NC	Targinine
344		ve	06	06		Е	5
189.1	1	Positi	12	14	30	NC	Asparagine butyl
344		ve				Е	ester
189.1	1	Positi	14.	17	30	NC	Νε,Νε,Νε-
598		ve	3			Е	Trimethyllysine
190.0	1	Positi	1.5	3.5	50	NC	Kynurenic acid
499		ve				Е	
195.0	1	Positi	0.8	2.8	50	NC	Caffeine
875		ve				Е	
204.1	1	Positi	11.	13.	40	NC	Acetyl-L-Carnitine
231		ve	9	9		Е	, j
218.1	1	Positi	11.	13.	40	NC	Propionyl-L-
537		ve	2	2		Е	Carnitine
232.1	1	Positi	10.	12.	40	NC	Butyryl-L-
783		ve	2	2		Е	Carnitine
232.1	1	Positi	10.	12.	40	NC	Isobutyryl-L-
783		ve	4	4		Е	Carnitine
246.2	1	Positi	9.3	11.	40	NC	Isovaleryl-L-
04		ve		3		Е	Carnitine
246.2	1	Positi	9.5	11.	40	NC	2-Methylbutyryl-L-
04		ve		5		Е	Carnitine
260.1	1	Positi	8.3	10.	40	NC	Hexanoyl-L-
855		ve		3		Е	Carnitine
282.1	1	Positi	8.2	10.	30	NC	1-Methyladenosine
201		ve		2		Е	
288.2	1	Positi	7.2	9.2	40	NC	Octanoyl-L-
172		ve				Е	Carnitine
316.2	1	Positi	6.9	8.9	40	NC	Decanoyl-L-
481		ve				Е	Carnitine
344.2	1	Positi	6.5	8.5	40	NC	Lauroyl-L-
796		ve				Е	Carnitine
372.3	1	Positi	5.9	7.9	40	NC	Myristoyl-L-
11		ve				Е	Carnitine
400.3	1	Positi	5.5	7.5	40	NC	Palmitoyl-L-
422		ve				Е	Carnitine
403.2	1	Positi	0.3	2.3	30	NC	Acetyl tributyl
326		ve	1	1		Е	citrate
466.3	1	Positi	4.4	6.4	20	NC	Glycocholic acid
163	-	ve	6	6		E	,
489.1	1	Positi	12.	14.	30	NC	CDP-Choline
146		ve	3	3		E	

583.2				1	Positi	2.3	4.3	30	NC		Biliverdin
551					ve				Е		
585.2				1	Positi	0.5	2.5	30	NC		Bilirubin
708					ve				Е		
79.04				1	Positi	8	10	20	NC		Glycine_IS
3					ve				Е		
110.0				1	Positi	7.5	9.5	20	NC		Serine_IS
568					ve				Е		
139.1				1	Positi	5.5	7.5	20	NC		Isoleucine_IS
189					ve				Е		
125.0				1	Positi	7	9	20	NC		Threonine_IS
759					ve				Е		
181.1				1	Positi	12.	14.	40	NC		Arginine_IS
388					ve	1	1		Е		
124.0				1	Positi	6.4	8.4	20	NC		Valine_IS
999					ve				Е		
153.1				1	Positi	12	17	10	NC		Lysine_IS
328					ve				Е		
171.1				1	Positi	12	14	40	NC		Carnitine-D9
689					ve				Е		
207.1				1	Positi	11.	13.	40	NC		Acetyl-L-
489					ve	9	9		Е		Carnitine-D3
221.1				1	Positi	11.	13.	40	NC		Propionyl-L-
726					ve	2	2		Е		Carnitine-D3
235.1				1	Positi	10.	12.	40	NC		Butyryl-L-
974					ve	2	2		Е		Carnitine-D3
255.2				1	Positi	9.2	11.	40	NC		Isobutyryl-L-
616					ve		2		Е		Carnitine-D9
403.3				1	Positi	5.4	7.4	30	NC		Palmitoyl-L-
605					ve				Е		Carnitine-D3
154.0				1	Positi	9.2	11.	30	NC		Glutamic Acid_IS
741					ve		2		Е		
153.0				1	Positi	8.2	10.	30	NC		Glutamine_IS
901					ve		2		Е		
147.0				1	Positi	8.2	10.	30	NC		Glutamine
764					ve		2		Е		
148.0				1	Positi	9.2	11.	30	NC		Glutamic acid
605					ve		2		Е		
Mass	Form	Form	Spec	С	Polar	Sta	En	(N)	(N)	Μ	Comment
[m/z]	ula	ula	ies	S	ity	rt	d	CE	CE	SX	
	[M]	type		[z		[mi	[mi		type	ID	
				]		n]	n]				
73.02				1	Nega	2.8	4.8	40	NC		Propionate
95					tive				E		
87.00				1	Nega	1.5	3.5	50	NC		Pyruvic acid
876					tive				Е		

89.02		1	Nega	3.1	5.1	40	NC	Lactic acid
441			tive				Е	
102.0		1	Nega	5	7	20	NC	N-Formylglycine
196			tive				Е	
103.0		1	Nega	2.4	4.4	30	NC	2-Hydroxybutyric
4			tive				Е	acid
103.0		1	Nega	2.8	4.8	30	NC	3-
4			tive				Е	Hydroxyisobutyric
								acid
103.0		1	Nega	3.3	6	30	NC	3-Hydroxybutyric
4			tive				Е	acid
105.0		1	Nega	4.4	6.4	20	NC	Glyceric acid
193			tive				E	
115.0		1	Nega	7.1	9.1	10	NC	Fumaric acid
037			tive				E	
116.0		1	Nega	5.7	7.7	30	NC	N-Acetylglycine
353			tive				E	
117.0		1	Nega	6.4	8.4	10	NC	Succinic acid
193			tive				Е	
128.0		1	Nega	5.9	7.9	30	NC	Pyroglutamic acid
353			tive				Е	
129.0		1	Nega	1.9	3.9	40	NC	Citraconic acid
193			tive	5	5		Е	
129.0		1	Nega	6	8	40	NC	Itaconic acid
193			tive				Е	
130.0		1	Nega	5.1	7.1	20	NC	N-Acetyl-L-alanine
509			tive				Е	
130.0		1	Nega	8.6	10.	30	NC	3-
619			tive	6	66		Е	Guanidinopropioni
								c acid
131.0		1	Nega	8	10	20	NC	Asparagine
462			tive				Е	
132.0		1	Nega	8.6	12	30	NC	Aspartic acid
302			tive				E	
133.0		1	Nega	7	10.	20	NC	Malic acid
142			tive		6		E	
137.0		1	Nega	0.5	2.5	50	NC	Salicylic acid
244			tive				E	
144.0		1	Nega	5.4	7.4	20	NC	4-
666			tive				E	Acetamidobutyric
								acid
145.0		1	Nega	6.7	8.7	20	NC	α-Ketoglutaric acid
142			tive				Е	
145.0		1	Nega	7	9	10	NC	3-Methylglutaric
506			tive				Е	acid
145.0		1	Nega	8.2	10.	20	NC	Glutamine

618		tive		2		Е		
146.0	1	Nega	5.4	7.4	30	NC	N	I-Acetyl-serine
459		tive				E		
146.0	1	Nega	9.2	11.	30	NC	G	lutamic acid
459		tive		2		E		
147.0	1	Nega	7.1	9.1	10	NC	2	-Hydroxyglutarate
294		tive				E		
151.0	1	Nega	0.5	2.5	10	NC	Ν	Iandelic acid
4		tive	5	5		E		
153.0	1	Nega	0.3	2.3	50	NC	2	,3-
193		tive				Е	D	Dihydroxybenzoic
							a	cid
153.0	1	Nega	0.5	2.5	50	NC	3	,4-
193		tive	1	1		E	D	Dihydroxybenzoic
							a	cid
160.0	1	Nega	5.5	7.5	10	NC	N	I-Methyl-L-
615		tive				Е	g	lutamic acid
160.0	1	Nega	9.8	11.	20	NC	2	-Aminoadipic acid
615		tive		8		E		-
161.0	1	Nega	6.6	8.6	20	NC	3	-Hydroxy-3-
455		tive				Е	m	nethylglutaric acid
167.0	1	Nega	2.6	4.6	50	NC	U	Jric acid
21		tive				Е		
173.0	1	Nega	6.1	8.1	20	NC	tr	ans-Aconitic acid
091		tive				Е		
174.0	1	Nega	8.9	10.	10	NC	N	I-Acetyl-L-
408		tive		9		Е	as	spartic acid
175.0	1	Nega	2.6	4.6	10	NC	A	scorbic acid
248		tive				Е		
176.0	1	Nega	2.3	4.3	30	NC	N	I-Formyl-L-
387		tive				E	n	nethionine
179.0	1	Nega	5.1	7.1	30	NC	Ν	lyo-
556		tive				E	ir	nositol/Fructose
181.0	1	Nega	3	5	40	NC	D	ulcitol/MANNIT
717		tive				Е	C	DL
182.0	1	Nega	0.5	2.5	40	NC	4	-Pyridoxic acid
459		tive	5	5		Е		
187.0	1	Nega	3.2	5.2	30	NC	А	zelaic acid
976		tive				E		
188.0	1	Nega	0.6	2.6	30	NC	3	-Indolepropionic
715		tive				Е	a	cid
190.0	1	Nega	2.9	4.9	20	NC	N	I-Acetyl-
543		tive				Е	n	nethionine
190.0	1	Nega	4.1	6.1	20	NC	5	-Hydroxyindole-
505		tive				Е	3	-acetic acid
191.0	1	Nega	8.9	15	30	NC	C	Citric acid

197			tive				Е	
191.0		1	Nega	8.9	15	30	NC	Isocitric acid
197			tive				Е	
191.0		1	Nega	5.5	7.8	50	NC	Quinic acid
561			tive				Е	
193.0		1	Nega	6.1	8.1	10	NC	Glucuronic acid
354			tive				Е	
195.0		1	Nega	6.1	8.1	30	NC	Gluconate
51		_	tive				E	
203.0		1	Nega	3.9	5.9	30	NC	Tryptophan
826		-	tive	0.12	0.15		E	
207.0		1	Nega	41	61	20	NC	Kynurenine
775		1	tive		0.1	20	E	Trynarennie
210.0		1	Nega	52	72	50	NC	3-Methoxy-I -
772		1	tive	5.2	1.2	50	E	tyrosine
212.0		1	Nega	0.2	22	50	NC	3-Indoxyl sulfate
018		1	tive	7	7	50	F	5 mdoxy1 sunate
218.1		1	Nega	45	65	40	NC	Pantothenic acid
034		1	tive	1.5	0.5	10	E	i untotneme ueru
239.0		1	Nega	10	12	30	NC	Cystine
165		1	tive	6	6	50	F	Cystille
308.0		1	Nega	6.8	88	20	NC	N-
987		1	tive	0.0	0.0	20	F	A cetylneuraminic
707			uve				L	acid
327.2		1	Nega	0.3	23	30	NC	Docosahevaenoic
327.2		1	tive	6	6	50	F	acid(DHA)
305.1		1	Nega	02	22	50	L NC	Pregnenolone
807		1	tive	6	6	50	F	sulfate
1/8 3		1	Nega	26	16	50	L NC	Glycoursodeoxych
060		1	tive	2.0	4.0	50	F	olic acid
152.0		1	Nogo	0.2	11	20		Glutamia A aid IS
505		1	tivo	9.2	11. 2	30	F INC	Olutanne Acid_15
152.0		1	Nogo	82	10	20		Glutamina IS
725		1	tivo	0.2	$\frac{10}{2}$	20	F INC	Olutainine_15
723		1	Nogo	2.0	2 5 0	20		Truntanhan IS
102		1	tivo	5.9	5.9	30		Tryptopnan_13
193		1	Nogo	15	25	50		Dumuyata IS
90.01		1	Inega	1.3	3.3	30		Pyruvate_15
0/		1	Nee	2.2	(	20		2
107.0		1	Nega	3.3	0	30		J Harden and Arten to H
334			uve				E	Hydroxybutyrate_1
150.0		1	Naat	67	07	20	NC	
130.0			inega	0./	ð./	20		VO_12
309		1	nve	7 1	0.1	10	E	
152.0			Nega	/.1	9.1	10		HG_IS
465			tive	7 1	0.1	10	E NG	
119.0		1	Nega	7.1	9.1	10	NC	Fumaric Acid_IS

169			tive				Е	
121.0		1	Nega	6.4	8.4	10	NC	Succinic Acid_IS
327			tive				Е	
197.0		1	Nega	8.9	15	30	NC	Citric Acid_IS
396			tive				Е	
137.0		1	Nega	8.9	12	30	NC	Aspartic Acid_IS
405			tive				Е	

Supplementary Table 4. Inclusion list for targeted lipidomics (PRM).

Mass	Form	Formu	Spe	CS	Polar	Start	End	(N)	(N)C	MS	Comment
[m/z]	ula	la type	cies	[z]	ity	[min	[min	CE	E	Х	
	[M]					]	]		type	ID	
344.2				1	Posit	1	2	30	NCE		AcCa 12:0
795					ive						
372.3				1	Posit	2.5	3.5	30	NCE		AcCa 14:0
108					ive						
370.2				1	Posit	1.4	2.4	30	NCE		AcCa 14:1
952					ive						
368.2				1	Posit	1	2	30	NCE		AcCa 14:2
795					ive						
400.3				1	Posit	4.1	6	30	NCE		AcCa 16:0
421					ive						
404.3				1	Posit	4.1	6	30	NCE		AcCa 16:0-
552					ive						13C4
403.3				1	Posit	4.1	6	30	NCE		AcCa 16:0-
606					ive						D3
398.3				1	Posit	2.9	4.5	30	NCE		AcCa 16:1
265					ive						
428.3				1	Posit	5.4	7.5	30	NCE		AcCa 18:0
734					ive						
426.3				1	Posit	4.3	6	30	NCE		AcCa 18:1
578					ive						
424.3				1	Posit	3.4	5	30	NCE		AcCa 18:2
421					ive						
456.4				1	Posit	6.9	7.9	30	NCE		AcCa 20:0
047					ive						
454.3				1	Posit	5.5	6.5	30	NCE		AcCa 20:1
891					ive						
452.3				1	Posit	4.6	5.6	30	NCE		AcCa 20:2
734					ive						
450.3				1	Posit	3.9	4.9	30	NCE		AcCa 20:3
578					ive						
448.3				1	Posit	3	4.3	30	NCE		AcCa 20:4
421					ive						
484.4				1	Posit	8.3	9.3	30	NCE		AcCa 22:0

36			ive					
476.3		1	Posit	4.3	5.3	30	NCE	AcCa 22:4
734			ive					
474.3		1	Posit	3.5	4.5	30	NCE	AcCa 22:5
578			ive					
472.3		1	Posit	3.1	4.1	30	NCE	AcCa 22:6
421			ive					
512.4		1	Posit	9.5	10.5	30	NCE	AcCa 24:0
673			ive					_
300.2		1	Posit	5.3	6.3	30	NCE	AEA 16:0
897		_	ive					
328.3		1	Posit	6.9	7.9	30	NCE	AEA 18:0
21		-	ive	015	,.,	50	TTOL	
326.3		1	Posit	54	64	30	NCE	AEA 18·1
054		-	ive	5.1	0	50	TTOL	
324.2		1	Posit	4.5	5.5	30	NCE	AEA 18:2
897		1	ive	1.5	5.5	50	TYCE	1111110.2
540.5		1	Posit	12.6	13.6	25	NCE	Cer
35		1	ive	12.0	15.0	20	TTEL	18:0:2/16:0
624.6		1	Posit	15.1	16.1	25	NCE	Cer
289		1	ive	10.1	10.1	20	TTEL	18:0:2/22:0
638.6		1	Posit	15.5	16.5	25	NCE	Cer
446		-	ive	10.0	10.0	20	TTOL	18:0:2/23:0
652.6		1	Posit	15.9	16.9	25	NCE	Cer
602		_	ive					18:0:2/24:0
650.6		1	Posit	14.9	15.9	25	NCE	Cer
446			ive					18:0;2/24:1
666.6		1	Posit	16.2	17.2	25	NCE	Cer
759			ive					18:0;2/25:0
482.4		1	Posit	10.2	11.2	25	NCE	Cer
568			ive					18:1;2/12:0
538.5		1	Posit	12.2	13.2	25	NCE	Cer
194			ive					18:1;2/16:0
566.5		1	Posit	13.1	14.1	25	NCE	Cer
507			ive					18:1;2/18:0
594.5		1	Posit	14	15	25	NCE	Cer
82			ive					18:1;2/20:0
622.6		1	Posit	14.8	15.8	25	NCE	Cer
133			ive					18:1;2/22:0
636.6		1	Posit	15.2	16.2	25	NCE	Cer
289			ive					18:1;2/23:0
650.6		1	Posit	15.6	16.6	25	NCE	Cer
446			ive					18:1;2/24:0
648.6		1	Posit	14.6	15.6	25	NCE	Cer
289			ive					18:1;2/24:1
646.6		1	Posit	13.9	14.9	25	NCE	Cer

133					ive						18:1;2/24:2
678.6				1	Posit	16.3	17.3	25	NCE		Cer
759					ive						18:1;2/26:0
676.6				1	Posit	15.3	16.3	25	NCE		Cer
602					ive						18:1;2/26:1
620.5				1	Posit	14	15	25	NCE		Cer
976					ive						18:2;2/22:0
634.6				1	Posit	14.4	15.4	25	NCE		Cer
133					ive						18:2;2/23:0
648.6				1	Posit	14.8	15.8	25	NCE		Cer
289					ive						18:2;2/24:0
646.6				1	Posit	13.9	14.9	25	NCE		Cer
133					ive						18:2;2/24:1
662.6				1	Posit	15.2	16.2	25	NCE		Cer
446					ive						18:2;2/25:0
636.6				1	Posit	15.1	16.1	25	NCE		Cer
289					ive						d19:1_22:0
650.6				1	Posit	15.4	16.4	25	NCE		Cer
446					ive						d19:1_23:0
664.6				1	Posit	15.7	16.7	25	NCE		Cer
61					ive						d19:1_24:0
662.6				1	Posit	14.7	15.7	25	NCE		Cer
446					ive						d19:1_24:1
608.6				1	Posit	15.6	16.6	25	NCE		Cer
341					ive						m18:0_22:
(0)()()						1.6.0	1 - 0		MOR		0
636.6				1	Posit	16.2	17.2	25	NCE		Cer
654					ıve						m18:0_24:
(24.6				1	D i	15.0	16.0	25	NOT		0
634.6				1	Posit	15.2	16.2	25	NCE		Cer
497					ıve						m18:0_24:
(0)((				1	Denit	14.0	15.0	25	NCE		l Car
000.0				1	Posit	14.8	15.8	25	NCE		Cer = 18.1 - 22.
10					ive						$1116:1_{22}$
624.6				1	Dogit	15.6	16.6	25	NCE		0 Cor
108				1	ive	15.0	10.0	23	INCE		m18.1 24.
490					IVC						0
650.6				1	Posit	16.5	17.5	25	NCF		Cer
812				1	ive	10.5	17.5	23	INCL		m19.0 24.
											0
648.6			<u> </u>	1	Posit	154	164	25	NCE		Čer
653				1	ive	12.1	10.1				m19:0 24
											1
6126	1	1	1		1		1	1	1	1	-
1042.0				1	Posit	19.3	20.3	10	NCE		ChE 16:0

640.6		1	Posit	18.4	19.4	10	NCE	ChE 16:1
027			ive					
670.6		1	Posit	19.9	20.9	10	NCE	ChE 18:0
497			ive					
668.6		1	Posit	19.1	20.5	10	NCE	ChE 18:1
34			ive					
675.6		1	Posit	19.1	20.5	10	NCE	ChE
779			ive					18:1D7
666.6		1	Posit	18.6	19.6	10	NCE	ChE 18:2
184			ive					
664.6		1	Posit	18	19	10	NCE	ChE 18:3
027			ive					
696.6		1	Posit	19.7	20.7	10	NCE	ChE 20:1
653			ive					
694.6		1	Posit	19.3	20.3	10	NCE	ChE 20:2
497			ive	10.6	10.6			
692.6		1	Posit	18.6	19.6	10	NCE	ChE 20:3
34			1ve	10.0	10.5	10	MOD	
690.6		1	Posit	18.2	19.5	10	NCE	ChE 20:4
184			1ve	1 - 6	10.6	10	MOD	
688.6		1	Posit	17.6	18.6	10	NCE	ChE 20:5
027		1	1ve	10.7	10.7	10	NOT	
/18.6		I	Posit	18.7	19.7	10	NCE	ChE 22:4
49/		1	1Ve	10.1	10.5	10	NCE	C1 E 22.5
/10.0		1	Posit	18.1	19.5	10	NCE	CnE 22:5
34 714.6		1	Dogit	10	10	10	NCE	ChE 22.6
184		1	ivo	10	19	10	NCE	CIIE 22.0
863.6		1	Posit	16.3	173	30	NCE	CoO10
912		1	ive	10.5	17.5	50	INCL	00010
584.5		1	Posit	12.8	13.8	20	NCF	 DAG 14.0-
249		T	ive	12.0	15.0	20	TTEL	18.1
605 5		1	Posit	13.2	14.2	20	NCE	DAG 15:0-
844		1	ive	13.2	1 1.2	20	TTOL	18:1D7
586.5		1	Posit	13.7	14.7	20	NCE	 DAG 16:0-
405		-	ive	1017	1,		1.02	16:0
584.5		1	Posit	12.8	13.8	20	NCE	DAG 16:0-
249			ive	_		_		16:1
614.5		1	Posit	14.5	15.5	20	NCE	 DAG 16:0-
718			ive					18:0
612.5		1	Posit	13.6	14.6	20	NCE	DAG 16:0-
562			ive					18:1
610.5		1	Posit	12.9	13.9	20	NCE	DAG 16:0-
405			ive					18:2
610.5		1	Posit	12.8	13.8	20	NCE	DAG 16:1-
405			ive					18:1

608.5		1	Posit	12.2	13.2	20	NCE		DAG 16:1-
249			ive						18:2
642.6		1	Posit	15.5	16.5	20	NCE		DAG 18:0-
031			ive						18:0
640.5		1	Posit	14.5	15.5	20	NCE		DAG 18:0-
875			ive						18:1
638.5		1	Posit	13.7	14.7	20	NCE		DAG 18:0-
718			ive						18:2
638.5		1	Posit	13.6	14.6	20	NCE		DAG 18:1-
718			ive						18:1
636.5		1	Posit	12.9	13.9	20	NCE		DAG 18:1-
562			ive						18:2
634.5		1	Posit	12.4	13.4	20	NCE		DAG 18:1-
405			ive						18:3
668.6		1	Posit	14.3	15.3	20	NCE		DAG 18:1-
188			ive						20:0
662.5		1	Posit	13.1	14.1	20	NCE		DAG 18:1-
718			ive						20:3
660.5		1	Posit	12.7	13.7	20	NCE		DAG 18:1-
562			ive						20:4
634.5		1	Posit	12.4	13.4	20	NCE		DAG 18:2-
405			ive						18:2
632.5		1	Posit	11.6	12.6	20	NCE		DAG 18:2-
249			ive						18:3
806.5		1	Posit	8.9	9.9	25	NCE		Hex2Cer
624			ive						18:1;2/12:0
834.5		1	Posit	10.1	11.1	25	NCE		Hex2Cer
937			ive						18:1;2/14:0
862.6		1	Posit	11.1	12.1	25	NCE		Hex2Cer
25			ive					ļ	18:1;2/16:0
890.6		1	Posit	12.1	13.1	25	NCE		Hex2Cer
563		-	ive						18:1;2/18:0
918.6		1	Posit	12.9	13.9	25	NCE		Hex2Cer
876		4	ıve	10 -			NGE		18:1;2/20:0
946.7		1	Posit	13.7	14.7	25	NCE		Hex2Cer
189		1	1ve	1.4.4	1.5.4	0.5	NGE		18:1;2/22:0
974.7		1	Posit	14.4	15.4	25	NCE		Hex2Cer
502		1	1ve	10.5	145	0.5	NGE		18:1;2/24:0
972.7		1	Posit	13.5	14.5	25	NCE		Hex2Cer
346		1	1ve	12.0	12.0	0.5	NOT	<b> </b>	18:1;2/24:1
970.7		1	Posit	12.8	13.8	25	NCE		Hex2Cer
189		1	1ve	10.2	11.0	25	NOT	<u> </u>	18:1;2/24:2
860.6		1	Posit	10.2	11.2	23	NCE		Hex2Cer
1024		1	1ve	10.0	11.0	25	NCE	<u> </u>	18:2;2/16:0
1024.		1	Posit	10.8	11.8	23	NCE		Hex3Cer
0/8			ıve						18:1;2/16:0

1052.		1	Posit	11.8	12.8	25	NCE	Hex3Cer
709			ive					18:1;2/18:0
1080.		1	Posit	12.7	13.7	25	NCE	Hex3Cer
74			ive					18:1;2/20:0
1108.		1	Posit	13.4	14.4	25	NCE	Hex3Cer
772			ive					18:1;2/22:0
1136.		1	Posit	14.2	15.2	25	NCE	Hex3Cer
803			ive					18:1;2/24:0
1134.		1	Posit	13.2	14.2	25	NCE	Hex3Cer
787			ive					18:1;2/24:1
644.5		1	Posit	9.3	10.3	25	NCE	HexCer
096			ive					18:1;2/12:0
700.5		1	Posit	11.5	12.5	25	NCE	HexCer
722			ive					18:1;2/16:0
728.6		1	Posit	12.4	13.4	25	NCE	HexCer
035			ive					18:1;2/18:0
756.6		1	Posit	13.2	14.2	25	NCE	HexCer
348			ive					18:1;2/20:0
784.6		1	Posit	14	15	25	NCE	HexCer
661			ive					18:1;2/22:0
798.6		1	Posit	14.4	15.4	25	NCE	HexCer
818			ive					18:1;2/23:0
812.6		1	Posit	14.8	15.8	25	NCE	HexCer
974			ive					18:1;2/24:0
810.6		1	Posit	13.8	14.8	25	NCE	HexCer
818			ive					18:1;2/24:1
808.6		1	Posit	13.1	14.1	25	NCE	HexCer
661			ive					18:1;2/24:2
782.6		1	Posit	13.3	14.3	25	NCE	HexCer
505			ive					18:2;2/22:0
810.6		1	Posit	14.1	15.1	25	NCE	HexCer
818			ive					18:2;2/24:0
808.6		1	Posit	13.1	14.1	25	NCE	HexCer
661			ive					18:2;2/24:1
468.3		1	Posit	1.5	3	30	NCE	LPC 14:0
085			ive					
454.3		1	Posit	2.4	3.4	30	NCE	LPC 14:0e
292			ive					
482.3		1	Posit	2.4	4	30	NCE	LPC 15:0
241			ive					
496.3		1	Posit	3.5	5.5	30	NCE	 LPC 16:0
398			ive					
482.3		1	Posit	4.5	6	30	NCE	 LPC 16:0e
605			ive	-				
494.3		1	Posit	1.9	3.9	30	NCE	LPC 16:1
241			ive					

480.3				1	Posit	4.5	5.5	30	NCE	LPC 16:1e
449					ive					
478.3				1	Posit	3.9	4.9	30	NCE	LPC 16:2e
292					ive					
510.3				1	Posit	4.2	6.2	30	NCE	LPC 17:0
554					ive					
508.3				1	Posit	2.9	4.9	30	NCE	LPC 17:1
398					ive					
524.3				1	Posit	5.2	7.2	30	NCE	LPC 18:0
711					ive					
510.3				1	Posit	6.4	7.4	30	NCE	LPC 18:0e
918					ive					
522.3				1	Posit	3.9	5.9	30	NCE	LPC 18:1
554					ive					
529.3				1	Posit	3.9	5.9	30	NCE	LPC
994					ive					18:1D7
508.3				1	Posit	4.7	6	30	NCE	LPC 18:1e
762					ive					
520.3				1	Posit	2.6	4.6	30	NCE	LPC 18:2
398					ive					
518.3				1	Posit	1.8	3	30	NCE	LPC 18:3
241					ive					
538.3				1	Posit	6	7.5	30	NCE	LPC 19:0
867					ive	1.0				
536.3				1	Posit	4.9	6.5	30	NCE	LPC 19:1
711				1	ıve	-	0.5	20	NGE	
552.4				l	Posit	1	8.5	30	NCE	LPC 20:0
024				1	1ve	7.0	0.0	20	NCE	
538.4				I	Posit	7.9	8.9	30	NCE	LPC 20:0e
231				1	1ve	5.2	7	20	NCE	
550.3				1	Posit	5.3	/	30	NCE	LPC 20:1
80/				1	1ve	4.2	5.(	20	NCE	L DC 20.2
548.5				1	POSIT	4.3	5.6	30	NCE	LPC 20:2
/11				1	lve Degit	2.5	5	20	NCE	L DC 20.2
540.5				I	Posit	3.3	3	30	NCE	LPC 20:3
544 2				1	Degit	26	4	20	NCE	L DC 20.4
200				1	POSIL	2.0	4	50	NCE	LPC 20:4
542.2				1	Dogit	1.0	2	20	NCE	L DC 20.5
242.3				1	rosit	1.0	5	50	INCE	LFC 20:3
580 /	+	+		1	Dogit	Q /	0.7	20	NCE	I DC 22.0
237				1	FUSIL	0.4	7./	50	INCE	LFC 22.0
579 /				1	Dogit	71	<b>Q</b> 1	30	NCE	I DC 22.1
18				I		/.1	0.1	50	INCL	LFC 22.1
574.3				1	Posit	10	5.0	30	NCE	I PC 22.2
867				I		7.7	5.7	50	INCL	LI C 22.3
007	1				110		1	1	1 1	

572.3		1	Posit	4.2	5.2	30	NCE	LPC 22:4
711			ive					
570.3		1	Posit	3.2	4.7	30	NCE	LPC 22:5
554			ive					
568.3		1	Posit	2.4	4	30	NCE	LPC 22:6
398			ive					
608.4		1	Posit	9.7	11	30	NCE	LPC 24:0
65			ive					
606.4		1	Posit	8.5	9.5	30	NCE	LPC 24:1
493			ive					
604.4		1	Posit	7.3	8.3	30	NCE	LPC 24:2
337			ive					
426.2		1	Posit	1.8	2.8	30	NCE	LPE 14:0
615			ive					
454.2		1	Posit	3.7	5	30	NCE	LPE 16:0
928			ive					
482.3		1	Posit	5.4	6.7	30	NCE	LPE 18:0
241			ive			•		
480.3		1	Posit	4	5.3	30	NCE	LPE 18:1
085			1ve			•	NGE	
487.3		1	Posit	4	5.3	30	NCE	LPE
524		1	1ve	2.6	_	20	NGE	18:1D7
478.2		1	Posit	2.6	4	30	NCE	LPE 18:2
928		1	1ve	2.4	4 7	20	NCE	
504.3		1	Posit	3.4	4./	30	NCE	LPE 20:3
502.2		1	Degit	26	2.0	20	NCE	L DE 20.4
028		1	ivo	2.0	5.9	30	NCE	LFE 20.4
526.2		1	Posit	2.5	38	30	NCE	I DE 22.6
920.2		1	ive	2.5	5.0	30	INCL	LI L 22.0
647.5		1	Posit	8.8	10.8	30	NCE	SM(d30.1)
123		1	ive	0.0	10.0	50	NCL	5101(050.1)
645.4		1	Posit	7.6	86	30	NCE	SM(d30.2)
966		1	ive	7.0	0.0	50	TUCL	5101(050.2)
677.5		1	Posit	10.5	11.5	30	NCE	SM(d32:0)
592		-	ive	10.0		20		211(00210)
675.5		1	Posit	10	12	30	NCE	SM(d32:1)
436			ive					(
673.5		1	Posit	8.9	10.5	30	NCE	SM(d32:2)
279			ive					
705.5		1	Posit	11.5	12.5	30	NCE	SM(d34:0)
905			ive					, ,
703.5		1	Posit	11.1	12.5	30	NCE	SM(d34:1)
749			ive					
701.5		1	Posit	10.1	12	30	NCE	SM(d34:2)
592			ive					

699.5			1	Posit	9.3	11	30	NCE	SM(d34:3)
436				ive					
733.6			1	Posit	12.2	13.6	30	NCE	SM(d36:0)
218				ive					
731.6			1	Posit	12.1	13.5	30	NCE	SM(d36:1)
062				ive					
729.5			1	Posit	11	13	30	NCE	SM(d36:2)
905				ive					
738.6			1	Posit	11	13	30	NCE	SM(d36:2
47				ive					 D9)
727.5			1	Posit	10.4	12.4	30	NCE	SM(d36:3)
749				ive					
759.6			1	Posit	13	14.5	30	NCE	SM(d38:1)
375				ive					
757.6			1	Posit	12.2	13.5	30	NCE	SM(d38:2)
218				1ve		10	•	NAT	
755.6			1	Posit	11.5	13	30	NCE	SM(d38:3)
062			1	1ve	12.0	16	20	NCE	 O(140,1)
787.6			I	Posit	13.8	16	30	NCE	SM(d40:1)
688			1	1ve	10	1.4.5	20	NGE	
785.6			I	Posit	13	14.5	30	NCE	SM(d40:2)
531			1	1ve	10	12.5	20	NOT	CN(140.2)
/83.0			I	Posit	12	13.5	30	NCE	SM(d40:3)
3/3			1	lve Degit	14.6	16.6	20	NCE	SM(442.1)
001			1	POSIL	14.0	10.0	30	NCE	SIVI(042.1)
<u>9126</u>			1	Dogit	12.5	15 5	20	NCE	SM(442.2)
813.0			1	ive	13.5	13.5	30	NCL	SWI(042.2)
811.6			1	Posit	12.8	1/1 5	30	NCE	$SM(442\cdot 3)$
688			1	ive	12.0	14.5	50	INCL	$51 \times 1(0+2.5)$
845 7			1	Posit	16.2	17.2	30	NCE	SM(d44.0)
47			T	ive	10.2	17.2	50	TICL	514(4++.0)
843 7			1	Posit	153	17	30	NCE	$SM(d44\cdot1)$
314			1	ive	10.0	17	50	THEL	511(41111)
841.7			1	Posit	14.4	16	30	NCE	SM(d44:2)
157			-	ive		10	20		211(2112)
839.7			1	Posit	13.6	15	30	NCE	SM(d44:3)
001				ive		_			
288.2			1	Posit	2	4	20	NCE	SPH d17:0
897				ive					
286.2		i t	1	Posit	2	3.5	20	NCE	SPH d17:1
741				ive					
302.3			1	Posit	3	5	20	NCE	 SPH d18:0
054				ive					
300.2			1	Posit	3	4.5	20	NCE	SPH d18:1
897				ive					

352.2		1	Posit	1	3	20	NCE	SPHP
247			ive					d16:1
368.2		1	Posit	1	5	20	NCE	SPHP
56			ive					d17:0
366.2		1	Posit	1	5	20	NCE	SPHP
404			ive					d17:1
382.2		1	Posit	2	6	20	NCE	SPHP
717			ive					d18:0
380.2		1	Posit	2	5	20	NCE	SPHP
56			ive					d18:1
378.2		1	Posit	1	4	20	NCE	SPHP
404			ive					d18:2
766.6		1	Posit	16.8	17.8	20	NCE	TAG 12:0-
919			ive					14:0-18:1
780.7		1	Posit	17.1	18.1	20	NCE	TAG 12:0-
076			ive					15:0-18:1
768.7		1	Posit	17.6	18.6	20	NCE	TAG 12:0-
076			ive					16:0-16:0
796.7		1	Posit	18.1	19.1	20	NCE	TAG 12:0-
389			ive					16:0-18:0
794.7		1	Posit	17.4	18.4	20	NCE	TAG 12:0-
232			ive					16:0-18:1
792.7		1	Posit	16.9	17.9	20	NCE	TAG 12:0-
076			ive					16:0-18:2
818.7		1	Posit	17	18	20	NCE	TAG 12:0-
232			ive					18:1-18:2
816.7		1	Posit	16.4	17.4	20	NCE	TAG 12:0-
076			ive					18:1-18:3
808.7		1	Posit	17.7	18.7	20	NCE	TAG 14:0-
389			ive					15:0-18:1
806.7		1	Posit	17.2	18.2	20	NCE	TAG 14:0-
232			ive					15:0-18:2
796.7		1	Posit	18.2	19.2	20	NCE	TAG 14:0-
389			ive					16:0-16:0
810.7		1	Posit	18.4	19.4	20	NCE	TAG 14:0-
545			ive					16:0-17:0
824.7		1	Posit	18.9	19.9	20	NCE	TAG 14:0-
702			ive					16:0-18:0
822.7		1	Posit	18.2	19.2	20	NCE	TAG 14:0-
545	 		ive					16:0-18:1
820.7	 	1	Posit	17.5	18.5	20	NCE	TAG 14:0-
389			ive					16:0-18:2
868.7		1	Posit	17	18	20	NCE	TAG 14:0-
389			ive					16:0-22:6
834.7	 	1	Posit	17.7	18.7	20	NCE	TAG 14:0-
545			ive					17:1-18:1

848.7		1	Posit	18	19	20	NCE	TAG 14:0-
702			ive					18:1-18:1
844.7		1	Posit	16.9	17.9	20	NCE	TAG 14:0-
389			ive					18:2-18:2
842.7		1	Posit	16.5	17.5	20	NCE	TAG 14:0-
232			ive					18:2-18:3
820.7		1	Posit	17.5	18.5	20	NCE	TAG 14:1-
389			ive					16:0-18:1
840.7		1	Posit	15.9	16.9	20	NCE	TAG 14:1-
076			ive					18:2-18:3
932.8		1	Posit	19.8	20.8	20	NCE	TAG 14:2-
641			ive					20:0-22:0
838.7		1	Posit	19	20	20	NCE	TAG 15:0-
858			ive					16:0-18:0
836.7		1	Posit	18.4	19.4	20	NCE	TAG 15:0-
702			ive					16:0-18:1
834.7		1	Posit	17.7	18.7	20	NCE	TAG 15:0-
545			ive					16:0-18:2
832.7		1	Posit	17.2	18.2	20	NCE	TAG 15:0-
389			ive					16:0-18:3
806.7		1	Posit	17.2	18.2	20	NCE	TAG 15:0-
232			ive					16:1-16:1
832.7		1	Posit	17.2	18.2	20	NCE	TAG 15:0-
389			ive					16:1-18:2
862.7		1	Posit	18.3	19.3	20	NCE	TAG 15:0-
858			ive					18:1-18:1
860.7		1	Posit	17.8	18.8	20	NCE	TAG 15:0-
702			ive					18:1-18:2
858.7		1	Posit	17.3	18.3	20	NCE	TAG 15:0-
545			ive					18:2-18:2
856.7		1	Posit	16.8	17.8	20	NCE	TAG 15:0-
389			ive					18:2-18:3
836.7		1	Posit	18.4	19.4	20	NCE	TAG 16:0-
702			ive					16:0-17:1
852.8		1	Posit	19.5	20.5	20	NCE	TAG 16:0-
015			ive					16:0-18:0
850.7		1	Posit	18.7	19.7	20	NCE	TAG 16:0-
858			ive					16:0-18:1
848.7		1	Posit	18.2	19.2	20	NCE	TAG 16:0-
702			ive					16:0-18:2
846.7		1	Posit	18	19	20	NCE	TAG 16:0-
545			ive					16:0-18:3
844.7		1	Posit	16.9	17.9	20	NCE	TAG 16:0-
389			ive					16:1-18:3
866.8		1	Posit	19.6	20.6	20	NCE	TAG 16:0-
171			ive					17:0-18:0

864.8		1	Posit	18.9	19.9	20	NCE		TAG 16:0-
015			ive						17:0-18:1
862.7		1	Posit	18.3	19.3	20	NCE		TAG 16:0-
858			ive						17:1-18:1
860.7		1	Posit	17.8	18.8	20	NCE		TAG 16:0-
702			ive						17:1-18:2
880.8		1	Posit	19.8	20.8	20	NCE		TAG 16:0-
328			ive						18:0-18:0
878.8		1	Posit	19.3	20.3	20	NCE		TAG 16:0-
171			ive						18:0-18:1
908.8		1	Posit	20.4	21.4	20	NCE		TAG 16:0-
641			ive						18:0-20:0
936.8		1	Posit	20.7	21.7	20	NCE		TAG 16:0-
954			ive						18:0-22:0
876.8		1	Posit	18.6	19.6	20	NCE		TAG 16:0-
015			ive						18:1-18:1
874.7		1	Posit	18.1	19.1	20	NCE		TAG 16:0-
858			ive						18:1-18:2
872.7		1	Posit	17.5	18.5	20	NCE		TAG 16:0-
702			ive						18:1-18:3
898.7		1	Posit	17.9	18.9	20	NCE		TAG 16:0-
858			ive						18:1-20:4
924.8		1	Posit	17.8	18.8	20	NCE		TAG 16:0-
015			ive						18:1-22:5
922.7		1	Posit	17.7	18.7	20	NCE		TAG 16:0-
858			ive						18:1-22:6
872.7		1	Posit	17.5	18.5	20	NCE		TAG 16:0-
702			ive						18:2-18:2
870.7		1	Posit	17.1	18.1	20	NCE		TAG 16:0-
545			ive						18:2-18:3
868.7		1	Posit	16.6	17.6	20	NCE		TAG 16:0-
389			ive						18:3-18:3
944.7		1	Posit	16.5	17.5	20	NCE		TAG 16:0-
702			ive						20:4-22:6
892.8		1	Posit	19.4	20.4	20	NCE		TAG 17:0-
328			ive						18:0-18:1
890.8		1	Posit	18.9	19.9	20	NCE		TAG 17:0-
171			ive						18:1-18:1
888.8		1	Posit	18.4	19.4	20	NCE		TAG 17:0-
015			ive					ļ	18:1-18:2
886.7		1	Posit	17.8	18.8	20	NCE		TAG 17:0-
858			ive					ļ	18:1-18:3
884.7		1	Posit	17.2	18.2	20	NCE		TAG 17:0-
702			ive						18:2-18:3
910.7		1	Posit	17.7	18.7	20	NCE		TAG 17:0-
858			ive						18:2-20:4

890.8		1	Posit	18.9	19.9	20	NCE	TAG 17:1-
171			ive					18:0-18:1
888.8		1	Posit	18.4	19.4	20	NCE	TAG 17:1-
015			ive					18:1-18:1
886.7		1	Posit	17.8	18.8	20	NCE	TAG 17:1-
858			ive					18:1-18:2
910.7		1	Posit	17.7	18.7	20	NCE	TAG 17:1-
858			ive					18:1-20:4
884.7		1	Posit	17.2	18.2	20	NCE	TAG 17:1-
702			ive					18:2-18:2
908.8		1	Posit	20.3	21.3	20	NCE	TAG 18:0-
641			ive					18:0-18:0
906.8		1	Posit	19.7	20.7	20	NCE	TAG 18:0-
484			ive					18:0-18:1
936.8		1	Posit	20.7	21.7	20	NCE	TAG 18:0-
954			ive					18:0-20:0
928.8		1	Posit	18.6	19.6	20	NCE	TAG 18:0-
328			ive					18:0-20:4
904.8		1	Posit	19.3	20.3	20	NCE	TAG 18:0-
328			ive					18:1-18:1
902.8		1	Posit	18.7	19.7	20	NCE	TAG 18:0-
171			ive					18:1-18:2
920.8		1	Posit	19.9	20.9	20	NCE	TAG 18:0-
641			ive					18:1-19:0
918.8		1	Posit	19.4	20.4	20	NCE	TAG 18:0-
484			ive					18:1-19:1
934.8		1	Posit	20.1	21.1	20	NCE	TAG 18:0-
797			ive					18:1-20:0
928.8		1	Posit	18.6	19.6	20	NCE	TAG 18:0-
328			ive					18:1-20:3
962.9		1	Posit	20.6	21.6	20	NCE	TAG 18:0-
11			ive					18:1-22:0
954.8		1	Posit	18.9	19.9	20	NCE	TAG 18:0-
484			ive					18:1-22:4
952.8		1	Posit	18.3	19.3	20	NCE	TAG 18:0-
328			ive					18:1-22:5
900.8		1	Posit	18.2	19.2	20	NCE	TAG 18:0-
015			ive					18:2-18:2
916.8		1	Posit	18.9	19.9	20	NCE	TAG 18:0-
328			ive					18:2-19:1
948.8		1	Posit	17.6	18.6	20	NCE	TAG 18:0-
015			ive					18:2-22:6
902.8		1	Posit	18.7	19.7	20	NCE	TAG 18:1-
171			ive	-				18:1-18:1
900.8		1	Posit	18	19	20	NCE	TAG 18:1-
015			ive					18:1-18:2

898.7		1	Posit	17.5	18.5	20	NCE	TAG 18:1-
858			ive					18:1-18:3
932.8		1	Posit	19.8	20.8	20	NCE	TAG 18:1-
641			ive					18:1-20:0
930.8		1	Posit	19	20	20	NCE	TAG 18:1-
484			ive					18:1-20:1
926.8		1	Posit	18.3	19.3	20	NCE	TAG 18:1-
171			ive					18:1-20:3
960.8		1	Posit	20.3	21.3	20	NCE	TAG 18:1-
954			ive					18:1-22:0
958.8		1	Posit	19.7	20.7	20	NCE	TAG 18:1-
797			ive					18:1-22:1
952.8		1	Posit	18.3	19.3	20	NCE	TAG 18:1-
328			ive					18:1-22:4
950.8		1	Posit	17.8	18.8	20	NCE	TAG 18:1-
171			ive					18:1-22:5
974.9		1	Posit	20.3	21.3	20	NCE	TAG 18:1-
11			ive					18:1-23:0
986.9		1	Posit	20.1	21.1	20	NCE	TAG 18:1-
11			ive					18:1-24:1
1016.		1	Posit	20.8	21.8	20	NCE	TAG 18:1-
958			ive					 18:1-26:0
896.7		1	Posit	17	18	20	NCE	TAG 18:1-
702			ive					 18:2-18:3
930.8		1	Posit	19.2	20.2	20	NCE	TAG 18:1-
484			ive					18:2-20:0
928.8		1	Posit	18.6	19.6	20	NCE	TAG 18:1-
328			ive					18:2-20:1
922.7		1	Posit	17.3	18.3	20	NCE	TAG 18:1-
858			ive					 18:2-20:4
958.8		1	Posit	19.7	20.7	20	NCE	TAG 18:1-
797			ive					 18:2-22:0
956.8		1	Posit	19	20	20	NCE	TAG 18:1-
641			ive					18:2-22:1
948.8		1	Posit	17.3	18.3	20	NCE	TAG 18:1-
015			ive					18:2-22:5
946.7		1	Posit	17.1	18.1	20	NCE	TAG 18:1-
858			ive					18:2-22:6
986.9		1	Posit	20.1	21.1	20	NCE	TAG 18:1-
11			ive					18:2-24:0
984.8		1	Posit	19.5	20.5	20	NCE	TAG 18:1-
954			ive					18:2-24:1
1014.		1	Posit	20.5	21.5	20	NCE	TAG 18:1-
942			ive				<u> </u>	18:2-26:0
1012.		1	Posit	19.9	20.9	20	NCE	TAG 18:1-
927			ive					18:2-26:1

896.7		1	Posit	17	18	20	NCE	TAG 18:2-
702			ive					18:2-18:2
894.7		1	Posit	16.4	17.4	20	NCE	TAG 18:2-
545			ive					18:2-18:3
928.8		1	Posit	18.6	19.6	20	NCE	TAG 18:2-
328			ive					18:2-20:0
920.7		1	Posit	16.8	17.8	20	NCE	TAG 18:2-
702			ive					18:2-20:4
944.7		1	Posit	16.5	17.5	20	NCE	TAG 18:2-
702			ive					18:2-22:6
892.7		1	Posit	15.9	16.9	20	NCE	TAG 18:2-
389			ive					18:3-18:3
920.7		1	Posit	16.8	17.8	20	NCE	TAG 18:2-
702			ive					18:3-20:3
918.7		1	Posit	16.3	17.3	20	NCE	TAG 18:2-
545			ive					18:3-20:4
829.7		1	Posit	18.2	19.2	20	NCE	TG
985			ive					15:0_18:1
								D7_15:0
720.5		1	Posit	12.6	14	30	NCE	PC(16:0e_
902			ive	7				16:0)
768.5		1	Posit	11.8	12.8	30	NCE	PC(16:0e
901			ive	5	5			20:4)
796.6		1	Posit	12.5	14	30	NCE	PC(16:0e
215			ive	_				22:4)
748.6		1	Posit	13.5	14.5	30	NCE	PC(18:0e
215		-	ive	3	3	50	TICL	16.0)
774.6		1	Posit	13.5	14.5	30	NCE	PC(18.0e)
371		1	ive	13.5	1	50	ICL	10(10.00 - 18.1)
709.6		1	Dogit	12.0	1/0	20	NCE	DC(18.0)
790.0		1	ive	15.0	14.0	50	NCE	$PC(10.0e_{-})$
924 (		1	Denit	12.5	J 14.5	20	NCE	20.3
824.6		1	Posit	13.5	14.5	30	NCE	PC(18:0e_
528			ive	10.1	12.1	•	MAT	22:4)
820.6		1	Posit	12.4	13.4	30	NCE	PC(18:0e_
21			ıve	7	7			22:6)
702.5		1	Posit	12.7	13.7	30	NCE	PE(16:0p_
432			ive	4	4			18:1)
700.5		1	Posit	12.1	13.1	30	NCE	PE(16:0p_
275			ive					18:2)
724.5		1	Posit	11.9	12.9	30	NCE	PE(16:0p_
275			ive	5	5			20:4)
722.5		1	Posit	11.3	12.3	30	NCE	PE(16:0p_
119			ive	7	7			20:5)
752.5		1	Posit	12.5	14	30	NCE	PE(16:0p_
58			ive					22:4)

748.5				1	Posit	11.7	12.7	30	NCE		PE(16:0p
275					ive	1	1				22:6)
730.5				1	Posit	13.5	14.5	30	NCE		PE(18:0p
745					ive	6	6				18:1)
728.5				1	Posit	13.2	14.2	30	NCE		PE(18:0p
588					ive						18:2)
752.5				1	Posit	12.7	13.7	30	NCE		PE(18:0p
587					ive						20:4)
780.5				1	Posit	13.3	14.3	30	NCE		PE(18:0p
902					ive	1	1				22:4)
778.5				1	Posit	12.7	13.7	30	NCE		PE(18:0p
745					ive	9	9				22:5)
776.5				1	Posit	12.5	13.5	30	NCE		PE(18:0p
588					ive	6	6				22:6)
750.5				1	Posit	11.8	13	30	NCE		PE(18:1p
432					ive						20:4)
774.5				1	Posit	11.6	12.6	30	NCE		PE(18:1p_
411					ive	5	5				22:6)
753.6				1	Posit	11.5	13	30	NCE		PC(18:1D7
13					ive	5					_15:0)
711.5				1	Posit	11.8	12.8	30	NCE		PE(18:1D7
664					ive						_15:0)
Mass	Form	Formu	Spe	CS	Polar	Start	End	(N)	(N)C	MS	Comment
			-						· · ·		
[m/z]	ula	la type	cies	[z]	ity	[min	[min	ĊÉ	È	Х	
[m/z]	ula [M]	la type	cies	[z]	ity	[min ]	[min ]	ĊÉ	È type	X ID	
[m/z] 599.3	ula [M]	la type	cies	[z] 1	ity Nega	[min ] 4.5	[min ] 6	ĊĔ	È type	X ID	LPI (18:0)
[m/z] 599.3 202	ula [M]	la type	cies	[z] 1	ity Nega tive	[min ] 4.5	[min ] 6	ĊÉ	È type	X ID	LPI (18:0)
[m/z] 599.3 202 597.3	ula [M]	la type	cies	[z] 1 1	ity Nega tive Nega	[min ] 4.5 2.5	[min ] 6 4.5	ĊÉ	È type	X ID	LPI (18:0) LPI (18:1)
[m/z] 599.3 202 597.3 045	ula [M]	la type	cies	[z] 1 1	ity Nega tive Nega tive	[min ] 4.5 2.5	[min ] 6 4.5	CÉ	È type	X ID	LPI (18:0) LPI (18:1)
[m/z] 599.3 202 597.3 045 595.2	ula [M]	la type	cies	[z] 1 1 1	ity Nega tive Nega tive Nega	[min ] 4.5 2.5 1.5	[min ] 6 4.5 3	ĊĔ	È type	X ID	LPI (18:0) LPI (18:1) LPI (18:2)
[m/z] 599.3 202 597.3 045 595.2 889	ula [M]	la type	cies	[z] 1 1 1	ity Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5	[min ] 6 4.5 3	ĊĔ	E type	X ID	LPI (18:0) LPI (18:1) LPI (18:2)
[m/z] 599.3 202 597.3 045 595.2 889 621.3	ula [M]	la type	cies	[z] 1 1 1 1 1	ity Nega tive Nega tive Nega	[min ] 4.5 2.5 1.5 2	[min ] 6 4.5 3 3.5	CE	E type	X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3)
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045	ula [M]	la type		[z] 1 1 1 1 1	ity Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2	[min] 6 4.5 3 3.5	CE	È type	X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3)
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2	ula [M]	la type		[z] 1 1 1 1 1 1	ity Nega tive Nega tive Nega tive Nega	[min ] 4.5 2.5 1.5 2 1.5	[min ] 6 4.5 3 3.5 3	CE	E type	X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:4)
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2 889	ula [M]	la type		[z] 1 1 1 1 1 1 1 1	ity Nega tive Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2 1.5	[min] 6 4.5 3 3.5 3	CE	E type	X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:4)
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2 889 433.2	ula [M]	la type		[z] 1 1 1 1 1 1 1 1	ity Nega tive Nega tive Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2 1.5 2.5	[min ] 6 4.5 3 3.5 3 4		E type	X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:4) LPA (18:2)
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2 889 433.2 361	ula [M]	la type		[z] 1 1 1 1 1 1 1 1 2	ity Nega tive Nega tive Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2 1.5 2.5	[min] 6 4.5 3 3.5 3 4		E type	X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:4) LPA (18:2)
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2 889 433.2 361 903.4	ula [M]	la type		<ul> <li>[z]</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>2</li> </ul>	ity Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2 1.5 2.5 8.95	[min ] 6 4.5 3 3.5 3 4 9.95		E type	X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:4) LPA (18:2) GD1a(d34:
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2 889 433.2 361 903.4 631	ula [M]	la type		<ul> <li>[z]</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>2</li> <li>2</li> </ul>	ity Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2.5 1.5 2.5 8.95	[min ] 6 4.5 3 3.5 3 4 9.95		E type	X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:4) LPA (18:2) GD1a(d34: 1)-2H
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2 889 433.2 361 903.4 631 917.4	ula [M]	la type		<ul> <li>[z]</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>2</li> <li>2</li> </ul>	ity Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2.5 1.5 2.5 8.95 10.0	[min ] 6 4.5 3 3.5 3 4 9.95 11.0		E type	X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:4) LPA (18:2) GD1a(d34: 1)-2H GD1a(d36: L) 2H
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2 889 433.2 361 903.4 631 917.4 788	ula [M]	la type		[z] 1 1 1 1 1 1 2 2 2	ity Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2.5 1.5 2.5 8.95 10.0 3	[min ] 6 4.5 3 3.5 3 4 9.95 11.0 3		E type	X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:4) LPA (18:2) GD1a(d34: 1)-2H GD1a(d36: 1)-2H
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2 889 433.2 361 903.4 631 917.4 788 720.8 97	ula [M]	la type		[z] 1 1 1 1 1 1 2 2 2	ity Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2.5 1.5 2.5 8.95 10.0 3 9.64	[min ] 6 4.5 3 3.5 3 4 9.95 11.0 3 10.6			X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:4) LPA (18:2) GD1a(d34: 1)-2H GD1a(d36: 1)-2H GD3(d34:1
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2 889 433.2 361 903.4 631 917.4 788 720.8 97	ula [M]	la type		<ul> <li>[z]</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>2</li> <li>2</li> <li>2</li> <li>1</li> </ul>	ity Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2 1.5 2.5 8.95 10.0 3 9.64	[min ] 6 4.5 3 3.5 3 4 9.95 11.0 3 10.6 4		E type	X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:3) LPI (20:4) LPA (18:2) GD1a(d34: 1)-2H GD1a(d36: 1)-2H GD3(d34:1) )-2H
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2 889 433.2 361 903.4 631 917.4 788 720.8 97 1123. (72)	ula [M]	la type		<ul> <li>[z]</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>2</li> <li>2</li> <li>2</li> <li>1</li> </ul>	ity Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2.5 1.5 2.5 8.95 10.0 3 9.64 8.84	[min ] 6 4.5 3 3.5 3 4 9.95 11.0 3 10.6 4 9.84			X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:4) LPA (18:2) GD1a(d34: 1)-2H GD1a(d36: 1)-2H GD3(d34:1) )-2H GM3(d32: 1) )
[m/z] 599.3 202 597.3 045 595.2 889 621.3 045 619.2 889 433.2 361 903.4 631 917.4 788 720.8 97 1123. 675 1151	ula [M]	la type		<ul> <li>[z]</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>1</li> <li>2</li> <li>2</li> <li>2</li> <li>1</li> <li>1</li> </ul>	ity Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive Nega tive	[min ] 4.5 2.5 1.5 2.5 1.5 2.5 8.95 10.0 3 9.64 8.84	[min ] 6 4.5 3 3.5 3 4 9.95 11.0 3 10.6 4 9.84			X ID	LPI (18:0) LPI (18:1) LPI (18:2) LPI (20:3) LPI (20:3) LPI (20:4) LPA (18:2) GD1a(d34: 1)-2H GD1a(d36: 1)-2H GD3(d34:1) )-2H GD3(d34:1) )-2H

706			tive		4		1) <b>-</b> H
1149.		1	Nega	9	10		GM3(d34:
69			tive				2)-H
1179.		1	Nega	10.9	11.9		GM3(d36:
737			tive	1	1		1)-H
1235.		1	Nega	12.5	13.5		GM3(d40:
8			tive	1	1		1)-H
1263.		1	Nega	13.1	14.1		GM3(d42:
831			tive	9	9		1)-H
701.5		1	Nega	12.6	13.6		PA 18:0-
127			tive	8	8		18:1
699.4		1	Nega	11.9	12.9		PA 18:0-
97			tive	1	1		18:2
723.4		1	Nega	11.8	12.8		PA 18:0-
97			tive	6	6		20:4
747.4		1	Nega	11.6	12.6		PA 18:0-
97			tive				22:6
666.5		1	Nega	11.2	13		PA(18:1D7
097			tive	3			15:0)
750.5		1	Nega	11.0	12.0		PC 14:0-
291			tive	8	8		16:0
776.5		1	Nega	11.1	12.1		PC 14:0-
447			tive	5	5		18:1
774.5		1	Nega	10.5	11.5		PC 14:0-
291			tive				18:2
798.5		1	Nega	10.1	11.1		PC 14:0-
291			tive	9	9		20:4
790.5		1	Nega	11.7	12.7		PC 15:0-
604			tive				18:1
788.5		1	Nega	10.8	11.8		PC 15:0-
447			tive	6	6		18:2
778.5		1	Nega	12.0	13.5		PC 16:0-
604			tive	1	1		16:0
776.5		1	Nega	11.2	12.5		PC 16:0-
447			tive				16:1
806.5		1	Nega	13	14.5		PC 16:0-
917			tive				18:0
804.5		1	Nega	12.0	13.5		PC 16:0-
76			tive	1			18:1
802.5		1	Nega	11.5	13		PC 16:0-
604			tive				18:2
800.5		1	Nega	11	12		PC 16:0-
447			tive				18:3
832.6		1	Nega	12.8	13.8		PC 16:0-
073			tive	3	3		20:1
830.5		1	Nega	12.2	13.2		PC 16:0-

917				tive				20:2	
828.5			1	Nega	11.5	12.5		PC	16:0-
76				tive	7	7		20:3	
826.5			1	Nega	11.1	12.5		PC	16:0-
604				tive	8	8		20:4	
824 5			1	Nega	10.8	11.8		PC	16.0-
447			1	tive	10.0	11.0		20.5	10.0
854.5			1	Nega	11.8	12.8		20.5 PC	16.0-
034.3 917			1	tive	2	$\frac{12.0}{2}$		$22 \cdot 4$	10.0
852.5			1	Nega	11.2	12.2		22. <del>4</del> PC	16.0
76			1	tive	11.2	12.2		22.5	10.0-
70 850 5			1	Nogo	10.0	<del>4</del>		22.3 DC	16.0
630.3			1	tive	10.9	7		FC 22.6	10.0-
800 5			1	Nega	/	/		22:0 DC	16.1
800.5			1	inega	10.7	11./		PC	10:1-
44/			1	tive	10.2	11.2		18:2	1(1
824.5			1	Nega	10.2	11.2		PC	16:1-
44/			1	tive	/	/		20:4	15.0
818.5			I	Nega	12.5	14		PC	17:0-
917			-	tive				18:1	1 - 0
816.5			1	Nega	11.7	13		PC	17:0-
76				tive	9			18:2	
840.5			1	Nega	11.8	12.8		PC	17:0-
76				tive	6	6		20:4	
834.6			1	Nega	14	15		PC	18:0-
23				tive				18:0	
832.6			1	Nega	12.8	14.5		PC	18:0-
073				tive	3			18:1	
830.5			1	Nega	12.3	14		PC	18:0-
917				tive				18:2	
828.5			1	Nega	12	13		PC	18:0-
76				tive				18:3	
858.6			1	Nega	13.2	14.2		PC	18:0-
23				tive				20:2	
856.6			1	Nega	12.7	13.7		PC	18:0-
073				tive				20:3	
854.5			1	Nega	12.3	13.5		PC	18:0-
917			-	tive				20:4	
852 5			1	Nega	11.5	12.5		PC	18:0-
76			*	tive	4	4		20.5	10.0
882.6			1	Nega	13	. 14		PC	18.0-
23			T	tive	15	17		$22 \cdot 4$	10.0-
880.6			1	Nega	12.2	13.5		<u>22.</u> т	18.0
073			1	tive	12.3	13.5		22.5	10.0-
9795			1	Nogo	11.0	12.0		22.3 DC	18.0
0/0.3			1	tive	11.9	12.9		rU 22.4	10:0-
91/			1	N	12.0	12.0	<u>                                      </u>	 22:0 DC	10.1
830.3			1	Inega	12.0	13.0		PU	18:1-

917			tive	1	1		18:1
828.5		1	Nega	11.5	12.5		PC 18:1-
76			tive	7	7		18:2
846.6		1	Nega	13.1	14.1		PC 18:1-
23			tive	6	6		19:0
854.5		1	Nega	11.8	12.8		PC 18:1-
917			tive	2	2		20:3
852.5		1	Nega	11.2	12.2		PC 18:1-
76			tive	4	4		20:4
850.5		1	Nega	10.4	11.4		PC 18:1-
604			tive	9	9		20:5
878.5		1	Nega	11.9	12.9		PC 18:1-
917			tive				22:5
876.5		1	Nega	10.9	11.9		PC 18:1-
76			tive	6	6		22:6
826.5		1	Nega	10.6	11.6		PC 18:2-
604			tive	3	3		18:2
824.5		1	Nega	9.97	10.9		PC 18:2-
447			tive		7		18:3
858.6		1	Nega	13.3	14.3		PC 18:2-
23			tive				20:0
852.5		1	Nega	10.9	11.9		PC 18:2-
76			tive	7	7		20:3
850.5		1	Nega	10.4	11.4		PC 18:2-
604			tive	6	6		20:4
876.5		1	Nega	10.7	11.7		PC 20:3-
76			tive				20:4
874.5		1	Nega	10.2	11.2		PC 20:4-
604			tive	6	6		20:4
797.6		1	Nega	11.5	13		PC(18:1D7
043			tive	5			_15:0)
718.5		1	Nega	13.0	14.0		PE 16:0-
392			tive	9	9		18:0
716.5		1	Nega	12.2	13.2		PE 16:0-
236			tive	7	7		18:1
714.5		1	Nega	11.5	12.5		PE 16:0-
079			tive	5	5		18:2
738.5		1	Nega	11.4	12.4		PE 16:0-
079			tive	7	7		20:4
766.5		1	Nega	12.0	13.0		PE 16:0-
392			tive	4	4		22:4
764.5		1	Nega	11.4	12.4		PE 16:0-
236			tive	8	8		22:5
762.5		1	Nega	11.2	12.2		PE 16:0-
079			tive	1	1		22:6
744.5		1	Nega	13.0	14.0		PE 18:0-

549			tive	5	5		18:1	
742.5		1	Nega	12.4	13.4		PE	18:0-
392			tive	5	5		18:2	
768.5		1	Nega	12.6	13.6		PE	18:0-
549			tive	4	4		20:3	
766.5		1	Nega	12.3	13.3		PE	18:0-
392			tive	3	3		20:4	
794.5		1	Nega	12.8	13.8		PE	18:0-
705			tive	3	3		22:4	
792.5		1	Nega	12.3	13.3		PE	18:0-
549		-	tive	4	4		22:5	
790.5		1	Nega	12.1	13.1		PE	18:0-
392		-	tive		1011		22:6	1010
742.5		1	Nega	12.2	13.2		PE	18.1-
392			tive	3	3		18:1	1011
740.5		1	Nega	11.5	12.5		PE	18.1-
236		1	tive	5	5		18.2	10.1
764 5		1	Nega	11 4	12.4		PE	18.1-
236		1	tive	8	8		20.4	10.1
738 5		1	Nega	10.8	11.8		PE	18.2-
079		1	tive	5	5		18.2	10.2
786.5		1	Nega	10.4	114		PE	20.4-
079			tive	9	9		20:4	2011
709.5		1	Nega	11.8	12.8		PE(18	8:1D7
519		-	tive	1110	12:0		15:0	)
788.5		1	Nega	12.1	13.1		PS	18:0-
447			tive		_		18:1	
810.5		1	Nega	11.3	12.3		PS	18:0-
291			tive	2	2		20:4	
838.5		1	Nega	11.9	12.9		PS	18:0-
604			tive	1	1		22:4	
836.5		1	Nega	11.1	12.1		PS	18:1-
447			tive				22:4	
830.4		1	Nega	9.48	10.4		PS	20:4-
978			tive		8		20:4	
858.5		1	Nega	10.2	11.2		PS	20:4-
291			tive	6	6		22:4	
753.5		1	Nega	10.7	11.7		PS(18	3:1D7
417			tive	1	1		15:0	)
828.5		1	Nega	10.6	11.6		PI(18	:1D7
625			tive	_	-		15:0	)
861.5		1	Nega	11.2	12.2		PI	18:0-
499			tive	7	7		18:2	-
859.5		1	Nega	10.6	11.6		PI	16:0-
342			tive	4	4		20:3	
857.5		1	Nega	10.2	11.2		PI	16:0-

186			tive	7	7		20:4	
871.5		1	Nega	10.7	11.7		PI	17:0-
342			tive	4	4		20:4	
863.5		1	Nega	11.9	12.9		PI	18:0-
655			tive	4	4		18:1	
887.5		1	Nega	11.5	12.5		PI	18:0-
655			tive	2	2		20:3	
885.5		1	Nega	11.2	12.2		PI	18:0-
499			tive				20:4	
883.5		1	Nega	10.3	11.3		PI	18:0-
342			tive				20:5	
913.5		1	Nega	11.7	12.7		PI	18:0-
812			tive	9	9		22:4	
911.5		1	Nega	11.2	12.2		PI	18:0-
655			tive	3	3		22:5	
909.5		1	Nega	10.9	11.9		PI	18:0-
499			tive	7	7		22:6	
861.5		1	Nega	11.2	12.2		PI	18:1-
499			tive	7	7		18:1	
859.5		1	Nega	10.3	11.3		PI	18:1-
342			tive	8	8		18:2	
883.5		1	Nega	10.3	11.3		PI	18:1-
342			tive				20:4	

Supplementary Tables 5. Inclusion list for targeted proteomics (PRM).

Mas	For	For	Sp	С	Pol	St	Е	(N	(N	Μ	Comment
S	mul	mul	eci	S	arit	art	nd	)C	)C	S	
[m/	a	а	es	[	у	[	[	E	E	Х	
	[M]	typ		Ζ	-	mi	mi		typ	Ι	
		e		]		n]	n]		e	D	
497.				2	Pos	13	15				LLIYGASTR
29					itiv	.1	.1				
					e						
451.				2	Pos	18	20				ELLLSSLK
781					itiv	.7	.7				
5					e						
433.				2	Pos	12	14				FSGSLLGGK
242					itiv	.5	.1				
5					e	3	3				
545.				2	Pos	3.	6.				ASSLESGVPSR
280					itiv	4	9				
4					e						
814.				2	Pos	15	17				YSPSFQGQVTISADK
401					itiv	.7	.3				
8					e	4	4				
644			2	Pos	14	16	ESGSGA GTDETLK				
------	---	---	---	---------------	----	----	-----------------------	----			
214			2	105	7	2	ISOSOAOIDITEK				
314				1t1V	./	.3					
4				e	7	7					
532.			2	Pos	14	15	LLIYDASNR				
790				itiv	.0	.6					
4				e	4	4					
538			2	Pos	25	26	GLEWVGEIR				
708			2	itin	23	20					
/90				IUV	.∠	.0					
100			-	e	4	4					
408.			2	Pos	13	15	GLEWVGR				
721				itiv	.2	.2					
8				e							
519.			2	Pos	14	15	LLIYDASSR				
284				itiv	1	7					
0				0	7	7					
9			2	D	20	22					
831.			2	Pos	20	22	LLIYAASSLQSGVPSR				
464				1t1V	.9	.5					
7				e	1	1					
815.			2	Pos	10	11	VTEPISAESGEQVER				
899				itiv	.3	.9					
6				e	6	6					
637			2	Pos	11	13	VNEPSII EMSR				
037.			2	105	11	0	VINEI SILLIVISIC				
024				IUV	.4	.0					
1			_	e	6	6					
766.			3	Pos	31	33	ALPVFC[+57.0]DMDTEGGO	GΨ			
694				itiv	.9	.5	LVFQR				
3				e	1	1					
512.			2	Pos	14	16	YGIDWASGR				
746				itiv	.9	.5					
,				e	5	5					
626			2	Dag	11	12					
030.			Ζ	POS	11	15	SEAAC[+37.0]LAAOPOIR				
821				1 <b>t</b> 1V	.8	.4					
9				e	5	5					
795.			2	Pos	17	19	WIYHLTEGSTDLR				
899				itiv	.9	.5					
2				e	5	5					
409	ł	1	2	Pos	16	17	AFLLTPR				
250			-	itiv		6					
250					2	2					
2			_	e	3	3					
760.			2	Pos	20	22	ALYLQYTDETFR				
375				itiv	.7	.3					
				e	6	6					
602.			2	Pos	7.	10	EYTDASFTNR				
267				itiv	43	.3					
5				e		5					
640			2	Der	22	22					
049.			3	ros	32	55	GVNLQEFLNVISVHLFK				

022			itiv	.0	.6	
9			e	2	2	
763.		2	Pos	12	14	GDAC[+57.0]EGDSGGPFVMK
816			itiv	.6	.2	
1			e	8	8	
601.		3	Pos	25	28	MGNFPWOVFTNIHGR
963			itiv	.9	.1	
1			e	9		
783.		2	Pos	12	14	ODAC[+57.0]OGDSGGVFAVR
851			itiv	.5	.1	
9			e	3	3	
599.		3	Pos	21	22	VVLHPNYSOVDIGLIK
008		_	itiv	.3	.9	
6			e	4	4	
854.		 2	Pos	18	20	YVMLPVADODOC[+57.0]IR
413			itiv	.9	.5	
3			e	• •		
772.		2	Pos	17	18	VGYVSGWGOSDNFK
362			itiv	.3	.9	
4			e	5	5	
531.		2	Pos	21	23	SALVLOYLR
818			itiv	.5	.1	
9			e	9	9	
671.		 2	Pos	23	25	ETYDFDIAVLR
337			itiv	.7	.3	
9			e	2	2	
440.		4	Pos	21	24	RPDSLOHVLLPVLDR
256			itiv	.5	.3	
			e	9	5	
544.		2	Pos	18	20	WELC[+57.0]DIPR
763			itiv	.8	.4	
3			e	3	3	
619.		2	Pos	25	26	FVTWIEGVMR
323			itiv	.0	.6	
5			e	2	2	
860.		2	Pos	28	29	LTLQGIISWGSGC[+57.0]GDR
427			itiv	.1	.7	~ L J
8			e	7	7	
677.		3	Pos	30	32	NKPGVYTDVAYYLAWIR
022			itiv	.5	.1	
9			e	6	6	
754.		2	Pos	10	11	VSEADSSNADWVTK
846			itiv	.3	.9	
8			e	5	5	
708.		3	Pos	17	18	YGQTIRPIC[+57.0]LPC[+57.0]T
350			itiv	.2	.8	EGTTR
L			· · · · · · · · · · · · · · · · · · ·			

6			e	9	9		
752.		3	Pos	15	17		EIINVGHSFHVNFEDNDNR
685			itiv	.6	.2		
8			e	4	4		
715.		2	Pos	23	24		VAEGTQVLELPFK
898			itiv	.3	.9		
1			e	7	7		
411.		3	Pos	21	23		ANRPFLVFIR
580		C	itiv	.5	.1		
3			e		•-		
538.		2	Pos	24	25		LSSWVLLMK
812		-	itiv	2	.8		
3			e	3	3		
508.		2	Pos	18	20		SVLGOLGITK
311		-	itiv	7	3		
511			e	8	8		
697		2	Pos	15	17		NEDSLVEVOTDK
843		-	itiv	9	5		
5			e	7	7		
636		2	Pos	11	13		VTAAPOSVCI+57 01ALR
840		-	itiv	4	0		
1			e	3	3		
531		2	Pos	18	19		FIGELYLPK
297		2	itiv	3	9		
5			e	5	5		
480		2	Pos	10	11		ADLSGITGAR
759		-	itiv	$\frac{10}{2}$	8		
1			e	.2	.0 7		
862		2	Pos	31	33		VLSALOAVOGLIVAOGR
014		2	itiv	8	4		
9			e	.0	6		
719		2	Pos	21	23		SI DETEL DVA A EK
359		2	itiv	8	$\Delta^{23}$		
557			e	2	2		
443		2	Pos	15	17		ISLPESLK
765		-	itiv	9	5		
8			e	$\frac{1}{2}$	2		
701		2	Pos	25	27		SSI SVPVVIVPI K
421		-	itiv	5	1		
$2^{1}$				2	· 1 2		
2 724		2	Dog	<u> </u>	<u> </u>		
2/4.			F US	10	12		
244				0	0		
2		n	C Dar	7	ד 2		
/08.		2	ros	23 1	2/		VSIISIIVEINVEVK
43/				.4	.0 7		
0			e	/	/		

692			2	Pos	23	24	ENFL FL TPDC[+57 0]K
224			2	itin	23	0	
2					.5	.9	
5			2	e D	9	9	VEDEVAD
515.			2	Pos	22	23	YFIDFVAR
771				1t1V	.2	.8	
5				e	1	1	
906.			2	Pos	21	23	SC[+57.0]DLALLETYC[+57.0]
929				itiv	.5	.1	ATPAK
				e	4	4	
695			2	Pos	6	9	SSEDPNEDIVER
210			2	itin	0. 7	). 1	SSEDI NEDI VER
510				IUV	/	4	
1			•	e	10	1.4	
469.			2	Pos	12	14	IIVPLNNR
792				itiv	.9	.7	
7				e	8	8	
874.			2	Pos	21	23	LLIYDASNLETGVPSR
464				itiv	.5	.1	
9				e	8	8	
100			r	Dog	12	14	LLIVCASSD
490.			2	F 05	12	14	LLIIUASSK
282				111V	./		
2			_	e	2	2	
458.			2	Pos	16	17	IWLDNVR
256				itiv	.1	.7	
				e	5	5	
721.			2	Pos	29	30	IALGGLLFPASNLR
429				itiv	1	7	
9				e	••	• /	
702			2	Dog	22	24	EATSTETNITVD
702.			2	F 05	23	24	LAISITINIIIK
343				111V	.3	.9	
1				e	3	3	
727.			3	Pos	21	23	GQIHLDPQQDYQLLQVQR
046				itiv	.6	.2	
7				e	5	5	
624.			2	Pos	24	25	ITLPDFTGDLR
335				itiv	1	7	
2				e	4	4	
646			2	Doc	27	22	SDVTLLA AVMSI DEELINIV
040.			3	F05	32	55	ST V I LLAAV WISLYEENINK
011				111V	1.1	./	
8				e	2	2	
900.			3	Pos	34	36	LGC[+57.0]EVLGVSVDSQFTH
458				itiv	.4	.0	LAWINTPR
5				e	3	3	
741.			6	Pos	34	36	LVOAFOYTDEHGEVC[+57.0]P
354			Ĵ	itiv	4	0	AGWKPGSDTIKPNVDDSKFV
554					5	5	FSK
604			2		10	10	
604.			2	Pos	16	18	IAAENDFVILK

811			itiv	.9	.5	
5			e	6	6	
730.		2	Pos	34	36	VDLLNQEIEFLK
903			itiv	.5	.1	
4			e	3	3	
692.		2	Pos	21	23	GASQAGMTGYGMPR
310			itiv	.5	.1	
8			e	9	9	
807.		2	Pos	22	24	NALWHTGDTESQVR
387			itiv	.9	.5	
			e	5	5	
652.		2	Pos	12	14	S[+42.0]DKPDMAEIEK
805			itiv	.8	.4	
6			e	3	3	
564.		2	Pos	12	14	ENAGEDPGLAR
767			itiv	.8	.6	
6			e	5	5	
733.		3	Pos	21	23	STDTSC[+57.0]VNPPTVQNAH
027			itiv	.5	.1	ILSR
1			e	9	9	
791.		2	Pos	15	17	GQC[+57.0]LITQSPPYYR
887			itiv	.9	.5	
8			e	5	5	
658.		2	Pos	30	31	LTLLAPLNSVFK
402			itiv	.1	.7	
8			e	9	9	
577.		2	Pos	10	12	TGDAVEFQC[+57.0]K
761			itiv	.8	.8	
			e			
521.		2	Pos	25	27	EAEPLVDIR
282			itiv	.6	.2	
4			e	2	2	
883.		2	Pos	25	26	IAIIGAGIGGTSAAYYLR
993			itiv	.2	.8	
6			e	4	4	
646.		2	Pos	22	23	SPFAYC[+57.0]M[+16.0]MIR
285			itiv	.1	.7	
2			e	8	8	
610		2	Pos	15	17	SGTSASLAISGLR
335		_	itiv	.6	2	
7			e	2	2	
786		3	Pos	13	15	PGSAPTTVIVEDNORPSGVPD
055		5	itiv	9	5	R
8			ни v е	6	6	
676		r	Pos	18	20	NTLVI OMNSI P
852		2	1 US	10	20 5	
033			1111	.7		

2				e	6	6		
645.			2	Pos	8.	10		AEDTAVYYC[+57.0]AK
787				itiv	1	.4		
2				e				
515.			2	Pos	19	21		GLEWVANIK
29				itiv	.8	.4		
				e	8	8		
659.			2	Pos	7.	10		AEDTAVYYC[+57.0]AR
790				itiv	9	.9		
3				e				
899.			2	Pos	29	30		SGTASVVC[+57.0]LLNNFYPR
451				itiv	.1	.7		
3				e	7	7		
625.			3	Pos	12	14		VYAC[+57.0]EVTHOGLSSPVT
980				itiv	.5	.1		K
5				e	2	2		
593.			2	Pos	17	19		GPSVFPLAPSSK
827				itiv	.8	.4		
				e	6	6		
713.			3	Pos	19	21		TPEVTC[+57.0]VVVDVSHEDP
680			_	itiv	.8	.4		EVK
7				e	9	9		
598.			3	Pos	25	26		VVSVLTVVHODWLNGK
668				itiv	.3	.9		
5				e	1	1		
824.			1	Pos	10	12		GLPAPIEK
487				itiv	.1	.2		
6				e				
452.			3	Pos	3.	5.		TPLGDTTHTC[+57.0]PR
550				itiv	76	36		
6				e				
805.			3	Pos	22	24		TPEVTC[+57.0]VVVDVSHEDP
389				itiv	.9	.5		EVOFK
7				e	8	8		
415.			2	Pos	7.	10		GLPSSIEK
734				itiv	6	.4		
5				e				
639.			2	Pos	14	15		YAATSOVLLPSK
358				itiv	.2	.8		
6				e	2	2		
819.			2	Pos	34	35		VFAIPPSFASIFLTK
468			_	itiv	.1	.7		
7				e	5	5		
770			2	Pos	18	20		DASGVTFTWTPSSGK
867			_	itiv	.5	.1		
6				e	5	5		
	I			-	-			I I

466		2	Pos	10	12	TPI TATI SK
276		2	itin	6	2	
270			IUV	.0	.2	
0		_	e	0	0	
756.		2	Pos	18	20	DASGATFTWTPSSGK
851			itiv	.6	.2	
9			e	5	5	
409.		3	Pos	14	15	DAHLTWEVAGK
543			itiv	.1	.7	
7			e	••	• •	
619		2	Dog	24	25	
010.		2	F 05	24	23	DLAIVIVDVLK
347			1t1V	.3	.9	
7			e	7	7	
693.		2	Pos	28	30	VSFLSALEEYTK
861			itiv	.6	.2	
2			e	5	5	
865		2	Pos	16	18	SELEEOLTPVAEETR
925		2	itiv	7	3	
923				./	.5	
0		~	e	4	4	LONUTOOD
484.		2	Pos	9.		LGPLVEQGR
779			itiv	89	.4	
8			e		9	
784.		3	Pos	33	35	EPC[+57.0]VESLVSQYFQTVT
035			itiv	.5	.1	DYGK
1			e	_		
795		3	Pos	35	36	AGTELVNEL SVEVEL GTOPAT
727		5	105	22	0	A GILLANI LESTI VLLOIQIAI
157			IUV	.∠	.0	Q
3		_	e	_	~	
526.		2	Pos	7.	9.	EFGNTLEDK
748			itiv	23	4	
4			e			
601.		2	Pos	18	20	EWFSETFQK
279			itiv	.5	.1	
9			e	4	4	
642		2	Doc	16	10	FSISSWESAK
709		2	105	5	10	ESESSI WESAK
/98			111V	.3	.1	
6			e	8	8	
745.		3	Pos	34	35	STAAMSTYTGIFTDQVLSVLK
052			itiv	.0	.6	
2			e	8	8	
858.		2	Pos	13	15	DALSSVOESOVAOOAR
929		<b>-</b>	itiv	5	1	
$\begin{vmatrix} 2 \\ 2 \end{vmatrix}$				2	2	
<u> </u>		 2	D.	2	2 22	 CWWTDCE89LV
398.		2	POS	20	22	GWVIDGFSSLK
801			1t1V	.9	.5	
			e	8	8	
760.		2	Pos	20	22	GLIDEVNQDFTNR

870				itiv	.8	.4		
6				e	3	3		
815.			2	Pos	26	27		DSHSLTTNIMEILR
416				itiv	.1	.7		
9				e	5	5		
462.			2	Pos	3.	5.		TVIGPDGHK
250			-	itiv	68	28		
9				e	00	20		
809			2	Pos	15	16		TPC[+57 0]TVSC[+57 0]NIPVV
9			4	itiv	1	7		SGK
/				e	6	6		SOK
803			2	Pos	22	23		NVC[+57 0]GLPGEVWLGNDK
308			2	itiv	0	6		
398 7					.0 Q	.0 Q		
/ 512			2	Dog	0	0		AUVCCETVONEANIZ
570			3		1.	9.		ATTOUTIVQUEANK
579				nuv	4/	9		
4			2	e D.	11	10		VLOEIVNISNNIOK
/5/.			Ζ	POS		12		YLQEIYNSNNQK
367				1 <b>t</b> 1V	.0	.0		
/			2	e	8	8		FOFOUL ONTOTTEFUL OVER
/36.			3	Pos	23	24		EGFGHLSPIGIIEFWLGNEK
351				1t1V	.2	.8		
6			_	e	8	8		
745.			2	Pos	27	29		ADFLEQPVLGFVR
903				itiv	.4	.0		
7				e	5	5		
697.			2	Pos	10	11		IVLGQEQDSYGGK
351				itiv	.2	.8		
5				e	8	8		
643.			2	Pos	30	31		GYVIIKPLVWV
897				itiv	.2	.8		
2				e	1	1		
381.			2	Pos	9.	11		PAFSAIR
218				itiv	8	.8		
9				e				
571.			2	Pos	9.	11		SLGFC[+57.0]DTTNK
761				itiv	6	.6		
				e				
621.			3	Pos	14	15		FDHVITNMNNNYEPR
952				itiv	.0	.6		
9				e	4	4		
538.			2	Pos	15	17		GNLC[+57.0]VNLMR
770				itiv	.9	.5		
6				e	3	3		
542.			2	Pos	17	18		FOSVFTVTR
792			_	itiv	- '	.6		- (
, / 4		1		101 1				

9			e					
721.		2	Pos	13	15			Q[-17.0]THQPPAPNSLIR
381			itiv	.8	.4			
			e	8	8			
629.		2	Pos	11	13			TNQVNSGGVLLR
349			itiv	.4	.0			
1			e	8	8			
516.		2	Pos	4	5.			VVEESELAR
272			itiv		6			
			e					
788.		2	Pos	22	23			RPWNVASLIYETK
927			itiv	.3	.9			
7			e	4	4			
728.		2	Pos	23	24			AIEDYINEFSVR
359			itiv	.3	.9			
4			e	7	7			
886.		2	Pos	33	34			FIC[+57.0]PLTGLWPINTLK
992			itiv	.1	.7			
			e	5	5			
796.		3	Pos	17	18			ATFGC[+57.0]HDGYSLDGPEEI
003		_	itiv	-	.6			EC[+57.0]TK
6			e					
740.		4	Pos	28	29			LOELHLSSNGLESLSPEFLRPV
655			itiv	.3	.9			POLR
5			e	7	7			
590.		2	Pos	21	23			 DLLLPOPDLR
340			itiv	.8	.4			
2			e	9	9			
829.		3	Pos	29	30			DGFDISGNPWIC[+57.0]DONL
041			itiv	.3	.9			SDLYR
1			e					
904.		2	Pos	23	24			VTIMWTPPESAVTGYR
456			itiv	.3	.9			
			e	7	7			
555.		2	Pos	10	11		1	STTPDITGYR
774			itiv	.2	.8			
9			e	7	7			
678.		2	Pos	18	19			IYLYTLNDNAR
351			itiv	.0	.6			_
3			e	9	9			
898.		3	Pos	21	23			 GNDDHWIVDTDYDTYAVOYS
378			itiv	.5	.1			C[+57.0]R
5			e	7	7			
688		3	Pos	27	29			LLNLDGTC[+57 0]ADSYSFVF
994			itiv	.4	.0			SR
7			e	2	2			
· ·			-			1	1	

704		2	Pos	30	31	AFIOLWAFDAVK
881		2	itix	20	8	
00 <del>1</del>				·2 8	.0 Q	
0		2	C D	0	0	
854.		2	Pos	1/	18	EYC[+5/.0]GVPGDGDEELLK
8//			1t1V	.3	.9	
8			e			
876.		2	Pos	19	21	YVGGQEHFAHLLILR
980			itiv	.9	.5	
8			e			
871.		2	Pos	27	29	EQLGEFYEALDC[+57.0]LR
906			itiv	.4	.0	
3			e	3	3	
508		2	Pos	3	6	HTI NOIDEVK
917		2	itin	<i>J</i> .	0.	III LIQIDE V K
01/			IUV	90	90	
1		2	e	1.5	10	
672.		3	Pos	17	19	TVVQPSVGAAAGPVVPPC[+5
694			itiv	.1	.1	7.0]PGR
7			e			
789.		2	Pos	18	19	AGPHC[+57.0]PTAQLIATLK
427			itiv	.0	.6	
1			e	8	8	
683		2	Pos	18	20	GSPAINVAVHVFR
882		2	itix	7	20	OSIAMUUTA
1			IUV	./	.5	
1		~	e	2	2	
697.		2	Pos	17	19	AADDTWEPFASGK
814			itiv	.5	.1	
8			e	3	3	
476.		2	Pos	9.	11	DLGEENFK
224			itiv	3	.3	
5			e			
829		2	Pos	21	22	ONCI+57 0IEL FEOL GEYK
38		2	itiv	1	7	Quel + 5 / .0 JEEN EQUOL TR
50				.1	. /	
500		2	e D	4	4	
500.		2	POS	16	18	QIALVELVK
805			1t1V	.5	.1	
5			e	6	6	
840.		3	Pos	17	18	EVVSLTEAC[+57.0]C[+57.0]AE
010			itiv	.2	.8	GADPDC[+57.0]YDTR
4			e	3	3	
789		3	Pos	35	36	VPTADLEDVLPLAEDITNILSK
428			itiv	0	6	
$\frac{1}{2}$				0	0	
550		n	Dar	9	17	NIOSI EVICY
330.		2	POS	10		NIQSLEVIUK
819			1 <b>t</b> 1V		.6	
1			e			
708.		2	Pos	14	16	SVIPSDGPSVAC[+57.0]VK

363			itiv	.9	.5	
6			e			
815.		2	Pos	23	24	EDPQTFYYAVAVVK
411			itiv	.0	.6	
6			e	7	7	
748.		2	Pos	19	20	YYC[+57.0]FQGNQFLR
343			itiv	.2	.8	
			e	2	2	
487.		2	Pos	28	30	LWWLDLK
278			itiv	.5	.1	
9			e	7	7	
462.		2	Pos	13	15	GGISGYTLR
250			itiv	.9	.5	
9			e	4	4	
730.		2	Pos	12	13	IAYGTQGSSGYSLR
362			itiv	.2	.8	
4			e	7	7	
703.		2	Pos	18	19	LVGITSWGEGC[+57.0]AR
348			itiv	.2	.8	
3			e	9	9	
791.		2	Pos	15	17	FSAIC[+57.0]QGDGTWSPR
359			itiv	.8	.4	
4			e	9	9	
735.		2	Pos	23	25	LSLEIEQLELQR
911			itiv	.5	.1	
8			e			
652.		2	Pos	10	11	GQYC[+57.0]YELDEK
776			itiv	.2	.8	
8			e	8	8	
823.		2	Pos	28	30	DVWGIEGPIDAAFTR
912			itiv	.6	.2	
3			e	4	4	
745.		3	Pos	17	19	ELNQAGQETLVTGWGYHSSR
025			itiv	.9	.5	
9			e	8	8	
328.		4	Pos	17	18	YLDWIHGHIR
175			itiv	.2	.8	
5			e	3	3	
506.		2	Pos	23	24	TGISPLALIK
823			itiv	.2	.8	
7			e	8	8	
654.		2	Pos	28	30	GFEPTLEALFGK
845		-	itiv	.6	.2	
4			e	2	2	
715		3	Pos	28	30	LAGYLHTLVONLVNNGYVR
391		5	itiv	7	3	
571	I	I	101 1	• /		

9			e	3	3			
712.		2	Pos	21	22			ITTTSPWMFPSR
355			itiv	.2	.8			
6			e	8	8			
876.		3	Pos	34	36			DLLAGLPAPGVEVYC[+57.0]L
468			itiv	.7	.3			YGVGLPTPR
2			e	4	4			
872.		2	Pos	32	34			AIWNVINWENVTER
444			itiv	.5	.1			
3			e	2	2			
562.		2	Pos	27	29			DGYLFQLLR
808			itiv	.9	.5			
6			e	2	2			
745.		2	Pos	21	23			GGEGTGYFVDFSVR
849			itiv	.8	.4			
2			e	2	2			
686.		2	Pos	11	13			HOFLLTGDTOGR
852			itiv	.4				
			e					
544.		2	Pos	14	16			ATWSGAVLAGR
796			itiv	.9	.5			
			e	6	6			
437.		2	Pos	12	13			SLVNLGGSK
753			itiv	.1	.7			
3			e	7	7			
720.		2	Pos	35	36		 	YAGSOVASTSEVLK
372			itiv	.0	.6			
5			e	1	1			
807.		2	Pos	25	27			LVINGNPITIFOER
454			itiv	.5	.1			~
1			e					
812.		1	Pos	17	18			O[-17.0]ASEGPLK
414		_	itiv	.3	.9			
9			e	5	5			
829.		2	Pos	13	15			C[+57.0]PNPPVOENFDVNK
385		-	itiv	.6	.2			
6			e	2	2			
615		2	Pos	14	16			NILTSNNIDVK
838		-	itiv	.9	.5			
1			e	6	6			
779		2	Pos	24	26			TLYLADTFPTNFR
898		<b>–</b>	itiv	.6	_6			
7			e					
613		2	Pos	19	21			AAAATGTIFTFR
83		-	itiv	.8	.4			
			e	2	$\frac{1}{2}$			
L	1	1	-	-		1		

558.		2	Pos	13	15	LLDSLPSDTR
798		-	itiv	9	5	
4			e	5	5	
593		2	Pos	23	24	FOPTI I TI PR
353		2	itiv	0	6	i gi illilik
2				.0	.0	
2 729		2	Dog	17	10	CIETSI AECE+57 OITETV
720. 952		2		1/	19	OLEISLAEC[+57.0]IFIK
0.00				.9	.)	
1		2	e D.	0	0	VERLOWCEVIK
390. 921		2	Pos	1	23	VFSLQWGEVK
821			1t1V	.1	./	
/	 -		e	3	3	
574.		3	Pos	12	14	SGYLLHGSNEITC[+57.0]NR
273			1t1V	.6	.2	
9			e	3	3	
759.		3	Pos	20	22	QGYDLSPLTPLSELSVQC[+57.
710			itiv	.8	.4	0]NR
8			e	2	2	
884.		2	Pos	26	28	GDTYPAELYITGSILR
959			itiv	.6	.2	
4			e	7	7	
657.		2	Pos	24	25	LDTLAQEVALLK
387			itiv	.1	.7	
4			e	7	7	
748.		3	Pos	22	24	GGTLGTPQTGSENDALYEYL
025			itiv	.6	.2	R
6			e			
742.		2	Pos	14	15	EGOMESVEAAMSSK
323			itiv	.3	.9	
8			e	4	4	
561		2	Pos	29	30	SFMLLILER
323		2	itiv	$\frac{2}{2}$	8	STWEETEER
525			P	6	6	
410		2	Pos	21	23	IAIDI FK
252		2	itix	5	1	IAIDLIK
232					.1	
4		2	e Daa	9	9	ETVIDDEL ELIVELID
031.		3	POS	28	29	FIVDRPFLFLIYEHK
684			1t1V	.3	.9	
2		_	e	10	• •	
542.		2	Pos	18	20	TSC[+57.0]LLFMGR
767			itiv	.7	.3	
5			e	8	8	
646.		4	Pos	23	24	ESILFHYTDWVDDQRPENYR
552			itiv	.1	.7	
9			e	3	3	
599.		2	Pos	11	13	YLTLNTESTR

309			itiv	.4	.0	
1			e	8	8	
607.		2	Pos	16	18	NYLAWYOOK
303			itiv	.5	.1	
7			e	8	8	
561		2	Pos	21	23	LLIYWASTR
818		4	itiv	8	$\frac{23}{4}$	
9			e	.0	1	
475		 2	Pos	7	0	VTISVDTSK
263		2	itiv	7. 55	). 15	VIISVDISK
205				55	15	
882		 1	Pos	7	10	
002.		1	F US	/.	10	IASDITIK
430			nuv 2	02	.0	
/		 2	e D.	17	2 10	
000. 251		2	POS	1/	19	AGALNSNDAFVLK
351			1 <b>t</b> 1V	.6	.2	
3		 	e	2	2	
879.		2	Pos	24	25	PIC[+57.0]LPC[+57.0]IMEANL
938			1 <b>t</b> 1V	.1	./	ALR
6		 	e	2	2	
786.		3	Pos	31	33	FFQVGLVSWGLYNPC[+57.0]L
724			itiv	.9	.5	GSADK
4			e	8	8	
817.		2	Pos	26	27	SELTQQLNALFQDK
922			itiv	.1	.7	
9			e	6	6	
598.		2	Pos	7.	9.	VEPYGENFNK
782			itiv	99	59	
8			e			
611.		4	Pos	13	15	DC[+57.0]KDVDEC[+57.0]SLK
274			itiv	.6	.2	PSIC[+57.0]GTAVC[+57.0]K
7			e	1	1	
875.		2	Pos	28	29	SODILLSVENTVIYR
472			itiv	.0	.6	
7			e	3	3	
890.	1	2	Pos	22	24	VDATEESDLAOOYGVR
921			itiv	.6	.2	
			e	1	1	
497.		2	Pos	10	12	MESLGITSR
255		2	itiv	9	5	
3			e	4	4	
860		2	Pos	8	10	
912		4	itiv	7	7	
$\frac{1}{2}$				/	. /	
429		2	C Dec	10	20	
410			1 105	ιīð	1 20	
716		4	105	7	2	

2			e	5	5		
809.		2	Pos	24	26		IPGIFELGISSQSDR
925			itiv	.4	.0		
4			e	6	6		
720.		3	Pos	18	20		AEATTLHVAPQGTAMAVSTFR
368			itiv	.6	.2		
6			e	3	3		
685.		3	Pos	23	25		YGFC[+57.0]EAADOFHVLDE
979			itiv	.5	.1		VR
2			e	6	6		
697.		2	Pos	34	36		FVFGTTPEDILR
869			itiv	.9	.5		
4			e	5	5		
538.		2	Pos	18	19		MNTVIAALSR
300			itiv	.1	.7		
1			e				
882.		2	Pos	23	25		WSAGLTSSQVDLYIPK
962			itiv	.8	.4		
			e	7	7		
749.		2	Pos	12	14		NPDAVAAPYC[+57.0]YTR
343			itiv	.5	.1		
2			e	2	2		
555.		3	Pos	16	17		LPETIDLGALYLSMK
304			itiv	.2	.8		
			e				
889.		2	Pos	28	30		LTVGAAQVPAQLLVGALR
038			itiv	.5	.1		
4			e	2	2		
776.		3	Pos	23	24		SITC[+57.0]IHGVWTQLPQC[+
060			itiv	.1	.7		57.0]VAIDK
9			e	6	6		
827.		2	Pos	12	13		AGEQVTYTC[+57.0]ATYYK
874			itiv	.2	.8		
5			e	6	6		
617.		2	Pos	14	16		LC[+57.0]QDLGPGAFR
305			itiv	.8	.4		
9			e	9	9		
760.		3	Pos	27	29		DSFHLDEQFTVPVEMMQAR
685			itiv	.5	.1		
6			e	3	3		
739.		2	Pos	30	31		FSLVSGWGQLLDR
393			itiv	.1	.7		
5			e	9	9		
882.		2	Pos	28	30		SNALDIIFQTDLTGQK
462			itiv	.5	.1		
3			e	3	3		

686			2	Pos	12	14	EDTPNSVWEPAK
822			-	itiv	12	0	
6				e	.т 1	.0	
<u>81</u> /			2	Dog	25	26	ΟΛΑΕΩΛΛΌΤΑ Α ΑΛΛΩΙ Κ
01 <del>4</del> . 474			2	105	25	20	F VAI'S V VF IAAAAV SLK
4/4				111V	.2	.8	
3			-	e	4	4	
684.			2	Pos	30	31	DSSTWLTAFVLK
363				itiv	.2	.8	
9				e	8	8	
655.			2	Pos	28	30	GSSTWLTAFVLK
361				itiv	.7	.3	
2				e	9	9	
717.			2	Pos	20	22	AEMADQAAAWLTR
345				itiv	.9	.5	
7				e	• •		
495			2	Pos	3	5	AGVETTTPSK
758			2	itin	5. 62	22	NOVETTISK
0					05	23	
0			2	e D	10	20	
652.			2	Pos	19	20	NSLESYAFNMK
303				1 <b>t</b> 1V	.1	.7	
				e	5	5	
652.			2	Pos	7	9.	AEDTALYYC[+57.0]AK
795				itiv		9	
				e			
903.			2	Pos	25	26	YSAWAESVTNLPQVIK
475				itiv	.3	.9	
3				e	1	1	
902.			2	Pos	15	17	GOSISVTSIRPC[+57.0]AAETO
946			_	itiv	5	1	
5				e	8	8	
607			2	Pos	26	28	ASSUDEL FODR
251			2		20	20	ASSIIDELFQDK
551				IUV	./	.3	
3			~	e	3	3	
4//.			2	Pos	/.	9.	FMEIVAEK
733				1t1v	11	4	
7				e			
476.			2	Pos	23	24	WLTFSLGK
268				itiv	0.	.6	
6				e	7	7	
630.	-		2	Pos	32	33	FTVNNLAEPQK
832				itiv	.3	.9	
8				e	4	4	
629		<u> </u>	2	Pos	11	13	DGI GEC[+57 0]AL IHR
821			-	itiv	5	1	
7						.1	
(17			2	е р.	4	4	
647.			2	Pos	28	30	LAILGIHNEVSK

379			itiv	.9	.9	
9			e	3	3	
557.		2	Pos	25	27	VPLALFALNR
342			itiv	.4	.0	
6			e	5	5	
854.		2	Pos	18	19	GSLGGGFSSGGFSGGSFSR
389			itiv	.1	.7	
7			e	6	6	
763.		4	Pos	34	36	TIDDLKNQILNLTTDNANILLQ
912			itiv	.7	.3	IDNAR
3			e	6	6	
748.		2	Pos	17	18	GEVLDNSFTGGIC[+57.0]K
856			itiv	.3	.9	
1			e	4	4	
613.		2	Pos	23	24	TFSEWLESVK
308			itiv	.0	.6	
6			e	5	5	
647.		4	Pos	21	23	HLYVLEFSDHPGIHEPLEPEV
081			itiv	.5	.1	K
3			e	9	9	
491.		2	Pos	11	13	SIPQVSPVR
787			itiv	.4	.0	
6			e	2	2	
462.		3	Pos	18	20	YGFIEGHVVIPR
922			itiv	.6	.2	
5			e	7	7	
473.		2	Pos	18	20	FLNVLSPR
279			itiv	.4	.0	
5			e	5	5	
412.		2	Pos	3.	5.	AAVHLEGK
734			itiv	82	42	
9			e			
878.		2	Pos	18	20	NWGLSFYADKPETTK
930			itiv	.7	.3	
7			e	3	3	
704.		3	Pos	30	32	EQLGEFYEALDC[+57.0]LC[+5
995			itiv	.7	.3	7.0]IPR
8			e	5	5	
423.		2	Pos	7.	9.	IYLQPGR
745			itiv	3	9	
3			e			
669.		2	Pos	18	20	FYNQVSTPLLR
364			itiv	.4	.0	-
2			e	6	6	
669.		3	Pos	15	17	FAHYVVTSQVVNTANEAR
341			itiv	.6	.2	~

2			e	3	3		
781.		2	Pos	33	35		LWAYLTIQELLAK
453			itiv	.9	.5		
1			e	2	2		
561.		2	Pos	23	24		SLFTDLVAEK
805			itiv	.3	.9		
7			e	2	2		
620.		2	Pos	16	17		AVGYLITGYQR
837			itiv	.2	.8		
9			e	7	7		
503.		2	Pos	15	16		ALLAFOESK
782			itiv	.1	.7		
			e	8	8		
577.		2	Pos	11	13		ESGMTMEELK
757			itiv	.6	.2		
			e	7	7		
817.		2	Pos	14	15		NSC[+57.0]PPTSELLGTSDR
378			itiv	.1	.7		
			e	6	6		
657.		2	Pos	24	25		FLVGPDGIPIMR
865			itiv	.3	.9		
6			e	6	6		
366.		3	Pos	16	17		LFQPLTHLK
222			itiv	.0	.6		
			e	9	9		
801.		2	Pos	22	24		LSNNALSGLPQGVFGK
435			itiv	.4	.0		
9			e	4	4		
511.		2	Pos	18	20		ENFVLTTAK
779			itiv	.7	.3		
5			e	3	3		
635.		2	Pos	10	11		DC[+57.0]SLPYATESK
784			itiv	.2	.8		
6			e	2	2		
589.		2	Pos	15	17		TGYYFDGISR
777			itiv	.9	.5		
5			e				
801.		3	Pos	32	34		HVEDVPAFQALGSLNDLQFFR
741			itiv	.5	.1		
2			e	2	2		
564.		2	Pos	7.	9.		AGEVQEPELR
288			itiv	92	92		
2			e				
796.		4	Pos	30	31		GTELQHLLHAVVPGPWQEDV
883			itiv	.0	.6		ADAEEC[+57.0]AGR
4			e	6	6		

758.		2	Pos	15	17	FLDOGLDDNYC[+57.0]R
330			itiv	4	.0	
3			e	4	4	
819		2	Pos	. 18	20	EVOPVEL PNC[+57 0]NLVK
019.		2	itiv	6	20	
525				.0	.2	
628		2	C Dec	<i>y</i>	9	
028.		3	POS	23	23	IFF Y DSENPPASE V LK
644			1 <b>t</b> 1V	.6	.2	
		-	e	7	1	
745.		2	Pos	8.	10	SISC[+57.0]QEIPGQQSR
356			itiv	13	.4	
8			e			
847.		2	Pos	30	32	FSISGSYVLDQILPR
959			itiv	.9	.5	
2			e	7	7	
514.		2	Pos	24	25	LGFTDLFSK
276			itiv	.3	.9	
6			e			
793		2	Pos	12	13	VOAL FEANNDLENK
886		-	itiv	3	9	
5				6	6	
520		2	Dog	14	16	
<i>33</i> 0. 795		2	105	6	6	TLEDIDNTK
105			IUV	.0	.0	
3		 2	e	/	10	
566.		2	Pos	10	12	EALQGVGDMGR
///4			1t1V	.6	.2	
4			e	8	8	
616.		3	Pos	18	20	AYWDIMISNHQNSNR
953			itiv	.8	.4	
1			e			
650.		3	Pos	25	26	LQQELDDLLVDLDHQR
669			itiv	.0	.6	
1			e	1	1	
727.	İ	2	Pos	29	30	NLIAAVAPGAFLGLK
940			itiv	.3	.9	
1			e	4	4	
835		2	Pos	32	34	VAGLLEDTEPGLLGLR
977			itiv	7	2	
Δ				6	6	
		n	Dec	14	15	
007.			105	14	13	
033					1	
(22		2	e D		1	
632.		3	POS	54	36	EIPDEISILLLGVAHFK
027			1tiv	.6	.2	
7			e	2	2	
738.		2	Pos	11	13	ITC[+57.0]AEEGWSPTPK

345			itiv	.5	.9	
4			e	4		
537.		2	Pos	3.	5.	LGGSQEDQIK
774			itiv	75	35	
9			e			
540.		 2	Pos	10	12	SHLIIAOVAK
332			itiv	.1	.2	
2			e			
654.		2	Pos	20	22	LSSGLVTAALYGR
369		-	itiv	.6	.2	
5			e	9	9	
573		2	Pos	12	13	ICI+57 01AMEGI POK
785		2	itiv	$\frac{12}{2}$	8	
9			e	6	6	
857		2	Pos	22	24	IAPOI STEELVSI GEK
057. 467		2	itiv	0	5	IN QUSTELL'SLOEK
1				.)	.5	
1 684		 2	Pos	12	14	VECI+57 OISDNI FTOP
00 <del>4</del> . 814		2	itin	$\frac{12}{2}$	14	VEC[157.0]SDNEFTQK
014 2				.2 7	.4	
3 916		2	C Dog	/	21	TCVITSDDEDNDVDV
010. 017		2		19	$\frac{21}{2}$	IGVIISEDFENETEK
917			IUV	• /	.)	
961		 2	e Daa	0	0	
801. 901		3	Pos	34	30	LVYHLGLPFSFLIFPYVEEAIK
801			111V	.8	.4	
4		2	e	<u> </u>	2	
549. 702		2	Pos		12	LPIDSELAPR
/93			1 <b>t</b> 1V	.3	.9	
1		 -	e	/	/	
834.		2	Pos	26	28	SLEYLDLSFNQIAR
933			1t1V	.9	.5	
2		 _	e	6	6	
846.		3	Pos	27	28	NIPTVNENLENYYLEVNQLEK
090			itiv	.1	.7	
4			e	4	4	
850.		2	Pos	32	33	DGWQWFWSPSTFR
386			itiv	.3	.9	
2			e			
782.		2	Pos	35	36	SIVVSPILIPENQR
956			itiv	.0	.6	
5			e	7	7	
874.		2	Pos	23	24	GPDGLTAFEATDNQAIK
428			itiv	.1	.7	
5			e	7	7	
652.		3	Pos	19	21	VAPEEHPVLLTEAPLNPK
026			itiv	.4	.0	

3				e	4	4	
796.			4	Pos	26	27	TTGIVMDSGDGVTHTVPIYEG
659				itiv		.6	YALPHAILR
				e			
747.			2	Pos	32	34	INVNEIFYDLVR
901				itiv	.5	.1	
2				e	1	1	
852.			3	Pos	30	31	SNFLNC[+57.0]YVSGFHPSDIE
080				itiv	.3	.9	VDLLK
9				e	7	7	
654.			3	Pos	19	21	YPIEHGIITNWDDMEK
308				itiv	.7	.3	
5				e	5	5	
652.			3	Pos	18	20	VAPEEHPTLLTEAPLNPK
686				itiv	.4	.0	
1				e	3	3	
649.			3	Pos	31	32	VNPTVFFDIAVDGEPLGR
338				itiv	.1	.7	
8				e	4	4	
799.			2	Pos	21	22	IIPGFMC[+57.0]OGGDFTR
876				itiv	.0	.6	
3				e	7	7	
652.			2	Pos	15	16	FLIPNASOAESK
845				itiv	.0	.6	
9				e	7	7	
780.			3	Pos	28	30	EENVGLHOTLDOTLNELNC[+
709				itiv	.9	.5	57.011
4				e	9	9	
657.			2	Pos	14	16	VNVDEVGGEALGR
836				itiv	.4	.0	
1				e	5	5	
445.			4	Pos	28	30	LLGNVLVC[+57.0]VLAHHFG
004				itiv	.9	.5	K
				e	2	2	
765.			2	Pos	9.	11	VGAHAGEYGAEALER
370			_	itiv	6	.6	
8				e	Ĭ		
536			2	Pos	21	23	MFLSFPTTK
280			-	itiv	.8	.4	
8				e	1	1	
648			3	Pos	28	30	HVSSPLASYFLSFPYAR
000				itiv	9	5	
1				e	.,		
730			2	Pos	16	18	IADVTSGLIGGEDGR
373			-	itiv	.9	.5	
				e	5	5	
<u> </u>	L	1	1	Ĭ	2	5	

789.		3	Pos	18	20	PGOAPVLVVYDDSDRPSGIPE
736		-	itiv	6	2	R
2			e	6	6	IX
2 870		2	Pos	16	17	ALL VTA SOC $[+57,0]$ OOPA ENK
079. 116		2	itin	2	0	ALLV IASQC[+57.0]QQIALINK
440			IUV	.3	.9	
2		•	e		1	
539.		2	Pos	7.	9.	LEAC[+57.0]ESLIR
763			itiv	33	4	
5			e			
766.		3	Pos	22	24	SQFVQPIC[+57.0]LPEPGSTFP
384			itiv	.6	.6	AGHK
3			e	7	7	
867.		2	Pos	11	12	EHLVQATPENLQEAR
942			itiv	.3	.9	
1			е	4	4	
773		3	Pos	21	23	STSIVIMI TDGDANVGESRPE
721		5	itix	8	8	V
121				.0 2	.0 2	K
706		C	Daa	2	5	
/90.		Ζ	POS	23	23	ELSEALGQIFDSQR
899			1t1V	.8	.4	
4		 _	e	4	4	
799.		2	Pos	15	17	YSSDYFQAPSDYR
841			itiv	.8	.4	
5			e	4	4	
849.		2	Pos	21	23	SGVQQLIQYYQDQK
428			itiv	.4	.0	
3			e	4	4	
544.		2	Pos	12	14	ADOVC[+57.0]INLR
779			itiv	.8	.4	
5			е	8	8	
716		2	Pos	31	33	I VEENALAPDESK
×60		2	itiv	5	0	EVELIVIENI DI SIX
6				.5	.9	
749		 2	C Dec	22	24	
/48.		2	POS	52	34 1	IIFELV YEELLK
916			1 <b>t</b> 1V	.5	.1	
		-	e	3	3	
572.		2	Pos	13	14	GPDVLTATVSGK
814			itiv	.2	.8	
1			e	5	5	
315.		2	Pos	3.	5.	GLGAGVR
190			itiv	71	31	
1			e			
468.		2	Pos	6.	8.	MVGLEGSDK
228		_	itiv	66	26	
8			6	00	20	
810		2	Doc	76	20	I GEEWI GNDNIU ALTA OCTOR
040.		Э	FUS	20	∠0	LOLI WLONDNINALIAUUISE

094				itiv	.2	.2		LR
3				e				
706.			2	Pos	10	12		GDIGETGVPGAEGPR
344				itiv	.6	.2		
2				e	7	7		
866.			3	Pos	34	36		LGHPEALSAGTGSPOPPSFTY
429			-	itiv	.8	.4		AOOR
6				e	8	8		
540.			2	Pos	14	16		LLPAOLPAEK
326			-	itiv	.7	3		
6				e	8	8		
599			2	Pos	25	27		FLLALIOLER
363			2	itiv	6	$\frac{2}{2}$		
7				e	8	8		
652			3	Pos	18	20		ναρρεμρίι ι τεαρί Νρκ
026			5	itiv	10 4	0		
3					.т З	.0		
5 858			2	Pos	3/	36		I ACI CLOOL DEGLESP
050. 067			2	F US	54 1	50		LAOLOLQQLDEOLI'SK
907					.4	.0		
795			2	C Dog	22	24		SI TI CIEDVSDTSI D
105.			2		33	54 7		SLILGIEPVSPISLK
440				IUV	.1	./		
770			2	e D.	10	10		
271			2	Pos	18	19		AQVSPIASDMLHMR
3/1				111V	.0	.0		
4			2	e D	0	6		MOLTCAD
368.			2	Pos	<i>3</i> .	) ) ) )		MSLIGAR
194				1t1V	//	31		
5			2	e	10	20		
/01.			2	Pos	18	20		FC[+57.0]DMPVFENSR
299				1t1V	.6	.2		
9			-	e	10	20		
460.			2	Pos	18	20		VYLPWSR
753				1t1V	.7	.3		
1		 	-	e				
795.			2	Pos	29	31		GFGGLTGQIVAALSTAK
946				itiv	.6	.2		
1				e	7	7		
825.			2	Pos	27	29		GLPNVVTSAISLPNIR
980				itiv	.7	.3		
5	ļ			e	6	6		
448.			2	Pos	17	19		YPLYVLK
268				itiv	.6	.2		
				e				
684.			2	Pos	21	23		DTGTYGFLLPER
843				itiv	.8	.9		

603. 2 Pos 14 15 MMAVAADTLQR	
802       itiv .1  .7	
1 e 4 4	
409. 3 Pos 22 23 EEILMHLWR	
549 itiv .1 .7	
9 e 1 1	
606. 3 Pos 22 23 PSLSHLLSOYYGAGVAR	
988 itiv .3 .9	
1 e 4 4	
746. 2 Pos 29 31 TDC[+57.0]PGDALFDLLR	
858 itiv .5 .1	
7 e 6 6	
879. 3 Pos 23 24 LODIPYNIFNLPNIVELSVGH	HN
806   itiv .1 .7   K	
e 7 7	
420. 2 Pos 3. 5. EHVDALR	
222 itiv 71 31	
826. 3 Pos 32 33 GGLGSLFYLTLDVLETDC[+5	+57
761 itiv .3 .9 .0]HVLR	
4 e 3 3	
456. 2 Pos 22 24 LVVLPFPK	
799 itiv .6 .2	
5 e 4 4	
855. 2 Pos 29 30 IFSPFADLSELSATGR	
938 itiv .0 .6	
5 e 2 2	
602. 2 Pos 21 23 VMVTNVTSLLK	
852 itiv .6 .2	
630. 2 Pos 20 22 VAYDLVYYVR	
834 itiv .8 .8	
8   e 6 6	
784. 2 Pos 35 36 VNGVLTALPVSVADGR	
443   itiv .0 .6	
8       e 7 7	